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The discovery of nitric oxide (NO) as the endothelium derived relaxing factor
(EDRF) in the late 1980s has sparked a breadth of research focussed around the
effects of this molecule in many aspects of mammalian biology. NO is implicated in
many processes in the body including vasodilation, the prevention of platelet
aggregation and thrombus formation, neurotransmission, wound repair and
immunomodulatory effect. The multifaceted properties of NO hold tremendous
possibilities for its use in prophylactic and therapeutic processes, especially in the
development of biocompatible coatings for medical devices.
This thesis presents a novel method to store and deliver NO at biologically relevant
amounts in a targeted manner through the use of cation-exchanged zeolite materials.
Zeolites are microporous materials that are extensively used for gas adsorption, due to
the high surface area available for chemical reactions. Zeolites are widely available,
cheaply produced and are easily manipulated to produce materials with varying NO
storage and release capacities, achieved through alteration of the cation exchanged in
the structure and composition of zeolite in the polymer binder. NO is liberated from
these structures on contact with an aqueous environment, making them ideal
candidates for the development of biocompatible coatings on medical devices.
The first experimental chapter examines the effects of two cation-exchanged zeolites
(Co2+ and Zn2+) and the ability to inhibit collagen-induced platelet aggregation of
human platelets ex vivo. The primary optimisation of zeolite design was carried out
by comparing the effects of several compositions of Co2+ and Zn2+ zeolites in
different polymer binders (PTFE and PDMS) using NO electrode measurements,
platelet aggregation studies and fixed wire myography. Previous reports of sGC-
independent mechanisms of NO in platelets was also addressed in the platelet
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aggregation experiments through the use of specific inhibitors of sGC and by
comparison with other NO donors, DEA/NO and SNP, which have well characterised
mechanisms of anti-platelet action. These studies indicated that Zn2+ and Co2+
exchanged zeolites at high compositions of zeolite to the polymer binder had potent
anti-platelet effects that were associated with high concentrations of NO released for
approximately one hour. The anti-platelet effects lasted for up to 2 hours in platelet
rich plasma and washed platelets and were shown to be largely sGC-independent.
NO-release profiles varied considerably depending on several aspects of zeolite
design and the aqueous environment surrounding the zeolite. This is highlighted in
the study of whole-blood aggregation, which shows dramatically reduced anti¬
thrombotic potential of NO-loaded zeolites compared to that seen in PRP. Results
from this chapter conclude that the 50% Zn21 -exchanged zeolite in a PTFE binder had
the most promising NO release characteristics for further investigation in different
biological assays. Cytotoxicity was assessed using this zeolite by measuring lactate
dehydrogenase (LDH) release from platelets following zeolite incubation and
suggested no significant adverse effects of zeolite exposure on platelet viability.
Chapter 4 focuses on the effects of 50% Zn2+ exchanged zeolites on neutrophil
activation through the effect of exposure of zeolites on neutrophil activation markers
in isolated human neutrophils in vitro. Flow cytometric analyses of fluorescently
labelled conjugates of antibodies against neutrophil surface markers were investigated
in the absence and presence of the neutrophil activator, formyl Met-Leu-Phe (fMLP).
The results revealed a concentration dependent 'priming' effect ofNO on neutrophil
activation, indicating that high concentrations of NO have a pro-inflammatory effect
in this assay. Cell viability was assessed in parallel with the above experiment using
Annexin V/Propidium iodide staining. This revealed a small concentration-
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dependent, up-regulation in necrotic cell changes in neutrophils exposed to NO
released from these zeolites.
• • 2+ • •
Chapter 5 investigates the anti-bacterial effects of the 50% Zn zeolites against
common strains of Gram-negative and Gram-positive bacteria that are commonly
found in nosocomial infections caused by medical devices. The colony forming unit
assay was used to assess bacterial growth in the presence of the zeolites over several
time-points. Results revealed impressive anti-bacterial properties of NO-loaded
zeolites against all strains of bacteria studied over relatively short time-spans. The
bactericidal effect was concentration dependent and showed an interesting temporal
effect in one strain. Possible Zn2+ leaching from the NO-free zeolite control showed
bacteriostatic effects in Gram-positive bacteria, adding an extra dimension to the use
of these materials as ex vivo anti-bacterial agents.
The salient finding of this study is the success of NO-releasing zeolites to produce
effects in a number of different biological assays, which show promise for the use of
these material as anti-thrombotic and anti-infective coatings for medical devices.
Further optimisation of zeolite design is required to produce longer duration NO-
release materials and this thesis provides evidence of several ways in which this can
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Nitric oxide (NO), an endogenously produced free radical signalling molecule, is
involved in a plethora of physiological and pathophysiological processes. Interest in
NO biology has resulted in over 80,000 research papers since its discovery as the
endothelium derived relaxing factor (EDRF) in the late 1980s (Moncada & Higgs,
2006). NO is now known to be important for vascular haemostasis, due to its
intimate involvement in vasodilation, smooth muscle proliferation and the inhibition
of platelet activation and adhesion (Moncada et al., 1988; Palmer el al., 1987;
Radomski et al., 1987b, d). NO also plays an integral role in various aspects of
immune function and regulation, including inflammatory cell activation, adhesion,
apoptosis and microbial killing (Albina & Reichner, 1998; Bogdan, 1997; Kubes et
al., 1991). The impressive array of effects is further expanded by the capacity ofNO
to act as both a neurotransmitter and an adjuvant to wound healing (Sanders & Ward,
1992; Shabani et al., 1996). The dysfunction of NO production and signalling is
implicated in a wide range of diseases, such as hypertension, hypercholesterolemia,
diabetes and septic shock, yet NO-based therapeutics remain under-represented in
clinical treatment options (Kojda & Harrison, 1999; Megson & Webb, 2002). The
multifaceted effects of NO are both its greatest strength and its greatest weakness
when it comes to harnessing its potential in drug therapies. The production of
widespread vasodilation upon systemic delivery of NO-donor compounds is
potentially dangerous for most clinical applications. The localised delivery ofNO to
specific areas of need would avoid the detrimental effects of untargeted therapy. The
multifaceted properties of NO hold tremendous possibilities for its use in
1
Chapter 1- Introduction
prophylactic and therapeutic processes, especially in the development of
biocompatible coatings for medical devices. For example, the release of NO from
the surface of vascular stents would not only inhibit thrombus formation at the
surface, but could also aid in the prevention of neointimal thickening; a major cause
of restenosis of vessels following stent placement (Petrovic & Peterlin, 2005).
Additionally, biocompatibility ofmedical device coatings could also benefit from the
anti-microbial actions of NO to aid in the prevention of nosocomial infections
associated with medical device usage. NO-releasing polymers have produced
promising results in the production of materials with improved biocompatibility.
These polymers incorporate NO-donor molecules, which then release their NO
moiety upon contact with an aqueous environment. Potential drawbacks to the use of
these materials are the limited NO reservoir loaded into the polymer matrix, duration
and concentration of NO released and the leaching of potentially toxic donor
molecule by-products.
NO-loaded cation-exchanged zeolites are microporous materials with high capacity
gas storage properties due to the large surface area available for chemical reaction.
These materials liberate stores ofNO(g) on contact with an aqueous environment and
don't require molecular adducts to stabilise NO prior to release making them ideal
candidates for development as biocompatible surface coatings. Moreover, these
materials have tunable NO storage and release properties, achieved through
modulation of various aspects of zeolite design and subsequently offer the potential
to tailor NO-release to specific requirements, an attractive feature given the
complexity of NO signalling in the body. The biological efficacy of these NO-
2
Chapter 1- Introduction
releasing materials was investigated in this thesis, with respect to modulation of
platelet aggregation, neutrophil activation and bacterial growth responses to evaluate
the potential of these materials in a variety of biomedical applications. NO-loaded
zeolite materials also provide unique tools with which to investigate various aspects
ofNO biology with particular emphasis on localised delivery of pure NO.
The aim of this thesis is to characterise the biological efficacy of these novel NO-
releasing zeolite materials, with respect to their pharmacological potential in the
development of biocompatible coatings and as unique tools to aid in the further
understanding the physiology and pharmacology of locally delivered NO.
1.1 NITRIC OXIDE
The discovery of NO as the endothelium derived relaxing factor (EDRF) over 25
years ago lead the way in determining the importance of NO in the body. The
stimulation of isolated smooth muscle preparations with various agonists including
acetylcholine, bradykinin and thrombin produced vascular relaxation, but
importantly this was only evident when the endothelium was present (Furchgott el
al., 1987; Furchgott & Zawadzki, 1980; Ignarro, 1987; Ignarro et al., 1987c;
Moncada et al., 1988; Palmer et al., 1988; Palmer et al., 1987). An unknown factor
released from the endothelium, termed EDRF was shown to be responsible for the
relaxation of vascular smooth muscle and it was simultaneously shown that EDRF
was also a potent inhibitor of platelet aggregation and adhesion (Bhardwaj et al.,
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1988; Busse et ah, 1987; Hogan et al., 1988; Macdonald et al., 1988; Radomski et
ah, 1987c). The search for the elusive factor concluded when EDRF was shown to
be pharmacologically and chemically indistinguishable from NO (Ignarro et al.,
1987a; Ignarro et al., 1987b; Ignarro et al., 1988; Palmer et al., 1987; Radomski et
al., 1987a). It is now apparent that this inorganic, free radical molecule is involved
in a wide range of physiological and pathophysiological processes including
modulation of vascular tone (Moncada & Palmer, 1991; Radomski, 1995) , inhibition
of platelet (Hogan et al., 1988; Radomski et al., 1987b, c, d; Vane et al., 1990) and
inflammatory cell activation (Granger & Kubes, 1994; Kubes et al., 1993),
modulation of immune responses (Albina & Reichner, 1998; MacMicking et al.,
1997; Nicotera et al., 1995) and as a neurotransmitter in non-adrenergic non-
cholinergic (NANC) synapses (Berdeaux, 1993; Grozdanovic et al., 1994; Rand,
1992; Sanders & Ward, 1992). The importance of the key discovery of NO was
recognised when the Nobel Prize in Physiology and Medicine was awarded to
Furchgott, Ignarro and Murad in 1998. Research involving NO is now a major
theme producing over 80,000 publications to date from a diverse range of disciplines.
1.1.1 SYNTHESIS OF NO
NO is synthesised in the body by three isoforms of the enzyme NO Synthase (NOS).
NOS isoenzymes are cytochrome-P450-related type enzymes that catalyze the
formation of NO and L-Citrulline (L-Cit) from L-Arginine (L-Arg) and molecular
oxygen (O2) (Bredt et al., 1991b). The three isoforms ofNOS were first isolated and
described in a range of studies from the early 1990s. They are named endothelial
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NOS (eNOS or NOSIII), neuronal NOS (nNOS or NOSI) and inducible NOS (iNOS
or NOSH). These enzymes differ in their localisation and in the case of iNOS, by the
mechanism of regulation. eNOS is predominantly found in the endothelium and
platelets where it is constitutively active, producing low (pM-nM) concentrations of
NO important for vascular haemostasis (Forstermann et al., 1991a; Forstermann et
al., 1991b; Marsden et al., 1992; Nishida et al., 1992; Pollock et al., 1991). eNOS is
activated by several agonists, including thrombin, bradykinin and acetylcholine and
can also be stimulated by mechanical forces such as shear stress. nNOS is also
constitutively expressed and is found in non-adrenergic, non-cholinergic (NANC)
neurones where NO is produced at low concentrations (pM) and functions as a
neurotransmitter (Bredt et al., 1991a; Bredt et al., 1990; Sheng et al., 1992). The
activity of eNOS and nNOS is dependent on the increase in Ca2+ concentrations and
the subsequent binding of calmodulin (CaM) which promotes electron flow
necessary for the oxidation of L-Arg to NO (Schmidt et al., 1992a; Schmidt et al.,
1992b). The inducible isoform of NOS is usually expressed in inflammatory cells
such as macrophages and neutrophils (Ahn et al., 1994; Kadota et al., 1991; Yui et
al., 1991a; Yui et al., 1991b). The enzyme is activated in response to various
inflammatory cytokines and bacterial endotoxins, where it generates high local
concentrations of NO (nM-p,M) important for the immune response to infection
(Moncada & Palmer, 1991). iNOS has Ca2+/CaM permanently bound within the
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1.1.2 NOS CATALYTIC MECHANISM
NOS enzymes exist as homodimers, each monomer has a bidomain structure
consisting of a N-terminal oxygenase domain and a C-terminal reductase domain
linked by a Ca2+/calmodulin-binding region. The oxygenase domain contains the
binding sites for the co-factor, tetrahydrobiopterin (BH4), L-Arg and a haem
prosthetic group. The reductase domain contains the biding sites for flavin
mononucleotide (FMN), flavin adenine dinucleotide (FAD), and nicotinamide
adenine dinucletide (NADPH). Electrons donated from NADPH flow via flavins in
the reductase domain to the haem group of the oxygenase domain where they reduce
ferric (Fe3+) haem to the ferrous (Fe2+) form thereby allowing O2 to bind.
The electron flow then stimulates the next step in NO synthesis through oxidation of
L-Arg to the intermediate N°' - hydroxy-L-arginine (NHA) and then NO. The co-
factor BH4 is thought to be necessary for the synthesis of NO by NOS, as studies
have indicated that lack of BH4 can lead to uncoupling of the NADPH enzyme and
subsequent superoxide (O2") formation (Vasquez-Vivar et al., 2003; Vasquez-Vivar
et al., 1998). BH4 is therefore thought to act as redox electron acceptor important for
the successful coupling of NADPH oxidation and NO synthesis and thereby
inhibiting the formation of the potent oxidant O2" (Vasquez-Vivar et al., 1999;
Vasquez-Vivar et al., 2003; Vasquez-Vivar et al., 1998; Vasquez-Vivar et al., 2002).
Uncoupling of enzymes such as NADPH and xanthine oxidase, which subsequently
leads to O2" production is now known to be an important contributor to oxidative
stress. Oxidative stress is a condition occurring when the balance of oxidant
formation exceeds the capacity of endogenous anti-oxidants such as superoxide
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dismutase (SOD). The increased presence ofO2 can mask the beneficial effects of
NO due to the high reactivity of NO with O2", leading to formation of the potent
oxidant peroxynitrite (ONOO"; see section 1.1.5.1). Oxidative stress has been linked
with many pathophysiological states including atherosclerosis, hypertension and
diabetes (Brune et al., 2003; Giugliano et al., 1996; Loscalzo, 2003).
NADPH
Figure 1.1. Schematic Representation of the Structure of NOS.
The electron is donated from the reduction of NADPH to NADP+ + H . The flow of
electrons (e ) passes through the flavins (FAD and FMN) of the reductase domain of one
subunit and is passed, via calmodulin (CaM) to the haem-group of the oxygenase domain in
the second subunit. Tetrahydrobiopterin (BH4) acts as a co-factor in the oxidation of L-Arg




NO has a high affinity for haem-containing enzymes especially soluble guanylate
cyclase (sGC), the enzyme generally regarded as the intracellular NO 'receptor'.
The majority of the effects ofNO are mediated through the activation of sGC and the
subsequent conversion of guanosine 5'-triphosphate (GTP) to the 3', 5'-cyclic
guanosine monophosphate (cGMP) (Schmidt et al., 1993). The production of cGMP
triggers downstream signalling events through protein kinase G (PKG),
phosphodiesterases (PDEs) and ion channels.
1.1.3.1 SOLUBLE GUANYLATE CYCLASE
The sGC enzyme exists as a heterodimer of a and (3 monomer subunits each with a 3
domain structure consisting of a C-terminal catalytic domain, a N-terminal haem
binding domain joined by a central dimerisation domain (figure 1.2; Garbers, 1990;
Hobbs, 1997; Koesling, 1999; Wedel et al., 1995). Two isoforms of the heterodimer
have been described (ai|3i and a2(3i) which are functionally indistinguishable. The
|3i subunit is ubiquitously expressed, whereas the expression of the two isoforms of
the a subunit has distinct localizations. The a2|3i heterodimer occurs mainly in the
brain and the ai|3i isoform is expressed in a much broader range of tissues and forms
the predominantly expressed isoform of sGC activated by NO (Gibb & Garthwaite,
2001; Hobbs, 1997; Koesling et al., 2004).
NO diffuses from the site of synthesis to activate sGC present in the cytosol. The
haem domain is important for the successful activation of sGC by NO. Several
amino acids in the (3 subunit have shown to be integral to the function of the enzyme
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through modulation of the haem-binding domain. Of these, the His 105 residue has
been shown to be essential for the activation of sGC by NO. It is the rupture of the
axial ligand between haem and sGC at His 105 upon NO binding which promotes the
increase in enzymatic activity (Bellamy et al., 2002; Hobbs, 1997; Wedel el al.,
1995). Other residues, including Cys 78 & 214 (Friebe et al., 1997) and Tyr 125 and
Arg 139 (Schmidt et al., 2004) have also been shown to be important for haem
binding to sGC. NO binds to the haem to form a nitrosyl-haem complex, which acts
to increase the enzymatic activity of sGC by up to 400 fold (Stone & Marietta,
1995). The active enzyme also shows a reduction in the Km for GTP, most likely
through the exposure of high affinity binding regions for GTP in the catalytic
domain, thereby increasing the conversion of GTP to cGMP (Hobbs, 1997). The
functional diversity of cGMP production by sGC in different cell types may account
for the equally diverse actions of NO in the body. It has been shown that many
factors can affect the desensitisation rate of sGC. These include the presence of
GTP, oxy-haemoglobin and thiols, which are thought to increase the rate of
deactivation of NO-sGC signalling. Thus, the half-life of sGC signalling varies
depending on cell type and is far more rapid than the determined rate of deactivation
of purified nitosyl-sGC, which is between 5 s and 3 min (Kharitonov et al., 1997).
The rapid desensitisation of sGC in intact cells, including human platelets has been
estimated to occur within seconds with recovery taking place in minutes (Bellamy et
al, 2000). This demonstrates that sGC is capable of rapidly responding to transient
NO concentrations and subsequently can produce functionally dynamic
concentrations of cGMP.
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GTP cGMP
Figure 1.2. Schematic Representation of the Structure of sGC.
The structure of sGC consisits of 3 domains as indicated which show the binding ofNO and
the catalytic conversion of GTP to cGMP. The Histidine residue at location 105 on the P
subunit is represented as important for the binding of NO to the haem prosthetic group.
Adapted from Hobbs (1997).
1.1.3.2 TARGETS FOR cGMP
An increase in cGMP production triggers signalling principally through high affinity
PKG and PDE pathways. PKG, of which there are 2 isoforms (PKG I and PKG II;
(Jarchau et al., 1994; Pohler et al1995; Smolenski et al., 1998) is a serine/threonine
protein kinase which acts to inhibit Ca2 signalling through triggering a reduction in
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intracellular Ca2+ concentrations [Ca2+]i in platelets and smooth muscle. The
decrease in [Ca2+]i is potentiated through the phosphorylation of a serine residue on
the inositol triphosphate (IP3) receptor on the sarcoplasmic reticulum which prevents
the efflux of Ca2+ into the cytoplasm (Komalavilas & Lincoln, 1994). The IP3
pathway of Ca2+ mobilisation is further inhibited via the inhibition of phospholipase
C (PLC), the enzyme involved in IP3 production (Carvajal et al., 2000; Lincoln &
Cornwell, 1993). In smooth muscle, cGMP also can affect Ca2+ concentrations via
direct interactions with Ca2+ channels and transporters (Carrier et al., 1997; Nara et
al., 2000). The involvement of PKG in the phosphorylation of other proteins
involved in the inhibition of platelet activation and smooth muscle relaxation include
heat shock proteins (Hsp; (Carvajal et al., 2000) and vasodilator-stimulated
phosphoprotein (VASP) in platelets (Butt et al., 1994; Halbrugge et al., 1990).
VASP is involved in the organisation of the cytoskeleton through the regulation of
actin polymerisation (Reinhard et al., 1995; Reinhard et al., 2001). Phosphorylation
of VASP by PKG results in the inability of VASP to interact with actin filaments
(Wang et al., 2006). This correlates with platelet GPIIb/IIIa receptor inhibition
(Horstrup et al., 1994).
PDEs catalyse the hydrolysis of cGMP and cAMP to their corresponding inactive 5'-
nucleotides, thereby altering the levels of cGMP in the intracellular environment.
There are a large family of PDE isoforms that exist in mammals (Beavo et al., 1994;
Soderling & Beavo, 2000), with representative isoforms expressed in different cells
(Kuthe et al., 2001). The PDE-V isoform has received much attention following the
discovery that selective inhibitors of this enzyme, tested for cardiovascular purposes,
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had impressive side-effects on male penile erection (Moreland et al., 1998; Uckert et
al., 2001). As a result, these drugs are now primarily marketed to treat erectile
dysfunction, where inhibition of PDE-V in the corpus cavernosum results in the
accumulation of eGMP, thereby prolonging vessel dilation to aid in penile erection
(Corbin et al., 2002; Doh et al., 2002; Kuthe et al., 2002).
1.1.4 NO MEDIATED cGMP-INDEPENDENT MECHANISMS
It is now evident that NO can produce effects via cGMP-independent mechanisms.
The involvement of cGMP-independent pathways is particularly evident in the anti¬
platelet activity of select NO-donors (Crane et al., 2005; Sogo et al., 2000a; Ward et
al., 2000) and the regulation of inflammatory cell apoptosis (Ward et al., 2000).
The contribution of sGC-independent effects have also been described in the smooth
muscle relaxing properties ofNO (Bellamy et al., 2002; Bradley et al., 1998; Miller
et al., 2004). Despite the known involvement of NO-mediated sGC-independent
effects, little is known regarding the pathway through which NO exerts its effects in
the absence of active sGC. However, it has been postulated that these sGC-
independent effects are linked to situations where high concentrations of NO are
present in the extracellular environment (Crane et al., 2005). The relative lack of
sGC-independent anti-platelet effects in the presence of peroxynitrite donating
compounds (eg SIN-1; see section 1.1.8.4) or S-nitrosothiols (eg. SNAP; see section
1.1.8.2) suggests an exclusive effect of NO in these responses (Sogo et al., 2000a).
The activation of ion channels and/or transporters have been implicated as a possible
mechanism of sGC-independent effects in some tissues (Bolotina et al., 1994;
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Bradley et al., 1998; Gupta et al., 1994; Homer & Wanstall, 2002; Plane et al., 1996)
possibly through the nitrosation of critical protein residues on the cell membrane
(Crane et al., 2005). OONO" is a potent nitrating species capable of nitrating protein
residues critical for cell signalling, and has been linked with the production of sGC-
independent induction of apoptosis in neutrophils (Ward et al., 2000).
The use of the specific inhibitor of sGC, 1 -H-\ 1,2,4]oxadizolo[4,3-cf|quinoxalin-l-
one (ODQ; figure 1.3) has been pivotal in the discovery and the advancement of our
understanding of cGMP-independent effects of NO. ODQ rapidly oxidises the
ferrous haem of sGC to the ferric form thereby effectively reducing the capacity for
NO to bind and stimulate the enzyme in an irreversible manner (Feelisch et al., 1999;
Zhao et al., 2000). ODQ has benefits over previously used inhibitors, methylene
blue and LY 83583 (6-anilino-5,8-quinolinequinone), which can generate superoxide
anion (O2") and interfere with prostanoid synthesis (Gryglewski et al., 1986;
Hasegawa et al., 2004; Marczin et al., 1992; Wolin et al., 1990). ODQ has been
described by many as a selective inhibitor of sGC (Garthwaite et al., 1995;
Schrammel et al., 1996), but evidence suggests that ODQ can interfere with other
heme protein-dependent processes in vascular tissue, including NOS activity at ODQ
concentrations > 30pM (Feelisch et al., 1999). Thus, careful consideration is
required when interpreting results using ODQ mediated inhibition of sGC.
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Figure 1.3. The Structure of ODQ.
1.1.5 NO BIOCHEMISTRY
The biochemistry of NO is complex due to the diversity of the reactions involving
this radical species. NO can rapidly react with a number of molecules resulting in
the production of a variety NO-related species, which can exert biological effects on
their own. The array ofNO-related products produced by the many reactions of NO
goes some way in explaining the 'double edged sword' paradox associated with NO
in the body. The concentration of NO and the relative presence of each biological
species in particular tissues and organs determines the eventual signalling pathway of
NO. The redox environment can be dramatically altered in several physiological and
pathophysiological conditions, resulting in pro and anti-oxidant outcomes for NO.
The most physiologically relevant reactions of NO in the body are those with
superoxide, haem, molecular oxygen, thiols and tyrosine.
1.1.5.1 REACTIONWITH SUPEROXIDE
Superoxide (O2") is a reactive oxygen species (ROS) generated in mammals through
several enzymes including xanthine oxidases, NADPH oxidases, NOS,
cycloxygenases and enzymes of the respiratory chain (Forman & Torres, 2002; Nohl
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et al., 2003; Souza el al., 2002; Terada el al., 1991; Vasquez-Vivar & Kalyanaraman,
2000; Zhang et al., 1998). The body removes O2" via the action of the enzyme
superoxide dismutase (SOD) and catalase to produce oxygen and water (equation 1).
This process is important to regulate the potent oxidant effects of O2", however
increased production of O2" can overcome these regulatory mechanisms and reduce
the bioavailabilty ofNO. O2" reacts with NO at almost diffusion limited rates (rate
constant - 6.7 x 109M"' s"1) (Huie & Padmaja, 1993) to produce peroxynitrite
(ONOO"; equation 2). This preferential reaction ofNO for O2" masks the beneficial
effects of NO by reducing NO bioavailability, and is increasingly associated with
disease pathology (Cuzzocrea, 2006; Kojda & Harrison, 1999; Loscalzo, 2003;
Miller et al., 1998; Thomas et al., 2006).
202"+2H+ SQD > O2+H2O2 catalase ^ 202+H20 (1)
NO + 02" ► ONOO" (2)
ONOO" is a potent oxidising agent, which may be responsible for the cytotoxic
effects associated with high concentrations of NO in a number of cell types and
immune responses (Bartosz, 1996; Virag et al., 2003). It is rapidly decomposed via
peroxynitrous acid (equation 3) to form NO2 and hydroxyl radicals (*OH; equation
4).
ONOO" + H+ ► ONOOH (3)
ONOOH ► N02 + -OH (4)
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1.1.5.2 REACTION WITH HAEM
The reaction ofNO with haem constitutes the majority of the physiological effects of
NO. The haem containing enzyme sGC (see section 1.1.3.1) is the main effector for
NO signalling, which catalyses production of cGMP upon activation. Other haem
containing enzymes are also important in NO biology. These include oxy and
deoxy-haemoglobin which bind NO to form methaemoglobin and nitrate (NO3") or
iron-nitrosyl-haemoglobin respectively. Oxy-haemoglobin is generally considered as
an NO scavenger and the likely route of NO inactivation (Kosaka et al., 1989;
Schechter & Gladwin, 2003). However, evidence suggests that deoxy-haemoglobin
can act to prolong NO bioactivity ofNO via the formation of S-nitosohaemoglobin.
To this end, the formation of intermediate S-nitrosohaemoglobin and other S-nitroso-
protein adducts also act as NO transporters, enabling the effects of NO to occur far
from the site of synthesis (Hobbs et al., 2002; Jia et al., 1996; Kosaka et al., 1989;
Rassaf et al., 2005). The high affinity of NO for haem results in the interaction of
NO with several other haemoproteins including COX, NOS and cytochrome P450
(Buga et al., 1993; Goodwin et al., 1998; Khatsenko et al., 1993; Wink et al., 1993).
The conformational change associated with NO-haem interactions confers inhibitory
actions on their catalytic activities.
1.1.5.3 REACTION WITH MOLECULAR OXYGEN
NO is oxidised by molecular oxygen (O2) to yield nitrogen dioxide (NO2; equation
5). This reaction is relevant for both O2 in gaseous and aqueous phases and thus
describes the reaction pathway through which NO2, a prominent air pollutant, is
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formed from internal combustion engines. In physiological solutions the reaction
between NO and O2 is relatively slow (approx 4 x 106 M"1 s"1). NO2 will react with
H20 to form nitrite (NO2") and nitrate (NO3"; equation 6; Butler et al., 1995) but the
reaction with NO to form N2O3 occurs in preference to this (equation 7). N2O3 is an
important physiological NO-species due to the potent thiol nitrosating properties of
this molecule (section 1.1.5.4). N2O3 will also react with H2O to form N02~ and H+
(equation 8).
NO + o2 ► N02 (5)
2N02 + H2o — ► N02" + NO3 + 2H+ (6)
N02 + NO — -► N2O3 (7)
N2O3 + h2o ► 2N02" + 2H+ (8)
1.1.5.4 REACTION WITH THIOLS
The potent nitrosating species in the body is N2O3, which reacts with thiols (general
formula R-SH) to form S-nitrosothiol species (general formula RSNO; equation 9).
N2O3 + RSH ► R-S-N=0 + H+ + N02" (9)
The NO moiety of S-nitrosated species is nitrosonium (NO+), which can be
transferred to other thiols via transnitrosation reactions (equation 10).
Ri-S-N=0 + R2SH ► RiSH + R2S-N=0 (10)
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The mechanism by through which S-nitrosothiols are activated to liberate NO is
unclear although decomposition is accelerated in the presence of Cu+ and can be
susceptible to light (equation 7).
+ Cu+
2R-S-N=0 ► 2RSSR + 2NO (11)
+ light
Storage of NO in S-nitrosothiol forms is now recognised to an important
physiological process and associated with the formation of intermediates that can
prolong NO bioactivity in the body (Crane el al., 2002; Stamler et al., 1992a;
Stamler et al., 1992b; Stamler et al., 1992c). Furthermore, the storage and transfer of
nitrosonium species occurs without the release the NO radical and is therefore not
subjected to the same potent scavenging and redox reactions. Thus, formation of
RSNO provides functional explanation as to how NO can exert effects in
environments containing high concentrations of scavengers such as haemoglobin
(Rassaf et al., 2005).
1.1.5.5 REACTION WITH TYROSINE
The NO-related species ONOO" is a potent nitrating species, reacting at sites of
electron density, such as aromatic rings, to transfer an N02+ moiety. Tyrosine
residues are common sites of nitration by ONOO". Nitration of critical tyrosine
residues, especially those involved in cell signalling phosphorylation events, is
implicated with effects associated with ONOO", including inhibition of platelet
aggregation. Formation of nitrotyrosine is also used as a marker of nitrative-stress
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associated with the progression of diseases such as Parkinson's disease,
atherosclerosis, arthritis, Alzheimer's and multiple sclerosis (Ischiropoulos, 1998;
Kamat, 2006; Nakazawa et al., 2000; Radi, 2004).
1.1.6 NO PHYSIOLOGY AND PATHOPHYSIOLOGY.
The ubiquitous presence of NO in the body means that it is has far-reaching roles in
the cardiovascular, immune and nervous systems. The physiological and
pathophysiological impact of NO in these systems is dependent upon relative
concentrations of NO produced, the target cell type and the surrounding biological
milieu. Reduced NO bioavailability is recognised as a significant risk factor in many
disease states including atherosclerosis, diabetes, hypertension and
neurodegenerative disorders (Li & Forstermann, 2000; Llorens & Nava, 2003).
Bioavailability ofNO can be reduced in a number ofways including reduction ofNO
synthesis by substrate or co-factor deficiencies, enzyme uncoupling, endothelial
injury or increases in NOS inhibitor asymmetric dimethylarginine (ADMA) (Boger
et al., 1998; Cooke, 1998; Kennedy et al., 2004; Kielstein et al., 2001; Rengasamy &
Johns, 1993; Vasquez-Vivar et al., 2003; Vasquez-Vivar et al., 1998). NO
bioavailability is also significantly impacted by changes in the redox environment.
The diffusion limited reaction ofNO with O2" results in ONOO" production (section
1.1.5.1), preventing NO from reaching its target while having potent nitrating effects





The synthesis of NO from vascular endothelium is integral in the maintenance of
vascular haemostasis through both modulation of vascular tone and inhibition of
platelet activation and adhesion. Reduced bioavailability of endothelial derived NO
is one of the main factors involved in endothelial dysfunction, a disorder implicated
in the progression of numerous diseases including athereosclerosis, hypertension and
diabetes (Cosentino & Luscher, 1998; Luscher, 1994; Wennmalm, 1994). Models of
eNOS deficiency demonstrate decreased vascular reactivity, hypertension,
atherosclerosis and increased injury following ischemic events (Bonthu et al., 1997;
Faraci et al., 1998; Fluang et al., 1996; Jones et al., 1999; Knowles et al., 2000).
Platelet-derived NO is also important in modulating platelet responses following
stimulation of aggregation, through prevention of further platelet recruitment
(Freedman & Keaney, 1999; Freedman et al., 1997; Freedman et al., 1998).
Dysfunction in platelet NO production has been linked with increased thrombotic
risk in patients with angina and acute coronary syndromes (Freedman & Loscalzo,
2003; Freedman et al., 1998; Tanus-Santos et al., 2002).
The expression of all isoforms of NOS can be found in the heart (Balligand &
Cannon, 1997; Balligand et al., 1994; Takimoto et al., 2000). Here, NO is important
• .... 2"F
for modulation of force and rate of contraction through interactions with Ca -
channel function and changes in cardiac preload and afterload through its vasoactive




The inflammatory response is a fundamental process for host defence against
infection and for mediating tissue repair. The inflammatory reaction involves the
recruitment of inflammatory cells to the site of injury or infection in response to
noxious chemical stimuli or microbial toxins (Driscoll et al., 1997). The
identification of foreign substances in the body is essential for the rapid and
successful clearance of infection, however, when the formidable array of
inflammatory effector molecules is targeted inappropriately, such as in chronic
inflammatory diseases and medical device placement, the resulting damage to host
tissue is harmful and potentially fatal.
1.1.6.2.1 RECRUITMENT OFINFLAMMATORY CELLS
NO is involved in many stages of the inflammatory response (Guzik et al., 2003).
Constitutively active eNOS produces low concentrations of NO released from the
vascular endothelium and platelets to inhibit platelet and inflammatory cell adhesion
(Granger & Kubes, 1994; Kubes et al., 1993; Thorn et al., 1994). Here, NO is
involved in the modulation of leukocyte and endothelial adhesion molecule
expression to prevent inflammatory cell recruitment from the blood stream into the
tissue. Rolling leukocyte/endothelial interactions are important for the "capture" of
inflammatory cells at the vessel wall, prior to firm adhesion and migration into the
tissue (Frenette & Wagner, 1997; Tedder et al., 1995). Adhesion is initiated by L-
selectin (CD62L), a leukocyte surface glycoprotein, which is shed upon exposure
with various ligands on the vessel surface to promote leukocyte rolling adhesive
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interactions (Hafezi-Moghadam et al., 2001; von Andrian & Arfors, 1993). Release
of NO from vascular endothelium prevents leukocyte rolling through inhibition of
CD62L shedding (Benjamim et al., 2002). Firm adhesion is partly mediated via the
leukocyte |32-integrin adhesion molecule CDllb (Mac-1; figure 1.4), which is up-
regulated at the leukocyte surface due to translocation from intracellular storage
pools during degranulation (Hughes et al., 1992). Inhibition of NOS by L-NAME
has been shown to increase the adhesion of leukocytes to the endothelium through
increased expression of leukocyte adhesion molecule, CD lib/CD 18 confirming the
role of NO in inhibiting inflammatory cell adhesion to the endothelium and
maintaining vascular haemostasis (Kubes et al., 1991; Ma et al., 1993). Inappropriate
recruitment of inflammatory cells into tissue can occur at sites of endothelial
dysfunction or injury, where endothelial production of NO is compromised.
Endothelial dysfunction is a common risk factor associated with many diseases
including atherosclerosis (Guerra et al., 1989; Napoli, 2002). Infiltration of
inflammatory cells into atherosclerotic plaques contributes to disease pathogenesis in
several ways; by promoting plaque progression through accumulation of
macrophage-derived foam cells, the non-discriminate attack of inflammatory cell
exudates on host tissues and by increasing the risk of plaque rupture through pro-
apoptotic effects on smooth muscle cells (Eriksson et al., 2001; Shaw et al., 2005).
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Figure 1.4. Neutrophil/endothelial cell interactions.
A representation of the stages of neutrophil adhesion to endothelium prior to migration
(diapedesis) and the receptor/ligands involved. The highlighted sections represent the
neutrophil adhesion markers L-selectin (CD62L) and Mac-1 (CDllb) and their
corresponding endothelial ligands. Adapted from Wagner and Roth, 2000.
1.1.6.2.2 MICROBIAL DEFENCE
High concentrations of NO are released by inflammatory cells, via activation of
iNOS in response to various inflammatory mediators and bacterial products
(Moncada & Palmer, 1991). During the response to injury or infection, NO is
important for the clearance of infecting pathogens (Bogdan, 1997) and for promoting
tissue repair (Stallmeyer et al., 1999). Murine iNOS knock-out models highlight the
importance ofNO synthesis during microbial infection as these mice show increased
susceptibility to infection (MacMicking et al., 1995). Furthermore, reduced
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expression of iNOS has been associated with the pathophysiology of cystic fibrosis,
a condition associated with increased susceptibility to bacterial lung infection
(Kelley & Drumm, 1998; Meng et al., 1998). The involvement ofNO in endogenous
microbial defence has increased the interest in NO-donors as antimicrobial agents,
particularly in wound healing, where risk of infection is high. NO-donors have
exhibited inhibitory actions against a variety of bacteria, fungi, viruses and parasites
(Ascenzi et al., 2003; Coban et al., 2003; Karupiah & Harris, 1995; Rementeria et
al., 1995). The mechanism by which NO exerts its anti-microbial actions are both
dependent upon the species of NO produced and the pathogen. For example, anti¬
parasitic actions ofNO have been related to the S-nitrosylation of cysteine proteases
(Ascenzi et al., 2003) and candidacidal activity has implicated the potent nitrating
species, OONO" (Vazquez-Torres et al., 1996). In addition, differences in
susceptibility to NO and NO-related species varies between strains of the same
microbial group. NO has greater anti-bacterial properties than OONO" against
Leishmania major and Giardia lamblia (Assreuy et al., 1994; Fernandes & Assreuy,
1997) whereas Salmonella typhimurium was more sensitive to OONO" and S-
nitrosothiol species and demonstrated no adverse effects from NO per se (De Groote
et al., 1995). Differences in the anti-microbial actions ofNO has been attributed to
the huge variety of microbial defenses including expression of stress regulons,
scavengers, detoxifying enzymes, repair systems and strategies to subvert or avoid
host phagocytes (Fang, 1997). Gram-positive and Gram-negative bacteria differ
fundamentally in the make-up of their membranes (see figure 1.5), which has
previously been shown to determine the sensitivity of bacteria to oxidant stress (Dahl
24
Chapter one - Introduction
et al., 1989). Gram-negative bacteria have a greater chance of oxidation of
membrane lipids and proteins and therefore show greater sensitivity to singlet
oxygen than Gram-positive bacteria that allow passage of singlet oxygen through to
the cytoplasm where it is inactivated (Dahl et al., 1989).
Gram Positive
Outer membrane





Figure 1.5. Schematic Representation of the Structure of Gram Positive and Gram
Negative Bacterial Membranes.
Although iNOS expression is undoubtedly important in immune defence
mechanisms, the over expression of this enzyme has also been associated with
detrimental immune responses, in particular, septic shock (Thiemermann, 1997).
Septic shock is a severe condition resulting in vascular collapse and potential death.
Murine iNOS and eNOS knock-out models demonstrate increased survival upon
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challenge with concentrations of LPS, highlighting a detrimental role for NOS
derived NO in this condition (Connelly et al., 2005; MacMicking et al., 1997;
MacMicking et al., 1995; Mashimo & Goyal, 1999).
1.1.6.2.3 APOPTOSIS
NO has a paradoxical role in the regulation of inflammatory cell apoptosis,
demonstrating both anti and pro- apoptotic effects (Albina & Reichner, 1998; Brune
et al., 1998; Mannick et al., 1997; Nicotera et al., 1995). Apoptosis is a highly
regulated, cell death process that is critical for the resolution of the inflammatory
response (Haslett et al., 1994; Savill, 1997). Regulation of apoptosis occurs through
a number of pro- and anti-apoptotic signaling pathways. The balance between these
two pathways determines the fate of the inflammatory cell in a cell specific manner.
The dual effect ofNO in apoptosis can be attributed to both the ability ofNO to form
a variety of species depending on the redox environment and the ability of these
species to interfere with pro- or anti-apoptotic cell machinery. Anti-apoptotic
responses have been linked with low concentrations ofNO that promote cell survival
through cGMP-dependent mechanisms and by direct S-nitrosylation of protein thiols
(Brune et al., 1998; Yoshioka et al., 2006). Pro-apoptotic effects are linked with
release of high concentrations ofNO and in particular, the formation of OONO" from
the interaction of NO with O2", which can induce apoptosis through cGMP-
independent mechanisms. Caspase cleavage, upregulation in Bcl-2 family protein
expression, inhibition of survival pathway signalling and release of mitochondrial
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cytochrome c of have all been implicated in the pro-apoptoic effects of NO and
related speices (Taylor et al., 2003; Tejedo et al., 1999; Ward et al., 2000).
Neutrophils are the most abundant cell type recruited to sites of injury or infection in
response to inflammatory mediators. When they reach the site, they kill and clear
pathogenic organisms or cell debris through release of histotoxic granule contents
and the production of ROS. The neutrophil then remains in situ, where it rapidly
undergoes apoptosis, characterised by cytoplasmic blebbing, chromatin
condensation, exposure of membrane phosphatidylserine residues and DNA
fragmentation (Haslett et al., 1994; Kerr et al., 1972; Ward et al., 1999a; Wyllie et
al., 1980). During apoptosis, the neutrophil membrane is maintained, allowing the
retention of the histotoxic contents before clearance by phagocytes (Savill, 1997). In
contrast, neutrophil necrosis is a death process in which the cell swells and the
membrane ruptures, allowing release of the histotoxic contents and resulting in the
exacerbation of the inflammatory response (Haslett, 1997). In conditions
characterised by chronic inflammatory reactions such as arthritis, the successful
resolution of the inflammatory response is often inhibited, leading to sustained pain
and swelling (Wong & Lord, 2004). Agents that promote the resolution of the
inflammatory response via the induction of apoptosis are highly sought after as
treatments for chronic inflammatory conditions, which are not adequately controlled
by conventional anti-inflammatory drugs (Marshall et al., 2007; Rossi et al., 2006;
Ward et al., 1999b). The role ofNO on the induction of neutrophil apoptosis and in
macrophage clearance of apoptotic cells has been one such avenue explored in this
regard (Savill, 1997; Shaw et al., 2005; Taylor et al., 2003; Ward et al., 2000). The
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complex interactions ofNO on apoptotic cell machinery limit the use ofNO as pro-
or anti-apoptotic therapeutics to promote resolution of inflammation due to the lack
of cell-specific apoptotic responses. This need is particularly important in the
resolution of inflammation in atherosclerotic plaques, which requires inflammatory
cell specific responses to avoid apoptosis of the smooth muscle, which could weaken
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Figure 1.6. Apoptotic and Necrotic death of the Neutrophil.
Necrotic cell death results in rupture of the cell membrane and release of histotoxic contents
into the surrounding environment and is thus a pro-inflammatory pathway. Apoptotic cell
death allows the retention of histotoxic contents and the clearance of cells by phagocytosis
thereby resolving the inflammatory response. When phagocytes are overwhelmed or not
present, apoptotic cells will undergo secondary necrosis, releasing the histotoxic contents




The wound healing properties of NO are linked with many processes including
decreasing bacterial load, angiogenesis, inflammation, collagen formation and cell
proliferation (Burrow et al., 2007; Hsu el al., 2007; Luo & Chen, 2005). Murine
models deficient in NOS demonstrate a reduced capacity for wound healing
demonstrating the importance of NO in this process (Lee et al., 1999; Stallmeyer et
al., 2002; Stallmeyer et al., 1999). Systemic and topical therapy with NO-donors has
shown improved healing responses in diabetic ulcers (Masters et al., 2002; Schaffer
et al., 2007) and burn wounds (Ghaffari et al., 2007; Zhu et al., 2007), highlighting a
possible role for NO in the treatment of wounds in patient subgroups that have
healing deficiencies and wounds that are not readily accessible to systemic wound
healing agents. Furthermore, NO could provide an alternative to conventional
antibiotic treatments, which are becoming less therapeutically viable due to increased
antibiotic resistant bacterial strains.
1.1.6.4 NERVOUS SYSTEM
NO synthesised by nNOS acts as a neurotransmitter in the peripheral and central
nervous system, where it contributes to the activity of both excitatory and inhibitory
NANC neurones The induction of inhibitory NANC neurone activity by NO in the
peripheral nervous system produces smooth muscle relaxation in blood vessels
(Bennett, 1997; Gumusel et al., 2001), the gastrointestinal tract (Van Geldre &
Lefebvre, 2004) and penile tissue (Andersson & Holmquist, 1994; Toda et al.,
2005). Expression of nNOS in the CNS is high within the brain, especially the
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cerebellum, where NO is suggested to contribute to long-term potentiation and
memory formation (Hopper & Garthwaite, 2006; Lee, 2000). The hypothalamus also
expresses high levels of nNOS, where NO is implicated in central cardiovascular
control functions (Zanzinger, 1999). Many of the effects produced by NO in the
nervous system are linked to increases in cGMP through stimulation of sGC,
although NO-related species can also stimulate neurotransmission through direct
modulations of ion-channels (Ahern et al., 2002; Hare, 2003). Expression of the
inducible form of NOS (iNOS) is found in astrocytes, which is suggested to be
important for defence against pathogens in the nervous system (Sparrow, 1994).
1.1.7 NO THERAPY
Therapy involving NO can be achieved through manipulation of the
NOS;NO;sGC;cGMP signalling pathway. Supplementation of L-Arg increases the
substrate for NOS dependent conversion to NO and has improved outcomes in
pathologies which are generally associated with decreased NO bioavailability (Boger
& Ron, 2005; De Nicola et al., 1997; Wu & Meininger, 2000). NO-independent
therapies include sGC stimulators, such as YC-1 and BAY-41-2272 and cGMP
analogues (8-bromo-cGMP) that can mimic the effects ofNO in platelets and smooth
muscle and have therefore been investigated as potential therapeutics for a range of
conditions (Boerrigter & Burnett, 2007; Doggrell, 2005; King et al., 1998; Teng et
al., 1997). Downstream inhibitors of the PDE enzymes, which prolong the effects of
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cGMP, have been successful in the treatment of erectile dysfunction (Corbin et al.,
2002; Doh et al., 2002; Kuthe et al., 2002).
Increased NO-production via iNOS implicated in the pathophysiology of septic
shock has resulted in the search for specific inhibitors of the iNOS enzyme for
potential clinical treatment of septic shock (Cobb, 2001; Rosselet et al., 1998;
Salerno et al., 2002).
The addition of an NO-moiety to commonly used drugs to enhance their activity or
counteract detrimental side effects associated with their use is an interesting area of
NO-based research. NO-aspirins incorporate the NO-moiety through ester linkage
with the aspirin molecule and are able to retain their COX inhibiting actions while
having the added benefits of reducing gastric ulceration due to release of NO
(Turnbull et al., 2006b; Velazquez et al., 2005). The potential for other NO-hybrid
drugs include NO linked ACE inhibitors and beta-blockers that could result in more
efficient reduction of blood pressure due to the direct anti-platelet and vasorelaxant
effects ofNO (Martelli et al., 2006). The furoxan derivatives are often utilised in the
development of NO-hybrid drugs which require biological activation by plasma
components, similar to the organic nitrates and could therefore encounter problems
with tolerance (Feelisch et al., 1992; Mu et al., 2000; Turnbull et al., 2006a).
1.1.8 NO DONORS
The discovery ofNO in a wide range of physiological processes and the association
of reduced NO bioavailability in a number of disease states, held great hopes for the
use of NO-based therapies in the treatment of a variety of ailments. However,
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clinical treatment options using NO as a therapeutic agent are limited, despite
massive research efforts to this end. The major consideration when determining the
therapeutic value of NO is delivery. The multifaceted targets of NO mean that
obtaining a specific effect for therapeutic benefit is difficult. Furthermore, stablising
this labile molecule until it is required for release in the body has also produced
challenges. Donors that require activation by tissue factors, help in achieving
biological activation, however this method of NO delivery is often associated with
tolerance, thereby limiting the therapeutic potential of such agents. Despite this, the
use of a variety of structurally diverse classes ofNO donating compounds has proved
to be invaluable as investigative tools with which to further our understanding ofNO
physiology and pharmacology. A new generation of NO-releasing materials show
promise in offering localised NO delivery for a variety of biomedical applications
providing a catalyst for advancement ofNO-based therapies in the clinic.
1.1.8.1 ORGANIC NITRATES
Organic nitrates, such as glyceryltrinitrate and isosorbide dinitrate (GTN and ISDN;
figure 1.7) have been used for centuries to provide relief from pain associated with
angina, however these NO-based therapeutics have significant drawbacks due to the
development of tolerance. These drugs cause smooth muscle relaxation, through
release ofNO moieties in an sGC-dependant mechanism. The mechanism by which
organic nitrates are activated is still not fully understood but is known to require
biological factors. There have been many candidate molecules implicated in the
activation of organic nitrate in vivo including cytochrome P450 and glutathione-S-
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transferase (McGuire et al., 1998; Simon et al., 1996). More recent data has
implicated the mitochondrial aldehyde dehydrogenase (mtADH) enzyme, as a
suitable candidate, fulfilling most of the criteria of the physiological GTN-activating
enzyme (Chen et al., 2002). Furthermore, inhibition of this enzyme and the
subsequent increased generation of 0{ in mitochondria have also been implicated in
the development of tolerance associated with nitrate use (Chen et al., 2002). The
oxidative stress concept of nitroglycerin tolerance is becoming more accepted as the
central factor predisposing the development of tolerance, as antioxidants, such as
folate have produced beneficial effects in regards to alleviating tolerance (Leopold &
Loscalzo, 2003; Munzel et al., 2005). Furthermore, increased oxidant stress impacts
regulation of down-stream targets of nitrates such as cGMP-degrading PDEs,
previously implicated in the development of tolerance (Kim et al., 2001; Munzel et
al., 2005).
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S-nitrosothiols are compounds with the general formula RS-N=0. These compounds
are found endogenously where they are formed from the nitrosation (transfer ofNO"1)
of reduced thiols. GSNO is an example of an endogenous S-nitrosothiol (figure 1.8),
formed from the nitrosation of glutathione (GSH). S-nitrosothiols can transfer the
NO+ moiety to reduced tissue thiols in transnitrosation reactions, a mechanism by
which S-nitrosothiols can be transported from extracellular sources into intracellular
stores (Zhang & Hogg, 2004). Furthermore, the transfer of NO+ occurs without the
release of NO radical thereby avoiding rapid oxidation or scavenging of NO and
prolonging the bioavailablilty of NO. Indeed, the formation of significant pools of
S-nitrosylated proteins, such as S-nitrosoalbumin and S-nitrosohaemoglobin has
been implicated in prolonged vasodilatory and anti-platelet actions ofNO (Crane et
al., 2002; Jourd'heuil et al., 2000; Rassaf et al., 2005). Moreover, the circulation of
S-nitrosothiols allow for the effects of NO to occur distant from the site of NO
production. The mechanism of decomposition of S-nitrosothiol species to release
free NO is not well understood, although it is evident that the release of NO is
• 2"b •
catalysed in the presence of Cu (section 1.1.5.4).
Synthetic S-nitrosothiol compounds, such as S-nitroso-N-acetylpenicillamine
(SNAP; figure 1.8) and S-nitroso-N-valeryl-D,L-penicillamine (SNVP; figure 1.8)
have provided promising therapeutic potential due to the selectivity of these
compounds for certain tissues. For example, the vasodilatory actions of these agents
in vitro have shown selectivity for tissues denuded of endothelium (Megson et al.,
1997; Megson et al., 1999; Sogo et al., 2000b). Furthermore, SNVP reduced
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adhesion of radiolabeled platelets to areas of endothelial damage in rabbit vessels
following balloon angioplasty, without affecting systemic blood pressure (Miller et
al., 2003). Thus, these compounds have the potential to target NO therapy to areas
ofwhere normal endothelial synthesis ofNO is compromised.
SNAP SNVP
Figure 1.8. The structures of GSNO, SNAP and SNVP.
1.1.8.3 SODIUM NITROPRUSSIDE
Sodium nitroprusside (SNP; figure 1.9) releases it's NO moiety intracellularly upon
activation by biological factors (Rochelle et al., 1994). The mechanism of action of
SNP in platelets is exclusively dependent upon cGMP formation as inhibition of sGC
by ODQ has shown to abolish the functional responses produced by this drug (Sogo
et al., 2000a). Clinical use of SNP is limited due difficulties with dose titration and
the risk of cyanide poisoning (Friederich & Butterworth, 1995; Papapetropoulos et










Figure 1.9. The structure of SNP.
1.1.8.4 SYDNONOMINES AND MESOIONIC OXATRIAZOLES
Sydnonomines and mesoionic oxatriazole derivatives are closely related classes of
compounds with similar chemical properties. The active metabolite of the
molsidomine precursor, 3-morpholinosydnonomine (SIN-1; figure1.10) was
discovered to generate O2" concomitantly with NO, resulting in this drug being
regarded as an ONOO" donor rather than a NO donor due to the near instantaneous
reaction of O2" and NO to form ONOO" (Feelisch et al., 1989; Noack & Feelisch,
1989). The structurally similar mesoionic 3-aryl-substituted oxatriazole-5-amine
derivative, GEA-3162 (figure 1.10), previously considered to be a pure NO donor,
has also shown clear evidence that this compound is in fact ONOO" donor (Taylor et
al., 2004). The generation of ONOO" holds tremendous significance when
considering the therapeutic potential of such agents due to the detrimental effects
associated with this potent oxidant, especially in inflammatory conditions where
ONOO" has significant modulatory and cytotoxic effects in inflammatory cells




Figure 1.10. The structures of SIN-1 and GEA-3162
1.1.8.5 DIAZENIUMDIOLATES
The diazeniumdiolate compounds are nucleophile adducts, onto which 2 molar
equivalents of NO are bound, hence the acronym, "NONOates". These compounds
decompose spontaneously at physiological temperature and pH, thereby bypassing
the need for biological cleavage mechanisms and the associated development of
tolerance. The rate of NO release occurs following first order kinetics, however,
duration of NO release can be altered by varying the nucleophile adduct (Davies et
al., 2001; Maragos et al., 1991). A diverse range of compounds exist from short-
acting compounds such as diethylamine diazeniumdiolate (DEA/NO; figure 1.11)
which has a half-life of approx 2 min, to much longer acting compounds, for
example (Z)-1 -[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1 -ium-1,2-
diolate (DETA/NO; figure 1.11) which has a half-life of approx 20 hrs. The
spontaneous yet predictable rate of decomposition of NONOates in physiological
solutions has provided researchers with excellent tools with which to investigate NO
physiology and pharmacology. However, there are still significant barriers to their
use in the clinical setting, due to the non-specific targets of NO delivered in this
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fashion. Untargeted NO therapy is inappropriate for most conditions due to
significant reduction in blood pressure caused by widespread vasodilation. Localised
NO delivery systems, including incorporation of tissue specific activators
(Chakrapani et al., 2007a; Chakrapani et al., 2007b) or the tethering of NONOates
onto medical grade materials have significant potential in achieving clinically viable
NO based therapeutics (Reynolds et al., 2006; Smith et al., 1996).
DEA/NO DETA/NO
Figure 1.11. The structures of DEA/NO and DETA/NO.
1.1.9 NO-RELEASING MATERIALS
The development of new NO donating therapies relies on the ability to localise the
effects of NO to areas of need. The recent development of NO-releasing materials
shows exceptional promise in overcoming the barrier to the successful use ofNO in
biology and medicine.
1.1.9.1 N-DIAZENIUMDIOLATE BASED NO-RELEASING POLYMERS
Many varieties of NO-releasing polymers have been developed, most of which
incorporate well-known NO donors such as the NONOates or S-nitrosothiols. The
diazeniumdiolates in particular have been the main types ofNO donor utilized in the
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development of NO-releasing materials (Annich et al., 2000; Jun et al., 2005;
Keefer, 2005; Reynolds et al., 2006; Shin et al., 2004; Shin & Schoenfisch, 2006;
Smith et al., 1996; Zhang et al., 2002; Zhang et al., 2003; Zhou & Meyerhoff, 2005).
The spontaneous decomposition of these compounds in physiological conditions
makes them an attractive candidate. Many species of NONOate have been used,
each with different, yet predictable rates ofNO release, allowing for the optimisation
of NO release capacities. The method of incorporating the donor compound can be
achieved in a number of ways, and the fundamental differences in these methods
impacts on the NO release properties of these polymers. This provides another
variable for the adjustment and optimisation of NO release from these materials.
Smith and co workers were the first to demonstrate the incorporation of NONOates
into polymers through 3 different methods described; (1) low molecular weight
donor compounds dispersed into the polymer structure (2) donor molecules attached
to the polymer backbone using lipophilic polymer pendant side-chains and (3) the
amine group of the donor covalently bound directly onto the polymer backbone
(Smith et al., 1996; figure 1.12). The covalent attachment of the donor results in the
amine by-product of the NONOate decomposition to remain bound to the polymer,
an attractive result considering the potential carcinogenic effects of some
nitrosoamine by-products (Mowery et al., 2000; Ward et al., 2000). However, the
diffusion of the full donor molecule into the local area, as seen with methods 1 and 2,
may also prove beneficial in circumstances where NO therapy requires deeper
penetration of tissues. The use of diazeniumdiolate substrates, which are benign if
nitrosated, are a potential solution to the use of diffusible NO donors in these
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materials and the PROLI/NO compound is one such example that uses proline, a
common amino acid residue, as the nucleophile adduct. The use of pendant side
chains that vary in length and can incorporate 'protecting' groups that are required to
be conformationally changed to allow release of the NO moiety. Such methods have
been shown to alter the availability of the NO donor compound for reaction and this
subsequently influences the NO release kinetics. For example, the release of NO
from a diazeniumdiolated poly(vinyl chloride) (PVC) synthesised using the 0(2)-
alkylated diazeniumdiolate of piperazine as a linker, was shown to be very slow due
to the slow rate of hydrolysis of the 0(2)-protecting group (Frost et al., 2005). As
well as the method of preparation, the variety of polymer used can also impact NO
storage and release capacities. There are hundreds of commonly used polymers with
ranging porosity and/or hydrophobicity which can be utilised to develop materials
that release NO for a wide range of time periods. Biodegradable polymers have also
been considered (Chaux et al., 1998). Polymer filler particles, such as
polyethyleneimine (PEI) microspheres and fumed silica particles that can be
entrapped in the pores of the polymer have also been used as carriers of
diazeniumdiolate compounds (Pulfer et al., 1997; Zhang et al., 2003). The
investigation of a diverse range of materials with an equally diverse range of NO
releasing capacities provides promising avenues of research for the outcome of
providing the long-awaited, successful use of diazeniumdiolates in a clinical setting.
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Figure 1.12. Representation of the different methods NONOate compounds can be
incorporated into polymer matrices. Adapted from Smith et al. 1996.
1.1.9.2 S-NITROSOTHIOL BASED NO-RELEASING POLYMERS
S-nitrosothiol based NO-releasing polymers release their NO-moiety via 3 different
mechanisms. Copper mediated decomposition requires Cu(II) to be reduced to
Cu(I), which then reacts with the S-nitrosothiol to release the NO moiety. The
endogenous presence of ascorbate and free thiolate in the body is sufficient to reduce
Cu(II) to catalyse the decomposition of S-nitrosothiols, however the reaction of S--
nitrosothiols with high mM concentrations of the reducing agent ascorbate can
directly release NO with the formation of free thiol and dehydoascorbate. The third
mechanism is homolytic cleavage of the S-NO bond by light, releasing NO and
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producing disulphide bonds from the substrate thiols (Seabra et al., 2005). The light
capable of producing this effect is in the range of 330-350nm and 550-600nm.
Several polymers have been developed which incorporate covalently linked S-
nitrosthiol compounds to the polymer backbone to prevent leaching of the donor or
its by-products (Shishido & de Oliveira, 2000; Shishido et al., 2003). The S-
nitrosothiol compounds can also be blended into the polymer matrix or, like the
diazeniumdiolates, can be tethered to surface of polymer fillers (Frost & Meyerhoff,
2005). The fundamental limitation of the development of non-covalently linked S-
nitrosothiol based polymers, is the potential leaching of the water-soluble S-
nitrosothiol or its by-products, a situation that would be exacerbated under
physiological flow conditions. As with the diazeniumdiolate-based polymers, the
ability to produce a range of materials with a range of NO release capacities exists.
The light sensitivity of S-nitrosothiol decomposition provides a unique approach to
the regulation and activation ofNO release from these polymeric materials. Work by
Etchenique et al demonstrated a photoinitiated release of NO from monolayers of
nitrosated dithiothreitol attached to gold surfaces (Frost et al., 2005). The flux of
NO could be increased with the use of increasing power of the light illuminating the
surface. The desirable temporal and spatial control ofNO release was limited in this
study due to the small initial reservoir of NO available in the monolayers. Indeed,
the initial NO reservoir is the major limiting factor for the development of all NO
releasing materials which at present can only sustain NO fluxes for hours to days.
More durable and longer lasting NO release capacities are required for more
permanent fixtures such as vascular grafts and stents which would benefit from NO
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release throughout the life-time of the device (weeks to years). The potential answer
to this lies in utilising endogenous nitrite or S-nitrosothiol in the blood for catalytic
reduction to NO through contact with copper complexes embedded in lipophilic
materials (Oh & Meyerhoff, 2004, 2003). These materials rely on sufficiently high,
endogenous levels of reducing agents such as ascorbic acid, cysteine or glutathione
for the catalytic reduction of Cu(II) to Cu(I). Ascorbic acid is readily given in
Vitamin C supplements and could easily be used in parallel with such materials to
aid in the continual reduction of Cu(II) and continual production of NO from the
surface of the materials. Free thiols immobilised in polymers have also been shown
to generate NO through exchange reactions with circulating nitrosothiols such as S-
nitrosoalbumin, which then spontaneously decomposes to release NO (Duan &
Lewis, 2002; Gappa-Fahlenkamp et al., 2004; Gappa-Fahlenkamp & Lewis, 2005).
The decomposition of the S-nitrosothiol at the surface of the material leaves behind
the original immobilised thiol, which can go through the same reaction, thereby
producing NO indefinitely. An L-cysteine immobilised on the surface of such a
material has shown to release physiologically relevant levels of NO capable of
inhibiting platelet adhesion in vitro (Duan & Lewis, 2002).
1.1.10 BIOLOGICAL APPLICATIONS OF NO-RELEASING
MATERIALS.
The controlled, localised delivery of NO might constitute the magic bullet in the
development ofNO based therapeutic for some applications. The diverse targets of
NO in the body and the development of materials with wide-ranging NO release
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capacities has potential for use in many biological applications. Such applications
for these materials include; anti-thrombotic surfaces for blood contacting medical
devices, wound healing promoters/dressings and antimicrobial agents.
1.1.10.1 BIOCOMPATIBLE COATINGS FOR MEDICAL DEVICES
Medical devices that come into contact with blood (cannulae, catheters, coronary
artery and vascular stents, vascular grafts, extracorporeal loops and renal dialysis
equipment) can promote thrombus formation at the surface that can both interfere
with the working of the instrument and have the potential to cause severe
complications for the patient. There is a current requirement for aggressive systemic
anti-coagulant treatments in patients undergoing interventional procedures, however
the use of such agents comes with risks, especially haemorrhage, which can be fatal.
The production of biocompatible coatings that can bypass the need for systemic anti¬
coagulants, and are able to resist thrombus formation are a very desirable prospect.
The potent anti-platelet effects of NO make it a good candidate for anti-thrombotic
coatings, as does its short half life in vivo, which provides an unrivalled localised
action and should avoid unwanted systemic side effects. Further to this, the
beneficial effects of NO on inhibition of inflammatory cell activation and smooth
muscle proliferation make it even more attractive for use on deices, which are
associated with vascular insult. Vessel damage caused by balloon angioplasty is
known to trigger smooth muscle proliferation and result in narrowing of vessels
caused from neointimal hyperplasia (Holmes, 2001). Restenosis of vessels following
this procedure is a significant problem, with 20-30% of all stent implant sites
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showing stenosis with the need for repeat angioplasty treatment within 1 year (Pearce
& McKinsey, 2003). The mechanisms of restenosis and subsequent stent failure are
related to smooth muscle proliferation and migration occluding the lumen of the
vessel (Hamon et al., 1998). Current drug-eluting stents (DES), which incorporate
drugs into the stent coating, have shown to be successful at reducing restenosis
compared to bare metal stents (Cheng-Lai & Frishman, 2004; Htay & Liu, 2005;
Thanigaraj et al., 2006; Young, 2007). However, the long-term efficacy of these
stents is unknown. Late adverse effects include aneurysm formation and
hypersensitivity reactions, as well as subacute and late stent thrombosis requiring
compliance with anti-platelet therapy for extended periods of time (Gurbel et al.,
2007; Stabile et al., 2004; Virmani et al., 2004). It is suggested that DES, which
inhibit smooth muscle cell proliferation and migration also inhibit the long-term re-
endothelialisation of the surface of the material which reduces its biocompatibility
compared to bare metal stents in longer time-scales (Luscher et al., 2007). NO-
releasing polymers have been proposed as suitable candidates for stent-based
therapies, which inhibit thrombosis, neointimal hyperplasia and promote re-
endothelialisation (Sarkar et al., 2006). Animal models of stent based NO-delivery
has already shown to be effective at reducing the incidence of neointimal hyperplasia
in a pig carotid artery overstretch model (Hou et al., 2005; Yoon et al., 2002),
reducing thrombus formation in a sheep model of arteriovenous bridge grafts (Fleser
et al., 2004) and limiting restenosis in a rabbit model (Do et al., 2004).
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1.1.10.2 ANTI MICROBIAL AGENTS
Medical devices, especially urinary catheters, contribute to a large proportion of
nosocomial infections, which are a significant cause of morbidity and mortality
within immuno-compromised, hospitalised patients (Karchmer et al., 2000; Warren,
2001). Furthermore, infections acquired due to device placement increases the
duration of hospitilisation and therefore impact unfavourably on healthcare budgets
(Plumridge & Golledge, 1996).
The liberation ofNO from polymer materials has shown to increase biocompatibility
of medical devices as anti-infective coatings. A range of experiments has
demonstrated reduced bacterial adhesion onto NO-releasing polymer materials
compared to the NO-free controls (Nablo et al., 2001; Nablo et al., 2005a; Nablo et
al., 2005b; Nablo & Schoenfisch, 2004). Susceptibility to the anti-adhesive
properties ofNO-releasing polymers varies considerably between different strains of
bacteria. Furthermore, the anti-adhesive properties of NO-releasing polymers,
although significant, have not shown complete resistance to colonisation by any
bacterial strain studied. The reduced ability to adhere is not the only factor in
bacterial virulence. Many device-associated infections result from the introduction
of pathogens from external sources, which can migrate to tissues independent from
the area of device placements (Pittet et al., 1999). Thus, a direct bactericidal effect
would be more favourable, especially when considering the limited NO reservoirs
stored by polymer materials, which when exhausted, provide no protection against
bacterial colonisation. Currently, device-associated bacterial infections are treated
with antibiotics. Given the worrying increase in antibiotic resistant strains of
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bacteria, particularly within hospital environments, alternative protocols are urgently
required to manage device-associated infections. NO and NO-related species have
demonstrated microbicidal effects against various pathogenic organisms (Ascenzi et
al., 2003; Coban et al., 2003; Karupiah & Harris, 1995; McMullin et al., 2005;
Rementeria et al., 1995). Current NO-release polymers have not demonstrated
microbicidal effects most likely due to low fluxes of NO that are in the picomolar
range. Thus, higher capacity NO-releasing materials may provide better protection
against device-associated infections, although NO-related toxicity to host tissue
would be a concern (Nablo & Schoenfisch, 2005).
1.1.10.3 WOUND HEALING PROMOTORS
NO has been proposed to be involved in wound healing (see section 1.1.6.3). The
use of NO in wound dressing to promote healing has become possible using NO-
releasing polymers and gels, which deliver NO topically at the site of the wound.
Accelerated wound repair was demonstrated in rat cutaneous wounds using an S-
nitrosoglutathione-containing hydrogel material and polymers incorporating
NONOate compounds (Amadeu et al., 2007; Shabani et al., 1996) Topical NO-
release for diabetic wound healing has received particular attention due to the
difficulty associated with skin healing in these patients. Animal models of impaired
healing have also shown benefits from NO-supplementation from engineered
dressings (Masters et al., 2002). Promising results from animal models have resulted
in recent human trials using NO-releasing dermal patches for the treatment of




Zeolites are naturally occurring and synthetic aluminosilicate crystalline structures
endowed with unique adsorptive, ion exchange, gas storage and catalytic properties
that have multiple uses in industrial, agricultural and medical applications. Hundreds
of zeolite structures exist, with unique pore sizes and physiochemical properties.
These materials are often referred to as "molecular sieves" due their ability to
separate molecules depending on their size, shape or isoelectric point (pi). The ion
exchange properties of these materials are most notable in the washing powder
detergent industry where the act to soften the water through the release of zeolite
bound alkali metals, such as potassium or sodium in exchange for "hard" ions such
as calcium and magnesium from the water. It is in this arena that zeolites are
produced in 1M tonne quantities annually. Ion-exchange properties of zeolites have
also been utilised to clean-up polluting metal ions and nuclear isotopes from
industrial waste effluent and fall-out (Hui et al., 2005; Mumpton, 1999). The
adsorptive properties of zeolites are further utilised for environmental benefit in the
removal of atmospheric pollutants (eg NO(X)) from exhaust fumes (Gomez-Garcia et
ah, 2005; Rudolf et ah, 2002; Sultana et ah, 2000). The catalytic properties of
zeolites also have indirect benefits on the environment due to their ability to improve
energy efficiency of chemical reactions, for example in petroleum refining
(Mumpton, 1999). Indeed, the majority of zeolite applications have been spawned
from environmental concerns. Currently, the hydrogen gas storage abilities of these
structures are being investigated in an attempt to provide more environmentally
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friendly energy sources to replace wasteful and toxic electrochemical fuel cells (Li &
Yang, 2006; Regli et al., 2005; Rosi et al., 2003).
In this thesis, the zeolite structure Linde Type A (LTA; figure 1.13) has been chosen
for modification to produce NO-storing and release materials for use in biological
settings. Cations are exchanged in to the structure to replace sodium so as to
increase the storage capacity for NO, a technique employed to increase the
absorption capacity of zeolites for toxic NOx from exhaust fumes (Sultana et al.,
2000).
Figure 1.13. Structural representation of zeolite Linde Type-A (LTA).
Figure from the database of zeolite structures, http://www.iza-structure.org/databases/
1.2.1 ZEOLITES IN MEDICINE
Several applications for zeolites exist in the medical arena. These molecular sieves
are used in filtration systems for anaesthesia to capture exhaled anaesthetic and
provide protection from the potent effects of these drugs to surrounding surgical
personnel (Boranic, 2000; Doyle et al., 2002; Janchen et al., 1998). Zeolites are also
incorporated into dialysis systems as filtration materials and as contrast materials in
NMR imaging (Boranic, 2000). Zeolites are also utililised as hemostatic agents in
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emergency field medicine. The success of these materials has resulted in the FDA
approval of Quikclot®, a zeolite incorporating hemostatic dressing, which improves
the coagulability of wounds due to the filtration of water molecules from the blood,
leaving the larger platelets and clotting factors at the wound site in concentrated
amounts (Gurdeep et al., 2006). However, similar dressing have resulted in thermal
injury due to the exothermic reaction related to the powerful desorption of water at
the wound site (McManus et al., 2007; Wright et al., 2004).
As well as the external uses, zeolites have potential in internal therapies as delivery
agents. Vitamins (Boranic, 2000) , antioxidants (Ivkovic et al., 2004) and drugs have
been loaded into encapsulated zeolite materials for delivery in the gastrointestinal
tract. Anthelmintic drugs have shown improved efficacy in animal models due to
slow release kinetics achieved from drug-loaded zeolite materials (Dyer et al., 2000).
The low solubility of these materials at physiological pH means that internal delivery
would be on a par with clay-eating, a commonly used therapy (Boranic, 2000).
However, potential detrimental side effects from ion exchange, including changes in
pH, effects on bacterial flora and possible cytokine release needs better
characterisation in animal models. Interestingly, the immune stimulatory effects of
zeolite powders have shown anti-metastatic effects in cancer cell lines and animal
models of cancer. This has been attributed to the ability of the powder to stimulate
expression of tumor suppressor proteins and inhibit protein kinase pathways, thereby
limiting tumor growth (Pavelic et al., 2001). The applications described involve the
use of pure zeolite materials, most commonly found in powdered form. The
tethering of zeolites onto medical grade devices as a mixture with commonly used
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polymers might therefore bypass the stimulation of inflammatory responses seen
with powdered formulations and provide a unique method for the use of zeolites in a
clinical setting.
1.2.2 NO-LOADED ZEOLITES
The use of zeolites as NO gas storage materials requires the structure to contain
transition metal ions, which have a high affinity for NO. The structure is such that
one molecule of NO can bind to each metal ion within the structure. This capacity
for NO storage in these zeolites is remarkable at up to lmmols of NO per mg of
zeolite (Wheatley el al., 2006). The delivery ofNO from zeolite structures occurs on
contact with aqueous media through the displacement ofNO by H2O. Thus, zeolites
provide a simple mechanism for NO delivery, which does not require chemical
decomposition or the presence of reducing compounds such as thiols. Furthermore,
zeolites are highly tunable compounds with the scope to optimise NO storage and
release properties through very easy adjustments to various aspects of zeolite design.
For example, the transition metal exchanged in the structure has an impact on the
amount of NO stored, likely due to alterations in pore size through electrochemical
interactions of the ions with the zeolite structure as well as the chemical attraction of
the metal for NO itself. Zeolites used in this thesis are bound in a polymer to make a
more robust structure for use in biomedical applications. The choice of polymer, of
which there are many, may also have an impact on NO storage and release. The
hydrophobicity of the polymer material may limit the H2O reaching the zeolite
thereby acting to limit and prolong the release ofNO from the structure, particularly
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beneficial for applications that require small fluxes of NO release over long periods
of time such as stent coatings. To this end, changing the composition of zeolite with
the polymer binder also provides an easy way to manipulate the amount of NO
present in the original reservoir and therefore limit or increase the total amount of
NO released. The production of NO-loaded zeolites has benefits over similar NO-
releasing materials, which require multi-step processes involving high pressures,
high temperatures or a low pH environment for the efficient loading of NO to the
structure. The stability of zeolites at room temperature also holds benefits over other
NO releasing materials which not only require argon storage but freezing
temperatures to remain stable (Robbins et al., 2004). Thus, zeolites provide an
affordable, dynamic and simple means by which NO can be stored and released for a
wide range ofbiological applications.
Figure 1.14. Structural representation of NO-storing Co2+-exchanged zeolite. Wheatley
et al. 2006.
Structure of the cobalt-NO complex in LTA zeolite. The cobalt is bound to three oxygen
atoms of a six-ring unit in the zeolite framework and bond to nitrogen of a bent mononitrosyl







1.3 PROJECT AIMS AND HYPOTHESES
The aim of this thesis is to characterise and optimise the first prototype NO-loaded
zeolite designs in biological experiments that assess the functional activity of these
materials in in vitro assays relevant to the development of zeolites as biocompatible
coatings for medical devices. Assays include platelet aggregation, neutrophil
activation and bacterial growth to assess the potential anti-thrombotic, anti¬
inflammatory and microbicidal properties ofNO released from zeolite materials. In
concert with these experiments, NO-loaded zeolites were investigated as novel tools
with which to investigate various aspects of the mechanism of action ofNO.
Thus, the hypotheses for this study are as follows:
1. NO-loaded zeolites are high capacity storage materials of NO with tunable
properties that allow NO-storage capacities to be easily altered.
2. NO-loaded zeolites are powerful inhibitors of collagen-induced platelet
aggregation in human platelet samples and are thus, suitable candidates for
the development of anti-thrombotic coatings for medical devices.
3. NO-loaded zeolites will stimulate NO-mediated sGC-independent
mechanisms in platelets and smooth muscle due to release of high
concentrations ofNO into the extracellular environment.
4. NO-loaded zeolites will produce either pro or anti-inflammatory actions in
human neutrophils is dependent on the concentration of NO exposed and
activation status of the neutrophil.
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5. NO-loaded zeolites can induce bacterial killing in Gram-negative and Gram-
positive bacterial strains due to release of high concentrations ofNO and are
thus suitable candidates for the development of anti-infective coatings for
medical devices.
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Chapter 2-Methods and Materials
2. Methods
2.1 Platelet Aggregation Studies.
2.1.1 Preparation ofPlatelet Rich Plasma (PRP)
Peripheral venous blood was drawn from the antecubital fossa of healthy human
volunteers aged 18-64. All volunteers were non-smokers and had not taken any
NSAIDs or other drugs known to affect platelet function within the past 10 days.
Blood was collected in 50ml polypropylene (BD Falcon) tubes with sodium citrate
(final concentration 0.38%). Platelet rich plasma (PRP) was separated from the
erythrocyte/leukocyte layer by centrifugation (300g; 25 min) and was carefully
aspirated into polypropylene tubes (BD Falcon). Platelet poor plasma (PPP) was
obtained by further centrifugation of the PRP (1200#; 10 min) to pellet the platelets.
The PPP was aspirated from the platelet pellet. The platelet count in PRP samples
was determined using a Coulter Ac.T8 Haematology Analyzer (Coulter Electronics,
Luton, U.K) and standardised to 250 x 109/1 via dilution with PPP.
2.1.2 Preparation of Washed Platelets (WP).
PRP was obtained as described above. The platelets were washed by centrifugation
(1200g; 10 min) in the presence of 300ng/ml prostacyclin to prevent aggregation.
The plasma supernatant was aspirated from the platelet pellet and the platelets were
re-suspended in Tyrodes buffer (137mM NaCl, 2.7mM KC1 1.05mM MgSCfi,
0.4mM NaFEPCfi, 12.5mM NaFICCfi, 5.6mM Glucose, lOmM HEPES in FEO at pH
7.4). A further centrifugation (1200g; 10 min) was performed, again in the presence
of 300ng/ml prostacyclin. The supernatant was aspirated to remove any remaining
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traces of plasma and the platelets were finally re-suspended in Tyrodes buffer with
calcium (137mM NaCl, 2.7mM KC1, 1.05mM MgS04, 0.4mM NafUPC^, 12.5mM
NaHC03, 5.6mM Glucose, lOmM HEPES, 0.8mM CaCl in H20 at pH 7.4). WPs
were then incubated at 37°C for approximately 10 min before use to allow the
inhibition of platelet activation by prostacyclin to subside. The platelet count was
determined using Coulter Ac.T 8 Haematology Analyzer (Coulter Electronics, Luton,
U.K) and standardized to 250 x 109 /I via dilution with Tyrodes buffer.
2.1.3 Turbidometric PlateletAggregometry
Platelet aggregation was performed using a 4-channel optical platelet aggregometer
(Chronolog, Labmedics, Stockport, UK) and data were captured via an analogue-
digital converter (Maclab 4c, AD Instruments, Sussex, U.K.). Turbidometric platelet
aggregation was determined by measuring changes in light transmission through test
samples (PRP/WP) compared to a reference sample (PPP/Tyrodes buffer). The
equipment was calibrated such that the difference in light transmission prior to
aggregation between the test and reference sample was approximately 80 mV.
Platelet aggregation was stimulated in test samples (500ul; 37°C) using a
supramaximal concentration of collagen (2.5ug/ml). The samples were left for 5 min
with continuous stirring (lOOOrpm) to enable maximal aggregation to be reached.
Aggregation of the platelets caused a decrease in the voltage corresponding to the
increase in light transmission through the test sample compared to the reference
sample. The zeolite treatments were achieved by suspending the prepared zeolite
discs (see materials section 2.8.1) below the surface of the 500pl sample, ensuring
not to interfere with light transmission through the sample or the mechanical stirring.
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After variation of the incubation period (1-120 min; 37°C) aggregation was initiated
using collagen (2.5p.g/ml). Platelet aggregation in test samples was expressed as a
percentage of the maximum aggregation determined by stimulation of a control
sample plus the stainless steel wire device with 2.5pg/ml collagen at the
corresponding time-point.
75% Zn2+ NO-loaded
















Figure 2.1. Turbidometric Platelet Aggregation.
An example of turbidometric platelet aggregation traces showing the fall from baseline mV
values in control platelets (500pl; PRP) following collagen (2.5pg/ml) stimulation and the
inhibition of aggregation responses in platelets treated with NO-loaded zeolite (75% Zn2+;1
min pre-collagen stimulation). The decrease in voltage is due to activation and aggregation
of platelets allowing greater transmission of light through the samples. Maximum
aggregation is reached within 5 min post collagen stimulation.
2.1.4 Whole blood aggregometry.
Peripheral venous blood was drawn via the antecubital fossa from healthy, non¬
smoking human volunteers aged 20-65. All donors had not taken any platelet active
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agents in the past 10 days. Blood was collected into falcon tubes containing 1 OU/ml
heparin and gently mixed by inverting the tubes 2-3 times. Aggregation of whole
blood was investigated using a 2-channel Chronolog aggregometer (Chronolog,
Labmedics, Stockport, U.K.) and data captured via an analogue-digital converter
(Maclab 4e, AD Instruments, Sussex, U.K). Aggregation was determined using an
impedance electrode, which measures the change in impedance between 2 closely
located metal electrodes. A small electrical current is passed between the two metal
electrodes and on contact with blood, a monolayer of platelets coat the surface.
When an aggregating agent is added, platelets aggregate on the monolayer increasing
the impedance (electrical resistance) to the circuit. An increase in impedance is
measured as an increase in voltage on the data acquisition system. The electrodes
were calibrated such that maximal aggregation caused an approximate lOOmV shift
in baseline voltage. Aggregation was stimulated using a supramaximal concentration
of collagen (2.5pg/ml). Test samples were prepared as follows; the blood was
diluted 1:1 using phosphate buffered saline (PBS) and aliquoted into 1 ml samples in
a cuvette containing a magnetic stir bar. Samples were incubated at 37°C with
stirring (lOOOrpm) and the electrodes were allowed to reach a steady baseline before
stimulation of aggregation. Zeolite treatments were achieved by suspending the
discs in the whole blood using a stainless steel holding device and incubation times
were varied (1-60 min) before initiation of aggregation by the addition of collagen.
Aggregation was expressed as a percentage maximal aggregation of a control sample
plus the stainless steel holding device determined after stimulation with 2.5ug/ml
collagen at a corresponding time-point
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2.2 Platelet viability; Lactate dehydrogenase (LDH) assay.
Cytotoxicity of 50% Zn2+ zeolites (NO loaded and NO free) to platelets in PRP was
investigated using a cell viability measure (LDH) obtained from Roche Applied
Sciences (Penzberg, Germany). The test measures the activity of LDH released from
the cytosol of damaged cells into the supernatent using a colourimetric assay.
Quantification of LDH release is measured by exploiting a two-step reaction in
which LDH catalyses conversion of a tetrazolium salt to a coloured formazan salt
that absorbs light at 490 nm. Therefore, absorption at 490 nm is proportional to the
number of damaged cells. As the assay is colourimetric, the protocol needed to be
optimised to find a concentration of platelets in the PRP that gave adequate and
representative measures with positive and negative controls that were within the
range of the spectrophotometer. To achieve this, several dilutions of PRP (250 xlO9
platelets/ml) solutions were tested using a positive control containing 2% Triton X to
lyse the cells, negative controls consisted of PPP where the cells had been removed
by centrifuation (1200g; 10 min). It was found that a 1 in 2 dilution of a 250 x 109
platelets/ml (i.e 125 x 109 platelets/ml) preparation of PRP with Tyrodes buffer
contained adequate cell numbers with which to run the assay.
A 500pl sample of PRP (approx 63 x 109 platelets) was incubated with 50% Zn2+-
exchanged zeolites (NO-loaded and NO-free) at 37°C for 2 h. Aliquots (1OOptl) of
each treatment were diluted in lOOp.1 Tyrodes and plated in triplicate wells in a 96-
well, flat-bottomed microtiter plate. Treatments included NO-loaded and NO-free
zeolites, untreated PRP controls, PRP + 2% Triton X (positive controls) and PPP
background samples (negative control). The assay reaction mixture was added to
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each well and left for 30 min in the dark at room temperature. The plate was then
read using a Dynex MRX plate reader (Dynatech Laboratories, Chantilly, V.A.) at
490 nm with prior shaking for 15 s. The absorbance values for each treatment were
directly compared after subtraction of the background absorbance obtained from PPP
samples.
2.3. Detection of NO
2.3.1 NO electrode
The concentration ofNO released from different NO donors was investigated using a
2mm isolated NO electrode (ISO-NOP, World Precision Instruments, Stevenage,
U.K) and data captured using an analogue-digital converter (Maclab 4e, AD
Instruments, Sussex, U.K). The ISO-NOP electrode measures NO generation in
solution via electrochemical detection. The electrode comprises a robust working and
reference electrode within a stainless steel sleeve, which has a NO gas permeable
membrane.
Prior to use each day, the electrode was calibrated by the chemical generation ofNO
via the addition of sodium nitrite (0.32-50p,M) in a solution of 0.1M potassium
iodide + 0.1M sulphuric acid. This method of calibration is based on the following
reaction:
2NaN02 + 2KI + 2H2S04 -» 2NO + I2 + 2H20 + K2S04 + Na2S04
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A known concentration of NaNC>2 is added to produce NO. The KI and H2SO4 are
present in great excess and so the limiting factor for the reaction is NaN02. Since the
reaction goes to completion, the equation above states that the ratio between NaN02
and NO is 1:1. Therefore the amount ofNO generated in the solution will be equal
to the amount ofNaN02 added.
The electrode is placed in a cuvette with the calibration solution and allowed to reach
a steady baseline and then set to zero on the data acquisition system. A change in
current (pA) is observed when NO is oxidised at the electrode producing a redox
current. A calibration curve was generated via the cumulative addition of NaN02
(0.8pM-50p,M) in 1ml of the 0.1M KI + 0.1M H2SO4 (figure 2.2a). A linear
relationship between concentration of NaN02 and change in current amplitude was
observed. These data were plotted and a straight-line equation generated from which
concentrations of NO produced during experiments could be calculated (figure 2.2
B). NO electrode experiments were performed in a number of different media
including PRP, PBS, 5% LB broth:PBS, WP and isolated neutrophils (see section
2.5.1; 0.5-2ml) for various times (45-120 min). NO generation was investigated by
firstly allowing the electrode to reach a steady state in the media before the addition
of the NO donor. In the case of the zeolite treatments, the discs were suspended in
the solutions using a stainless steel holding device. Each sample was incubated at
37°C and contained a magnetic stir bar, which stirred the solution at lOOOrpm for the
duration of the experiment. Relevant time-points were selected for analysis and
traces ofNO release over time were plotted.
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Figure 2.2 NO Electrode Calibration.
An example calibration trace (A) and the corresponding graph (B). The cumulative addition
ofNaN02 is indicated by the arrows (pM).
2.4. Fixed Mount Myography
2.4.1 Preparation ofrat aorta rings
Male Wistar rats (Charles River laboratories, U.K.) were sacrificed by cervical
dislocation and the aorta harvested into physiological buffer solution (Krebs buffer;
118.4mM NaCl, 25mM NaC03, llmM glucose, 4.7mM KC1, 1.2mM MgS04,
1.2mM KH2PO4, 2.5mm CaCb). The tissue was cleaned of fat and adventitia to





Myography measures the change in smooth muscle tension through a tension
transducer connected to wire mounts. The wire mounts are positioned in the lumen of
the rat aorta ring and the vascular ring segments were allowed to equilibrate in
standard Krebs buffer (37°C; 15 min) under no resting tension. Pre-tension was
gradually applied over 30 min to 14mN. The change in smooth muscle tension
through the stimulation of smooth muscle contraction or relaxation can then be
detected when tension on the wire mounts is either increased or decreased. The
change in tension correlates with either an increase or decrease in voltage on the data
acquisition system. The myography set-up consists of 4 x 6ml heated tissue baths,
containing Krebs buffer. Each bath is constantly bubbled with Carbogen gas (95%
O2; 5% CO2) throughout the experiment.
Before use in the experiments, the vessels were left to equilibrate at 14mN tension
for approximately 1 h. The buffer in the tissue bath was then replaced with Krebs
solution containing 60mM of potassium chloride to contract the vessels. This was
performed 3 times with a wash out using normal Krebs buffer to allow the vessels to
relax back to baseline values. This step is performed to ensure the integrity of the
smooth muscle in each vessel with repeats to ensure the maximum contraction is
reached. All vessels were required to contract to a minimum of 9mN (~lg) before
use in the experiment.
For the investigation of the smooth muscle relaxing properties ofNO-loaded zeolites,
a dose/response experiment was firstly carried out each day using the smooth muscle
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constrictor phenylephrine (PE; InM -lp-M) in order to calculate the ECgo value for
the constriction (figure 2.3 A). The ECso concentration of PE was then used to pre¬
contract the vessels before the addition of any smooth muscle relaxants (figure 2.3
B). Relaxation of the vessels following the addition of acetylcholine (ACh) to pre¬
contracted vessels was performed to ensure the integrity of the endothelium. Zeolites
were placed into the tissue baths so that they were located at the far end of the bath,
at the opposite end to the gas inlet. All vessels were pre-treated with the NOS
inhibitor, N(G)-nitro-L-arginine-methyl ester (L-NAME) (lOOiiM) to prevent
endogenous production of NO. Parallel treatments using the soluble guanylate
cyclase (sGC) inhibitor, lH-[l,2,4]Oxadiazole[4,3-a]quinoxalin-l-one (ODQ;
20pM), and the NO scavenger oxyheamoglobin (Hb; 40pM) were performed to
further characterise the relaxant properties of the NO-loaded zeolites. ODQ was left






Figure 2.3. Representative myography traces; estimation of EC8o of PE (A) and
relaxation of smooth muscle by NO-loaded zeolite (B).
The dose/response trace of smooth muscle contraction by cumulative addition of PE (A),
showing the estimation of the ECgo concentration (red). The addition of PE (nM) is indicated
by the arrows.
Trace B is a representative trace showing smooth muscle relaxation following NO-loaded
zeolite suspension in a tissue bath containing a PE pre-contracted (ECso concentration;
approx 300nM) rat aortic ring.
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2.5 Flow cytometry
2.5.1 Isolation ofhuman neutrophils.
Human neutrophils were isolated from peripheral venous blood drawn from the
antecubital fossa of healthy human volunteers aged 20-64. All volunteers were non-
smokers and had not taken any NSAIDs in the past 10 days. Approximately 40ml of
blood was collected into 4 separate 50ml polypropylene tubes (BD Falcon)
containing sterile sodium citrate (0.38% final concentration). The PRP was
separated from the whole blood by centrifugation (350g; 20 min) and aspirated from
the leukocyte/erythrocyte-rich layer.
The leukocytes were then separated from the erythrocytes by the addition of 2.5ml of
pre-warmed (37°C), Dextran T500 (6%) per 10ml blood cell suspension. Each tube
was then adjusted to a 50ml volume with pre-warmed (37°C) saline solution (0.9%)
and left for no longer than 30 min to allow the erythrocytes to sediment. The upper
leukocyte-rich layer was then aspirated into 2 x 50ml polypropylene tubes (BD
Falcon), the volume was adjusted to 50ml with pre-warmed saline (0.9%) and the
cell pellet was obtained by centrifugation (350g; 6 min). The leukocytes were
further separated into sub-populations using Percoll gradients. Isotonic Percoll
solution was prepared as a 9:1 (v:v) ratio of Percoll: 10X phosphate buffered saline
(PBS) without calcium (Ca2+) or magnesium (Mg2+). This solution was then further
diluted with lx PBS (without Ca2+ and Mg2+) to obtain 55%, 68% and 81% isotonic
Percoll solutions. Discontinuous gradients were prepared by carefully layering 3ml
of 68% Percoll solution on top of 3ml of the 81% solution in a 15ml polypropylene
tube (BD Falcon). The leukocyte cell pellet was combined in 3ml of the 55%
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solution before being carefully pipetted on top of the 68% layer to complete the
gradients. The neutrophils were separated by centrifugation of the gradients (720g;
20 min; acceleration and deceleration 0). Following the centrifugation, neutrophils
were found at the 68:81% gradient interface and mononuclear cells were obtained
from the upper 55:68% interface (figure 2.4). The cells were carefully harvested
from the surrounding layers and washed twice in 1 x PBS without Ca2+ and Mg2+ by
centrifugation (220g; 6 min).
The cell yield was estimated using a bright line haemocytometer. An aliquot (lOpl)
of the cell suspension was placed under the cover slip and the number of cells in the
central 25 squares was counted by light microscopy (xlO magnification using xlO
eye-peice). The total number of cells was then estimated by multiplying back
through the appropriate dilution factors and the cells finally were washed (220g; 6
min) and resuspended in PBS with Ca2+ and Mg2+ at 5 million/ml for use in assays.
Cell purity was assessed by flow cytometry and samples were excluded if the
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suspended in PBS (50ml).
Figure 2.4. Schematic diagram of the separation and preparation of PRP, WP and
isolated neutrophils from whole blood and their use within this thesis.
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2.5.2 CDllb and CD62L labelled neutrophils.
The effect of NO-releasing zeolites on neutrophil activation markers was
investigated using flow cytometry. Flow cytometry is a method of characterising
individual cells based on their size, granularity and expression of cell markers using
fluorescent agents. Cell suspensions are passed through a laser beam and cells are
sorted according to the level of fluorescence and/or the resulting scatter profiles.
Neutrophils have a characteristic change in forward scatter (FS) following
stimulation with inflammatory mediators such as LPS or fMLP, which corresponds
to the change in shape observed when neutrophils are activated. Forward scatter is
therefore an indicator of cell shape and size. Side scatter (SS) is used as an indicator
of granularity; the greater the side scatter profile the more granular the cell. This can
be used to distinguish cell types such as the granulocytes from the mononuclear cells
(see figure 4.1). Cell surface changes can be detected by labelling surface markers
using fluorescent- conjugates of antibodies raised against them. In this assay, the
effect of Zn2+-exchanged zeolites (50% NO-loaded and NO-free) on CD62L
shedding and CDllb upregulation was investigated using anti-human CD62L-PE
and anti-human CDllb-FITC antibodies. The fluorescent conjugates on these
antibodies, phycoerythrin (PE) and fluorescein isothiocyanate (FITC) can be detected
through the FL-2 and FL-1 channels of the flow cytometer. The level of
fluorescence detected is proportional to the level of surface marker labelled which is
in turn dependent upon the activation status of the cell (Russell et al., 1998; van
Oostrom et al., 2004). CD62L is involved in low affinity rolling adhesion
interactions at the endothelial surface while CDllb is a marker associated with
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neutrophil adhesion to endothelial cells at sites of inflammation (see section
1.1.6.2.1).
The samples for flow cytometric analysis were prepared as follows. The zeolites
were incubated in 1ml of neutrophils suspended in PBS with Ca2+ and Mg2+ (5
million/ml; 37°C) for 60 min with stimulation of the cells using the formylated
peptide N-formyl-MET-LEU-PHE (fMLP; 10"7M) at 30 min or fMLP vehicle (PBS)
for unstimulated controls. The antibodies (BD Biosciences; 6pl) were incubated in
200pl samples of the neutrophil suspension for 30 min at 4°C before analysis by
flow cytometry. Flow cytometric analysis was performed using a Coulter
FACSCalibur flow cytometer (Beckman Coulter, California, USA) and data were
captured using EXPOIM 32 v 2.1 analysis software (Beckman Coulter, California,
USA).
2.5.3 Neutrophil viability assay; Annexin-V/Propidium iodide (PI)
staining.
Flow cytometry was also used to investigate the effect of neutrophil viability after
treatment with zeolites using an Annexin-V/PI assay. Annexin-V binds to
externalised phosphatidylserine residues on the outer leaflet of the plasma membrane
of cells undergoing apoptosis. The Annexin-V for the assay is conjugated to a FITC
fluorochrome (Sigma Aldrich), which binds to exposed phosphatidylserine via a Ca2+
dependent mechanism. Apoptosis is therefore directly related to the fluorescence of
the FITC-conjugate, as measured by flow cytometry through the FL-1 channel. Cell
death is quantified using propidium iodide (PI) staining, a membrane impermeable
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nuclear stain. Only cells with compromised plasma membranes (i.e necrotic cells)
will allow the stain to reach the nucleus. PI fluorescence, measured through the FL-2
channel, together with Arrnexin-V positivity (FL-1 positive cells) can therefore be
used to quantify cell death in a population.
The samples for Annexin-V/PI staining were prepared as follows; post zeolite
treatments (see above), a 20pl sample of the neutrophil suspension (5million cells/ml
in PBS with Ca2+ and Mg2+) was taken and incubated (4°C; 10 min) in FITC-
conjugated Annexin-V in PBS solution containing 5 mM CaCl2. Following the 10
min incubation, the Annexin-V labelled cells were stained with PI (2pg/ml final
concentration) 1 min prior to analysis by flow cytometry. Flow cytometric analysis
was performed using a Coulter FACSCalibur flow cytometer (Beckman Coulter,
California, USA) and data were captured using EXPO™ 32 v 2.1 analysis software
(Beckman Coulter, California, USA). Apoptosis and necrosis was measured as a
percentage of total gated cells that were Annexin-V positive (FL-1) and Annexin-
V/PI positive (FL-1 and 2) respectively. Cells negative for both markers were
considered healthy.
2.5.4 Cytocentrifuge Preparations
Cytospins of cell populations (figure 5.1) isolated from whole blood were prepared
using 100pi of the cell suspension + 10% autologous serum. The suspension was
centrifuged (300rpm; 3 min) through filters onto glass slides. The cells on the slide
were allowed to dry at room temp and then stained in methanol (1 min), Quik-Diff
Red® (lmin) and Quik Diff-Blue® (1 min) and then washed in FLO. Cells were
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analysed for cell purity using light microscopy through an oil immersion lens (X250
magnification).
2.6. Bacterial Culture
Bacteria were cultured on a nutrient broth agar Luria-Bertani (LB) at room
temperature. Bacterial suspensions were prepared by inoculating 10ml of LB broth
with one colony of relevant bacteria and incubating overnight at 37°C in an orbital
shaker. Bacteria were sub-cultured with a 1/100 dilution of the original bacterial
suspension and incubated for 3 h to ensure experiments were conducted when
bacteria were in the exponential growth phase. The bacterial killing assays required
the bacteria to be suspended in a lower concentration of the nutrient broth solution to
control the bacterial growth rate throughout the experiment. The bacterial
suspension was washed by centrifugation (3000rpm; 15 min) and the bacterial pellet
was resuspended in a 5% solution of LB broth in PBS. This step was then repeated
once more to ensure adequate washing of the cells. The suspension was standardised
via dilution with 5% LB:PBS to an optical density (OD) of 0.1 at 595 nm using
spectrophotometry (UV1101, WPA Biochrom Ltd, Cambridge, UK). A 1 in 1000
dilution of this solution (5% LB:PBS) was used for the bacterial killing assays.
Bacterial killing was investigated in varying volumes (150-1200p,l) of a 1/1 dilution
of the bacterial suspension prepared above. Dilutions were done using 5% LB in
PBS solution. The treatments (zeolites and control) were carried out at 37°C on a
heated block with shaking at 400rpm for varying times between 2-120 min. For each
treatment, the number of viable bacteria was estimated by plating out dilutions of the
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• • • • 2 3bacterial suspension on LB agar plates in triplicate at 10" , and 10" . The plates were
left to incubate at 37°C overnight at 5% CO2 for approx 16 h and the number of
colonies formed were counted. The number of bacteria present in the suspension
post-treatments was estimated, assuming that 1 colony arises from a single
bacterium. The number of bacteria at time zero was also estimated each day.
Bacterial numbers from treatments were compared as a percentage of bacteria
estimated at t=0.
2.7 Statistics
Data were analysed using GraphPad Prism Version 4.0b. Statistical analysis was
performed using either one-way or two-way ANOVA with Bonferroni's or Dunnett's
post hoc test. Where appropriate, significance was confirmed using a non-parametric
Kruskall-Wallis test with Dunns post hoc test. Significance was indicated when p <
0.05 at a 95% confidence interval.
2.8 Materials
2.8.1 Zeolite materials.
These compounds are covered by a worldwide patent No.WO 2005/003032.
Zeolite discs were synthesised by Dr P.S Wheatley, Dr B Xiao and Prof. R.E Morris
at the University of St. Andrews. Briefly, cations (Zn2+ and Co2+) were exchanged
into sodium-LTA zeolite using solutions of zinc or cobalt-acetate. Following
filtration, the zeolite was ground with either PTFE or PDMS at various weight
percentages (i.e 50% zeolite with 50% PTFE) and pressed into 5mm discs (~ 20 mg)
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under 2 tons for 30s. Discs were then dehydrated and exposed to 2 atm of a mixture
of NO and Helium (10% NO: 90% He) and stored under Argon in sealed Schlenk
tubes. NO-free zeolite discs were not exposed to NO and were stored in tubes under
normal atmospheric conditions.
2.8.2. Other reagents.
All other reagents were prepared supplied as follows;
Axxora Ltd (Nottingham, UK)
DEA/NO was diluted in 0.01M NaOH, aliquoted (10"2M) and stored (-20°C). Prior
to its use each day, DEA/NO was diluted in PBS (10-2 - 10~7M).
BD-Biosciences (Oxford, UK)
FITC- and APC-conjugated anti-human CD lib, PE-conjugated anti-human CD62L
and fluorescent isotypes (IgGl) were purchased from BD biosciences and stored
(4°C). All antibodies were used at 6qg/ml final concentration.
Becton Dickinson Falcon (Oxford, UK)
50ml Falcon tubes were supplied sterile.
Bibby Sterlin Ltd (Stone, Staffs, UK)
Bug plates were supplied sterile.
British Oxygen Company (Surrey, UK)
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Charles River (Kent, UK)
Wistar Male rats were housed and terminated according to The Animal (Scientific
Procedures) Act 1986 (UK Home Office).
Fisher Scientific (Loughborough, UK)
Triton-X 100.
DMSO.
Buffer salts, EDTA, NaOH, HC1.
General plastics.
GE Healthcare (Amersham, UK)
Dextran was prepared at 6% in 0.9% NaCl and stored (4°C). Percoll was aliquoted
(27ml) and stored (4°C). Gradients were prepared by diluting Percoll to 90% stock
using 10X PBS and further dilution was using lxPBS.
Labmedics (Manchester, UK).
Collagen was supplied at lmg/ml and stored (4°C).
Aggregation and NO-electrode cuvettes and magnets.
Sigma Aldrich, Poole, Dorset
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Bovine Heamoglobin (Hb). Met-hemoglobin was reduced to the ferro form by
sodium dithionite and excess dithionite removed by dialysis (Martin et al., 1985).
Aliquots (ImM) were stored (-20°C) for less than 1 month.
SNP was diluted in PBS and aliquoted (10"2M) and stored (-20°C). Stocks were
diluted (10"5 - 10~7M) with PBS prior to use each day and protected from light.
General lab solutions (PBS with and without Ca2+ and Mg2+).
fMLP was stored (-20°C) in aliquots (10"2M) diluted prior to use in PBS.
FITC-conjugated Annexin-V was stored (-20°C) in aliquots and diluted prior to use
in Annexin-V binding buffer (prepared as HBSS plus 5|aM CaCl2).
PI was prepared (lmg/ml in H20) and stored (4°C) in aliquots, in light shielded
containers.
General buffer reagents, KC1, NaCl, NaC03, KH2PO4, glucose were stored (room
temperature).
NaN02 was prepared (10"2- 10~5M) using H20 prior to use each day.
LB broth and agar was made up according to manufacturers instructions.
Heparin was prepared at lOOU/ml in PBS and stored (4°C).
Phenylephrine hydrochloride was stored (-20°C) and diluted in PBS (10~2-10~7M)
prior to use.
L-NAME was stored (-20°C) and diluted in PBS prior to use.
Tocris Cookson (Bristol, UK)
ODQ was diluted in DMSO, aliquoted (20mM) and stored (-20°C).
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CHAPTER THREE
Optimisation of zeolite design; potential in anti¬
thrombotic coatings for medical devices.
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Chapter 3.
Optimisation of zeolite design; potential in anti¬
thrombotic coatings for medical devices.
3.1. Introduction
The discovery ofNO as an endothelium derived relaxing factor (EDRF) in the 1980s
sparked a wealth of research focussed around the involvement of this ubiquitous
molecule in a range of biological effects. It is now apparent that this inorganic, free
radical is involved in a wide range of physiological and pathophysiological processes
including modulation of vascular tone (Moncada & Palmer, 1991; Radomski, 1995) ,
inhibition of platelet (Hogan et al., 1988; Radomski et al., 1987a, b, c; Vane et al.,
1990) and inflammatory cell activation (Granger & Kubes, 1994; Kubes et al., 1993),
modulation of immune responses (Albina & Reichner, 1998; MacMicking et al.,
1997; Nicotera et al., 1995) and as a neurotransmitter in non-adrenergic non-
cholinergic (NANC) synapses. Despite increasing the knowledge ofNO physiology
and pathophysiology, the translation of massive research efforts into useful clinical
therapeutics has encountered substantial barriers. The widespread targets for NO in
the body mean that obtaining specific effects for therapeutic value is difficult. For
example, the systemic delivery of NO donors for anti-thrombotic purposes would
concurrently result in widespread vasodilation and hypotension, which can be
potentially fatal. The localised delivery ofNO to specific areas of need would avoid
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the problem of unwanted systemic side effects as the short half-life of NO in the
body ensures that effects are limited to the immediate locality of the site of release.
Harnessing the reactive NO radical for localised drug delivery has proved difficult
with currently available NO-donor compounds. The diazeniumdiolate NO donor
compounds consist of a diolate group [N(0-)N=0] bound to a nucleophile adduct (a
primary or secondary amine or polyamine) via a nitrogen atom. Many species of
these 'NONOate' compounds have been developed, so called due to the release of up
to 2 molar equivalents of NO per mole of compound. The NONOate compounds
liberate NO spontaneously, at physiological temperature and pH, with variable, yet
predictable, rates of NO release, that are dependent upon the structure of the
nucleophile adduct (Keefer et al., 2001). An added benefit of these NO donors is
that they do not require decomposition by biological tissues, thereby avoiding
development of tolerance associated with the most commonly used NO-based
therapeutic, GTN (Feelisch & Kelm, 1991; Feelisch et al., 1988). NONOate
compounds have proved beneficial in a number of animal models of vascular
diseases including pulmonary hypertension, erectile dysfunction, cerebral
vasospasm, yet these compounds are not used clinically (Megson & Webb, 2002).
Further characterisation of these compounds in biological systems is required in
order to fully evaluate their clinical usefulness and to establish the extent of the
problem posed through generation of potentially carcinogenic, nitrosamines
(Maragos et al., 1991). The development of NO therapy for anti-thrombotic and
anti-proliferative purposes has been a major focus for NONOate and S-nitrosothiol
compounds, particularly in an effort to improve outcomes following interventional
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procedures such as bypass grafting, balloon angioplasty and stent placement (Keefer,
2005, 2003; Sarkar et al., 2006).
The incorporation of NO donors into polymer or polymer-like matrices has gone
some way to avoiding the problem of localised NO delivery. Various groups have
demonstrated that the NONOate compounds can be covalently bound to a polymer
backbone and NO can be liberated upon contact with aqueous solutions, with the
effects persisting for hours to days (Mowery et al., 2000; Parzuchowski et al., 2002;
Smith et al., 1996). These NO-loaded polymers have proved efficacious in various
biological applications and show promise in the development of coatings for a wide
spectrum of blood contacting medical devices including extracorporeal loops, stents
and cannulae, all of which could benefit from increased biocompatibility achieved
from the inhibition of platelet and inflammatory cell activation and adhesion
(Mowery et al., 2000; Nablo et al., 2001; Pulfer et al., 1997; Schoenfisch et al.,
2000). In stent research, the multifaceted nature ofNO has additional benefits over
and above the anti-thrombotic properties due to its ability to reduce smooth muscle
proliferation, a major cause of vessel restenosis following stent placement (Hou et
al., 2005). At present, the major drawback to the translation of NO-loaded polymers
into the clinic is the duration of NO release, which would optimally be in the range
of weeks to years rather than the hours to days achieved to date. Furthermore, the
leaching of by-products from the polymer backbone is still a major concern. This
was shown in a study by Mowery and co workers, who demonstrated measurable
levels of nitrosamine following incubation of water-soluble diamine-based
diazeniumdiolate incorporating polymers (Mowery et al., 2000).
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NO-loaded zeolites provide a novel method for storing and releasing NO for
localised therapies that provides a direct source of NO radical, bypassing the
requirement for intermediate activation or cleavage mechanisms associated with
other NO-donating compounds (see section 1.1.8). Zeolites are micro-porous solids
that have impressive gas storing characteristics and are currently utilized in catalytic
converters to capture toxic oxides of nitrogen from exhaust fumes in the effort to
reduce air pollution (Sultana et al., 2000). The success of these zeolites as storage
materials for NO sparked an interest in zeolites as NO-storing and releasing
materials for use in biological settings. The exchange of sodium for transition metal
cations in the zeolite structure greatly enhances the binding capacity of the structure
for NO. The advantage of zeolites over other NO-polymers for NO storage and
release is the potential to tailor NO release capacities to specific requirements by
altering various aspects of zeolite design. These include changing the cation
exchanged in the zeolite structure, varying the composition of NO-loaded zeolite to
the polymer binder, changing the polymer binder itself and using different types of
zeolite, of which there are hundreds, each with unique structures. NO-loaded zeolite
materials liberate NO on contact with an aqueous solution, making them ideal
candidates for the development of anti-thrombotic coatings for blood-contacting
medical devices. Moreover, NO is directly displaced by H20 to liberate it from the
zeolite structure, thereby avoiding possible side-products associated with the zeolite,
assuming the zeolite structure remains intact. In this chapter, the NO-release
capacities, anti-platelet and smooth muscle relaxant effects of Zn2+ and Co2+-
exchanged Linde Type A (LTA) zeolites bound in various compositions of
polytetrafluoroethylene (PTFE) or polydimethylsiloxane (PDMS) polymer binder
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were investigated using in vitro techniques. These experiments will form the
primary optimisation of the first prototype zeolite designs for the potential
development of suitable anti-thrombotic coatings for blood-contacting medical
devices. Throughout these experiments, aspects of the mechanism of the anti¬
platelet and smooth muscle relaxant properties of NO-loaded zeolites were
investigated using ODQ, a specific inhibitor of sGC. The classical effects ofNO are
mostly achieved via the stimulation of sGC resulting in the up-regulation of cGMP
production and the subsequent decrease in intracellular calcium concentrations.
However, it is now apparent that NO can exert biological effects independent of
sGC, particularly in platelets (Crane el al., 2005; Sogo et al., 2000). In addition to
the excellent potential zeolites provide with respect to localised NO therapeutics,
these materials also offer a unique pharmacological tool with which to investigate
various aspects ofNO physiology.
Experiments in this chapter were designed to address the following hypotheses:
■ Zeolites are high capacity storage materials ofNO with tunable properties.
■ NO-loaded zeolites are powerful inhibitors of collagen-induced platelet
aggregation in human platelet samples and are thus, suitable candidates for the
development of anti-thrombotic coatings for medical devices.
■ NO-loaded zeolites will stimulate NO-mediated sGC-independent mechanisms in
platelets and smooth muscle in a concentration-dependent manner.
83
Chapter 3-Optimisation ofzeolite design; potential in anti-thrombotic coatings for medical devices
3.2. Materials and Methods
3.2.1 Zeolite materials.
Zeolite discs were synthesised by chemists at St Andrews University as described in
section 2.8.1. Zn2+ and Co2+-exchanged zeolites were used at compositions ranging
from 25-75% (weight ratio) of zeolite in polymer binder. Zeolite materials were
bound in PTFE polymer unless otherwise indicated. Zeolite:polymer materials were
loaded with NO gas, compressed into 5mm discs and stored under Argon gas until
ready for use. NO-free counterpart zeolite discs were used as zeolite controls where
stated.
3.2.2. Reagents and solutions
All reagents and solutions were purchased from suppliers and prepared for use as
described in section 2.8.2.
3.2.3. NO electrode
• • 2~b 21The concentration ofNO released from NO-loaded zeolites (Zn and Co ; 25-75%
in PTFE polymer binder) was investigated using a 2mm isolated NO electrode (ISO-
NOP, World Precision Instruments, Stevenage, U.K) and data captured using an
analogue-digital converter (Maclab 4e, AD Instruments, Sussex, U.K). The
electrode was calibrated prior to its use each day as described in section 2.3.1.
The electrode was left to reach equilibrium in 1ml of warmed (37°C) solution (PRP,
WP, whole blood, Tyrode's, PBS) prior to the addition of the zeolite disc. The
84
Chapter 3-Optimisation ofzeolite design; potential in anti-thrombotic coatings for medical devices
zeolite was suspended in the cuvette via a stainless steel holding device and the NO-
release was measured for 50-90 min. The solution was stirred using a magnetic stir
bar at lOOOrpm for the duration of the experiment. Time-points were chosen for
analyses ofNO concentration, which was calculated using linear regression obtained
during the calibration as detailed in section 2.3.
3.2.4 Platelet aggregation studies.
Samples of whole blood, PRP or WP were obtained and prepared as described in
sections 2.1.1-2.1.4.
Turbidometric platelet aggregation was carried using a 4-channel optical platelet
aggregometer (Chronolog, Labmedics, Stockport, UK) and data were captured via an
analogue-digital converter (Maclab 4c, AD Instruments, Sussex, U.K.). Samples of
PRP and WP were obtained as described in section 2.1.1-2.1.3. Zeolites were either
incubated in the platelet containing sample (PRP, WP; 500pl) for the full
experimental duration or were pre-incubated in the platelet-free solution (PPP or
Tyrode's) for the appropriate time prior to transfer to PRP or WP samples for 1 min
before collagen stimulation. Parallel experiments were incubated with ODQ (20uM)
where appropriate for at least 15 min prior to zeolite treatments. Haemoglobin
(10|xM) was added 1 min prior to zeolite treatments. After variation of the zeolite
incubation period (1-120 min; 37°C) aggregation was initiated using collagen
(2.5pg/ml).
Whole blood, impedence aggregation was carried out using a 2-channel Chronolog
aggregometer (Chronolog, Labmedics, Stockport, U.K) and data captured via an
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analogue-digital converter (Maclab 4e, AD Instruments, Sussex, U.K). Samples of
whole blood were collected and processed as described in section 2.1.4. Zeolites
2_|_ . . #
(50% Zn PTFE) were suspended in the sample (1ml) using a stainless steel metal
holding device and were incubated for 1-30 min prior to collagen stimulation
(2.5pg/ml). Samples were stirred at lOOOrpm using a magnetic stir bar for the
duration of the experiment. In all cases, aggregation was allowed to proceed for 5
min following collagen stimulation. Peak aggregation responses were noted and
compared as a percentage of control aggregation obtained from samples stimulated at
the appropriate time in the absence of zeolite.
3.2.5 Fixed wire myography; rat aortic rings.
Fixed wire myography experimental set-up was carried out as described in section
2.4. Vessels were pre-treated with the NOS inhibitor, L-NAME (200pM) to ensure
that no endogenous production of NO was involved in responses obtained. NO-
loaded Co2+-exchanged zeolites (75% in PTFE or PDMS polymer binder) were
placed in a 6ml (Kreb's solution) tissue bath containing a phenylephrine (PE; ECgo
concentration; see section 2.4) pre-contracted section of rat aorta. In parallel
experiments, ODQ (20pM) or Fib (40pM) was incubated in the tissue baths for 15
min and 1 min respectively before addition of zeolite discs. Relaxation of the aortic
ring was measured for approximately 40 min prior to zeolite suspension in the tissue
bath. Time-points for analyses were chosen and the relaxation was calculated as a
percentage of the ECgo tension response of the PE contracted vessel. The
mechanistic data (ODQ, Hb and NO-free zeolite controls) were analysed for peak
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relaxation responses and this value was calculated as a percentage of the pre¬
contracted tension response.
3.2.6 Platelet LDH release.
LDH release in PRP following 50% Zn2+-exchanged zeolite treatments (NO-free and
NO-loaded) was determined using a colourimetric assay as described in section 2.2.
Platelets in PRP (500pd; 125 x 109 platelets/ml) were treated with zeolites or control
(positive control-2% Triton X; negative control-PPP) for 2hrs at 37°C. Aliquots
(lOOpil) of each treatment were diluted in 100p.l Tyrode's and plated in triplicate
wells in a 96-well, flat-bottomed microtiter plates. The assay reaction mixture
(Roche Applied Sciences, Penzberg, Germany) was added to each well and left for
30min in the dark at room temperature. The plate was then read using a Dynex MRX
plate reader (Dynatech Laboratories, Chantilly, V.A.) at 490 nm with prior shaking at
for 15 s. The absorbance values for each treatment were directly compared after
subtraction of the background absorbance obtained from PPP samples.
3.3 Results
3.3.1. The NO-release capacities ofZn2+-exchanged zeolites.
The NO-release capacities of Zn2+-exchanged zeolites of varying (25-75%)
compositions of zeolite in PTFE polymer binder, suspended in PRP (lml; 37°C),
show an increase (figure 3.1 A) in NO release as the composition of NO-loaded
zeolite to PTFE binder is increased. The NO release capacities do not correlate
directly with the composition of zeolite as demonstrated by the NO release profile of
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the 50% zeolite (AUC=386.7 +/-195.9) which is more than double than that of the
NO released from the 25% zeolite composition (AUC= 42.6 +/- 12.8). The rate at
which NO is released from the 50% zeolite is considerably slower than that for 75%
zeolite, peaking at -30 min following suspension, as opposed to -10 min. NO stores
are exhausted to near baseline levels by around 60min in the case of 50-75% zeolites,
with the 25% zeolite composition showing undetectable levels ofNO by 40 min.
The NO-release profiles of 50% Zn2+ zeolites in Tyrode's solution (1ml; 37°C) had a
higher peak and more sustained release than that observed in PRP (AUC 673.5 +/-
83.5; figure 3.1 B;p< 0.05).
88
Chapter 3-Optimisation ofzeolite design; potential in anti-thrombotic coatingsfor medical devices
Figure 3.1 The NO-release profiles of Zn2+-exchanged zeolites.
The NO-release profiles of different compositions of Zn2+-exchanged zeolites;PTFE binder
in PRP (A; 1ml; 37°C) incubated for 90 min (25% - red line; 50% - green line; 75% blue
line) and the NO-release profiles of 50% Zn2+-exchanged zeolites in PRP (light green) and
Tyrode's solution (dark green) during 80 min incubations (B; lml; 37°C). Data points
represent the mean +/- the SEM of n=5-8 independent experiments (* p < 0.05; Two way
ANOVA).
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• 21
3.3.2. The NO-release capacities ofCo -exchanged zeolites.
NO-loaded Co2+-exchanged zeolites at 50 and 75% composition of zeolite to PTFE
binder have dramatically different NO-release profiles in PRP (1ml; 37°C; figure 3.2
A). The peak NO concentration from 75% zeolite reaches ~30uM compared to only
5pM reached by 50%. Area under the curve analysis further underpins the
difference in NO release between 50 and 75% zeolites with values of 68.3 +/- 19.6
and 599 +/- 189.2 respectively.
The suspension of the 75% zeolite disc in physiological saline solution (PSS; 1ml;
37°C; Figure 3.2 B) produced a rapid release of NO, peaking at - 30p,M within 1
min. Peak concentrations reach around 30pM within the first few minutes. A slower
release is observed in PRP with a similar peak concentration occurring after 20 min.
Levels of NO are still detectable and are comparable for both solutions by 50 min.
The total amount of NO released from the zeolite disc incubated in PSS is lower
(AUC 368.4 +/- 125.9) over the 50 min recording period than in PRP over the same
time (AUC 553.5 +/- 167.8).
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Time (min)
Time (min)
Figure 3.2 The NO-release profiles of Co2+-exchanged zeolites.
The NO-release profiles of different compositions (50%-orange; 75%-pink) of Co2+-
exchanged PTFE bound zeolites in PRP (A; lml; 37°C) for 90min. Comparison of the NO-
release profiles of 75% Co2+-exchanged zeolites in PRP (pink) and PSS solution (dark green)
for 50 min (B; lml; 37°C). Data points represent the mean +/- the SEM of n=5-6
independent experiments.
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3.3.3. The anti-thrombotic properties of Co2+-exchanged zeolites in
human platelets.
Co2-exchanged zeolite discs at compositions of 50 and 75% zeolite:PTFE binder
inhibited collagen-induced platelet aggregation at all time-points studied (1-120
min). The NO-ffee counterpart zeolite discs had no inhibitory effects on platelet
aggregation (figure 3.3). Interestingly, the 75% zeolite disc has a less powerful anti-
aggregating effect at lmin (approx 80% inhibition) compared to the 50% disc (100%
inhibition).
Co2+ 50% NO free
Co2+ 75% NO free
Co2+ 50% NO loaded
Co2+ 75% NO loaded
Figure 3.3. The anti-thrombotic properties of Co2+-exchanged zeolites in human
platelets.
The inhibition of collagen (2.5pg/ml)-induced platelet aggregation by 50% (orange) and
75% (pink) NO-loaded (filled triangles) and NO-ffee (empty triangles) zeolites incubated in
PRP (0.5ml; 37°C) for between 1-120 min prior to collagen stimulation. Data points
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3.3.4. The effect of two different polymer binders (PDMS and PTFE)
• 2+
on the smooth muscle relaxing properties of Co -exchanged
zeolites.
NO-loaded Co2+-exchanged zeolites in either PTFE polymer binder (75% zeolite:
25% polymer binder) relaxed pre-contracted rat aortic rings more rapidly and
potently than the same composition of zeolite in a PDMS polymer binder. Both
polymer bound zeolites relaxed the rings for approximately 40 min (figure 3.4 A).
The pre-incubation of the sGC-inhibitor, ODQ (20pM) had no significant effect on
the relaxation responses of both polymer bound zeolites although maximum
responses appear to be slightly reduced. The pre-incubation of the NO scavenger,
haemoglobin (40uM) did not significantly inhibit the relaxation produced by PTFE
bound zeolites but was able to significantly inhibit the response produced from
PDMS bound zeolites. NO-free zeolite counterpart discs did not produce any
relaxation effects in pre-contracted rat aortic rings (figure 3.4 B).
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75wt% Co 2+ Zeolites
■■ NO-loaded zeolite
■B NO-loaded zeolite + ODQ
I I NO-loaded zeolite + Hb
I I NO-free zeolite
Figure 3.4. The smooth muscle relaxing properties of Co2+-exchanged zeolites.
The duration of smooth muscle relaxation of PE pre-contracted rat aortic rings (A) following
suspension of NO-loaded Co2+-exchanged zeolites (75%:PTFE or PDMS polymer binder)
into the tissue bath (6ml; oxygenated PSS; 37°C). Relaxation is expressed as a percentage of
the value obtained from PE contraction of the ring and are the mean +/- SEM of n=7-8
independent experiments.
Graph B represents the maximum relaxation responses of rat aortic rings following NO-
loaded zeolite treatment alone (black), in the presence ofODQ (blue; 20pM), in the presence
of Hb (red; 40pM) and the NO-free zeolite control disc (white). Data are obtained using
75% Co2+ exchanged zeolites bound in either PTFE (pink) or PDMS (purple) polymers.
Data are the mean +/- SEM of 4-6 independent experiments. Asterisks denote statistical
significance from the appropriate NO-loaded zeolite treatment alone (* p < 0.05, ** p < 0.01
vs NO-loaded zeolite alone; one way ANOVA with Dunnet's post hoc).
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3.3.5. The anti-thrombotic properties of Zn -exchanged zeolites in
human platelets.
NO-loaded Zn2+-exchanged zeolites at compositions > 50% inhibit collagen induced
platelet aggregation for up to 80 min. The NO-free counterpart zeolites had no effect
on platelet aggregation (Figure 3.5A). The 25% NO-loaded zeolite produced varying
results on collagen induced platelet aggregation that correlated to two separately
produced sample batches with opposing effects on the inhibition of platelet
aggregation (Figure 3.5 B).
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25% Zn 2+ batch 1
■ 25% Zn 2+batch 2
Figure 3.5. The anti-thrombotic properties of Zn2+-exchanged zeolites in human
platelets.
The inhibition of collagen (2.5pl/ml) induced platelet aggregation by 25% (red), 50%
(green) and 75% (blue) NO-loaded (filled symbols) and NO-firee (empty symbols) zeolites
incubated in PRP (0.5ml; 37°C) for between 1-80 min prior to collagen stimulation. Data
points represent the mean +/- the SEM for n=6 independent experiments. Graph B shows the
inhibition of collagen-induced platelet aggregation by two separately produced batches of
the 25% NO-loaded zeolites. The symbols indicate the mean +/- the SEM of n=3 for each
batch.
96
Chapter 3-Optimisation ofzeolite design; potential in anti-thrombotic coatings for medical devices
3.3.6. The mechanism of anti-platelet action of NO-loaded Zn2+-
exchanged zeolites - inhibition ofsGC by ODQ (20pM).
NO-loaded zeolites and the NO-donor compounds, DEA/NO and SNP, composition
and concentration-dependently inhibit collagen-induced platelet aggregation (figure
3.7). NO-loaded Zn2+-exchanged zeolites at compositions >25% inhibit collagen-
induced platelet aggregation following lmin zeolite incubations (figure 3.7 A). The
addition of the sGC inhibitor, ODQ (20pM) had no effect on the inhibition of platelet
aggregation by 50 and 75% zeolite discs. The inhibition of platelet aggregation by
DEA/NO was significantly reversed by ODQ at the mid-range of DEA/NO
concentrations as indicated by the rightward shift in the log dose/response curve
(figure 3.7 B). Elowever, the inhibition of platelet aggregation by the highest
concentrations ofDEA/NO was not reversed by the addition of ODQ. The inhibition
of platelet aggregation by SNP was severely attenuated by the addition of ODQ
(figure 3.6 C).
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Figure 3.6. The mechanism of the anti-platelet action of NO-loaded Zn2+ exchanged
zeolites, DEA/NO and SNP; inhibiton of sGC by ODQ (20p.M).
The inhibition of collagen-induced platelet aggregation by various compositions (10-75%) of
NO-loaded Zn2+-exchanged zeolites (A) and log concentrations (-7 - (-)4M) of NO donors
DEA/NO (B) and SNP (C), in the absence (black) and presence (blue) of ODQ (20pM).
Data points represent the mean +/- SEM of n=6-8 independent experiments. Asterisks denote
statistical significance from the appropriate NO-donor in the absence of ODQ (* p < 0.05, **
p < 0.01, ***^> < 0.001; Two way ANOVA with Bonferroni's post hoc test).
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3.3.7. The mechanism of anti-platelet action of NO-loaded Zn2+-
exchanged zeolites - scavenging ofNO by Hb (1OpM).
Collagen-induced platelet aggregation is significantly inhibited following incubation
(lmin; 37°C) of NO-loaded Zn2+ exchanged zeolites at compositions > 50%. NO-
free counterpart zeolites had no effect on inhibition of aggregation. The addition of
the NO scavenger Hb, (lOpM), reversed the modest inhibition of aggregation by the
25% zeolite disc and significantly reversed the inhibition by the 50% zeolite (p <
0.05). The addition of Hb had no effect on inhibition of aggregation by the highest
composition (75%) of the NO-loaded Zn2+-exchanged zeolite disc.
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Figure 3.7. The mechanism of the anti-platelet action of NO-loaded Zn2+ exchanged
zeolites; scavenging of NO by haemoglobin (lOpM).
The inhibitions of collagen-induced platelet aggregation by various compositions (10-75%)
of NO loaded (black) and NO-free (dashed;A) Zn2+-exchanged zeolites in the absence and
presence (red) of Hb (10pM;B). Data points represent the mean +/- SEM of n=6-8
independent experiments. Asterisks denote statistical significance from NO-loaded zeolite
treatment alone at the appropriate zeolite composition (* p < 0.05, *** p < 0.001; Two way
ANOVA with Bonferroni's post hoc test.)
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• 2~I-
3.3.8. The mechanism of the anti-platelet action of NO-loaded Zn -
exchanged zeolites -pre-incubation ofzeolites in PPP/WP.
To investigate the potential of NO-stored plasma reservoirs on prolonged inhibition
of aggregation, WP samples were used. Pre-incubation of the zeolite disc in platelet
free medium, prior to the transfer of the disc to the platelet sample at the appropriate
time-point was also done to minimise the likely formation of plasma stores in PRP as
well as to investigate the anti-platelet effects of NO-released from the zeolites at
isolated time-points. The pre-incubation (l-80min) of 50% NO-loaded Zn7+ zeolites
in PPP or Tyrode's solution (0.5ml; 37°C) prior to transfer to PRP or WP (0.5ml;
37°C; lmin) for aggregation experiments demonstrated inhibition of collagen-
induced aggregation for the duration of the experiment (80 min) in both PRP and WP
(figure 3.7). The addition of the sGC inhibitor, ODQ (20pM) had no effect on the
inhibition of platelet aggregation at any time-point in PRP (figure 3.8 A) but
significantly reversed the inhibition of aggregation seen at the 80 min time-point
only in WP (p < 0.001; figure 3.8 B).
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Figure 3.8. The mechanism of the anti-plateiet action of NO-Ioaded Zn2+ exchanged
zeolites, pre-incubation of zeolite in PPP and Tyrode's.
The inhibitions of collagen-induced (2.5pg/ml) platelet aggregation by 50% NO-loaded
Zn2+-exchanged zeolites in PRP (A) and WP (B) following a pre-incubation period (1-80
min) in PPP or Tyrode's respectively before transfer of the disc (1 min) prior to stimulation
of aggregation in the absence (black) and presence (blue) of ODQ (20p.M). Data points
represent the mean +/- SEM of n=3-4 independent experiments. Asterisks denote
significance from NO-loaded zeolite treatment in the absence of ODQ at the corresponding
time-point (*** p < 0.001; Two way ANOVA with Bonferroni's post hoc test.)
PRP + 50% Zn 2+zeolite
PRP + 50% Zn 2++ ODQ
(20pM)
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3.3.9. The anti-thrombotic effects of NO-loaded 50% Zn2+-exchanged
zeolites in whole blood.
The inhibition of collagen-induced platelet aggregation following incubation (1ml;
37°C) ofNO-loaded 50% Zn2+ zeolites is markedly reduced compared to that seen in
PRP (figure 3.8) with a maximum of ~ 40% inhibition achieved at 1 min and
subsequent time-points showing a gradual reduction of the inhibition.




















Figure 3.9. Anti-platelet properties of 50% NO-loaded Zn2+-exchanged zeolites in
whole blood.
The % inhibition of collagen-induced (2.5pg/ml) platelet aggregation by 50% NO-loaded
Zn2+-exchanged zeolites in whole blood (1ml) following disc incubations between 1-30 min.
Data points represent the mean +/- SEM of n=6 independent experiments.
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3.3.10. Platelet viability following treatment with 50% Zn2+-
exchanged zeolites; LDH release.
PRP samples (500ptl; 125 x 109platelets/ml) treated with 50% Zn2+-exchanged zeolite
discs (NO-free and NO-loaded) for 2 h (37°C) caused no significant release of LDH
compared to control, untreated samples (figure 3.10). Significant release of LDH
can be observed upon treatment of PRP samples with the positive control (2%
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Figure 3.10. Platelet LDH release following treatment with 50% Zn2+-exchanged
zeolites.
Colourimetric assay determining LDH release from platelets in PRP (500pl; 125 x 109
platelts/ml) following control (white), 2% Triton-X (black) and NO-free (light green) and
NO loaded (dark green) 50% NO-loaded Zn2+-exchanged zeolte treatments for 2 h at 37°C.
Absorbance was measured at 490nm. Bars represent the mean +/- SEM of n=5 independent
experiments all done in triplicate. Asterisks denote significance from control (** p < 0.01;
one way ANOVA with Dunnetf s post hoc).
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3.4. Discussion.
3.4.1 The tunable NO-release properties ofNO-loaded zeolites.
Cation-exchanged zeolites are high capacity storage materials of NO with dynamic
properties that have the potential for tailored NO-storage and release according to
specific need. Results in this chapter demonstrate several ways that NO release
properties of zeolites can be altered. Firstly, the type of cation exchanged in the
structure was shown to impact on the amount of NO released. The NO-release
profiles of Zn2+ and Co2+ exchanged zeolites differed not only in quantity of NO
released but also in its rate of NO release. Furthermore, the composition of the
zeolite to the polymer binding material also changed the NO-release profiles of these
zeolites, which subsequently altered the biological effects produced. Low
compositions (10%) of zinc exchanged zeolites failed to inhibit collagen-induced
aggregation whereas high compositions (50-75%) consistently abolished platelet
aggregation for up to 2h. Interestingly, changing the composition of the zeolite in
the polymer did not predictably change NO-storage capacities of the materials. For
example, 50% composition of Zn2+ zeolite contained double the amount of potential
NO storing zeolite than the 25% composition, but the NO-release from 25% Zn2+
zeolites was almost 10 times less than that observed from the 50% zeolite. Zeolites
are stored under argon until ready for use and have been shown to reliably retain
their NO stores for a significant time-period (>16weeks;Wheatley et al., 2006). The
reason for the dramatic loss ofNO release from the lower compositions is not known
but it could be possible exclusion of water from the zeolite by the higher composition
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of hydrophobic PTFE polymer causes a substantial hindrance on NO-release from
the zeolite.
As well as duration, kinetics of release can also be important. Experiments in this
chapter have demonstrated how zeolite design influences NO release kinetics but it
was also evident that the surrounding media had an impact on NO release. This is
most obvious with the 75% Co2+ exchanged zeolite, which had a lag phase before the
rapid release of NO occurred at 10 min in PRP. In a physiological salt solution
(PSS), there was no lag phase and peak NO-release was achieved within the first 5
min. The answer to this change is differences in constituents of the solution. PRP
contains many large proteins, such as albumin, that could easily block the pores of
the zeolite material thereby slowing down the diffusion of H2O in, and NO out. The
50% Zn2+ zeolite did not show any lag phase in PRP compared to Tyrode's solution
and rate of release was similar in each solution (figure 3.1 B). The lack of any lag
phase in Zn2+ zeolites could be attributed to differences in pore sizes, which could
differ due to changes in electrostatic forces exerted on the zeolite structure from
different ions. Differences in these molecular forces may also explain the variation
in storage capacities of different ion-exchaged structures. Although rate of release of
NO from 50% Zn2+zeolites was unaffected by change in solution, lower peak NO
concentrations were released in PRP than in Tyrode's solution, providing further
evidence of how the aqueous media can impact NO release. The differences
observed here are most likely due to the presence of contaminating free haemoglobin
in PRP, reducing the NO signal in electrode experiments. Measurement of Hb
content in PRP has been done previously. This study demonstrated that
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approximately 0.35uM Hb can be found in PRP (Crane et al., 2005). A reduction in
'j i
NO concentration was not evident with the 75% Co zeolites in PRP compared to
PSS, although the much higher NO concentration released could make any small
scavenging effects appear negligible in this instance.
NO stores liberated from higher compositions of zeolite showed a great deal of
variation in total NO release, determined by NO electrode measurements, suggesting
that zeolite production techniques may influence the concentration of the NO
reservoir stored. Problems with NO storage in the 25% Zn2+ zeolite were especially
prominent in the functional platelet aggregation studies. Some discs were able to
abolish aggregation whereas others produced no effect at all (figure 3.5 B).
Standardisation of zeolite production techniques would be likely to help overcome
these issues for future research.
The concentration of endogenously produced NO required to inhibit platelet
aggregation in the body is very small (< nM). In our aggregation assay, the
concentration of NO released is in the micromolar range, far exceeding the
• 2"bconcentration required to produce effects in the body. However, the 50% Zn
zeolite, which was able to abolish aggregation in PRP and WP samples, showed
dramatically reduced anti-thrombotic effects in whole blood where NO is likely to be
quickly scavenged. There have been several groups working on different kinds of
NO-releasing polymer materials for the development of anti-thrombotic coatings
(Mowery et al., 2000; Oh & Meyerhoff, 2004; Reynolds et al., 2004; Schoenfisch et
al., 2000; Zhang et al., 2002). Many of these polymers have demonstrated fluxes of
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NO in the pico to nanomolar range that have still been capable of producing
biological effects in in vivo models (Schoenfisch et al., 2000; Zhang et al., 2002).
For stent or vessel graft-based materials, lower NO concentrations have been shown
to produce the beneficial anti-thrombotic and anti-proliferative effects (Annich et al.,
2000; Fleser et al., 2004; Hou et al., 2005; Zhang et al., 2002). Thus, although the
50% Zn2+ zeolite did not perform well in the whole blood aggregation study, this
does not best reflect the ability of the zeolite surface to remain free from adhering
platelets, the main end-point studied in NO-releasing polymer technologies. Further
studies are needed to quantify the anti-adhesive properties of the zeolite surface.
At present, the duration of NO release from zeolites is insufficient for most
applications on medical devices. Ideally, NO-release would last for days to weeks
for most applications. At present, none of the zeolite design alterations examined in
this chapter, including using different polymer binders has increased the duration of
release. Despite this, many other avenues are yet to be explored, including changing
the type of zeolite itself, of which there are hundreds with unique structures, or by
using different cations to exchange within the structures. Interest in the use of
copper (Cu) ion containing materials is increasing due to the ability of Cu1+ to
catalyse the production of NO from nitrite (Oh & Meyerhoff, 2004, 2003). A Cu2+
exchanged zeolite might therefore produce a preliminary burst of NO from stored
reservoirs, which would be ultimately oxidised to nitrite. The reduction of Cu2 h to
Cu1+ at the zeolite surface by endogenous reducing agents, such as ascorbate, then
creates the potential to recycle nitrite to NO at its surface, providing a potentially
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unending source of bioavailable NO. The major drawback with this technology is
the highly cytotoxic nature of Cu ions in vivo.
Duration of release is undoubtedly important for the development of anti-thrombotic
coatings on devices used in long-term procedures although short-term NO-release
from the surface of biomedical devices could also afford protection against
thrombotic and proliferative responses in the perioperative period when it is needed
the most. Short-term NO release could also prove useful in minor interventional
procedures such as cannulation. Indeed, other NO-releasing polymers have shown
effective anti-thrombotic potential in this arena, which has concomitantly led to
improved working life for intravascular sensing equipment such as glucose and
oxygen sensors (Oh et al., 2005; Schoenfisch et al., 2002; Shin et at, 2004; Shin &
Schoenfisch, 2006).
3.4.2 Mechanism ofaction ofNO-loaded zeolites.
As well as the therapeutic potential of NO-loaded zeolites, these materials offer a
unique tool with which to investigate the mechanism of action ofNO as they liberate
NO into the extracellular environment and in theory leave all potential zeolite by¬
products bound in the structure. Many of the classical effects of NO are produced
via the sGC enzyme which, when activated, catalyses the production of cGMP from
GTP (Schmidt et al., 1993). The stimulation of sGC by NO results in inhibition of
platelet aggregation through the modulation of Ca2+ levels important for initiating
aggregation (Busse et al., 1987; Radomski et al., 1987c). There have been several
reports of a sGC independent effects of NO, particularly in NO-mediated anti-
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platelet actions (Crane et al., 2005; Gordge el al., 1998; Homer & Wanstall, 2002;
Sogo et al., 2000; Wanstall et al., 2005). The potent inhibition of sGC can be
achieved through the use of ODQ. Pre-incubating platelets with ODQ completely
abolished the inhibition of platelet aggregation achieved from the NO donor SNP,
whereas it had no effect on the inhibition caused by another NO donor, DEA/NO, in
keeping with previous results (Crane et al., 2005; Sogo et al., 2000). The difference
observed between these two donors has been attributed to the site ofNO production
(Gordge et al., 1998; Wanstall et al., 2005), although NO concentration cannot be
ruled out. It is suggested previously that the site and concentration of NO
predisposes the occurrence of sGC-independent mechanisms (Crane et al., 2005;
Sogo et al., 2000). There is a relative lack of sGC-independent anti-platelet effects
with species ofNO donor that require bioactivation suggesting that liberation ofNO
in the intracellular environment may exclusively target sGC. SNP is an example of a
bioactivated, intracellular NO donor (see section 1.1.8.3) that was only able to inhibit
aggregation in the absence of ODQ, supporting this hypothesis (figure 3.7 B).
DEA/NO is a spontaneous NO donor that liberates NO both in the extracellular and
intracellular environment. ODQ was only partially able to reverse its effects on
platelet aggregation (figure 3.7 C) indicating that the effect of DEA/NO on platelets
is through both sGC-dependent and independent mechanisms. As zeolites release
high concentrations of NO into the extracellular environment and do not require
bioactivation to release NO, it was hypothesised that there would be an sGC-
independent component to the anti-platelet effects of NO-loaded zeolites. Indeed,
ODQ had no significant effect on the anti-platelet effect of 75% Zn2+ zeolites after 1
min zeolite incubation (figure 3.6). There was a partial reversal of the anti-platelet
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effects of the 50% zeolite after 1 min incubation indicating there is a partial sGC-
dependent effect at this time-point (figure 3.6). At later time-points (10-80 min), the
• 2~b • • • •
anti-aggregatory actions of 50% Zn zeolites were unaffected by inhibition of sGC
(figure 3.8), which could be related to the presence of higher NO concentrations
liberated at these time-points as indicated by NO-electrode profiles (figure 3.1 B).
The modest inhibition of platelet aggregation by the 25% Zn2+ zeolite after 1 min
was completely abolished by the ODQ, which is further evidence for the requirement
of high NO concentrations in the production of sGC-independent effects. These
studies support previous evidence highlighting the requirement for high
concentrations of extracellular NO in the production of NO-mediated sGC-
independent effects (Crane et al., 2005; Sogo et al., 2000). The alternative pathway
stimulated by NO is not clear although it has been suggested that the nitration of
surface platelet protein residues or direct modulation of Ca2+ ion channels and
transporters can result in decreased aggregation (Crane et al., 2005; Gupta et al.,
1994; Pernollet et al., 1996; Trepakova et al., 1999; Wanstall et al., 2005) as well as
surface thiol modifications (Gordge et al., 1998). Such surface modifications would
certainly be more likely with extracellular release of NO, particularly at high
concentrations which would have greater nitrating or oxidising actions on surface
proteins and lipids. Further to the mechanism of action in platelets, it was shown
that ODQ also partially inhibited the relaxation response of rat aorta preparations by
Co2+ zeolites, demonstrating an sGC-independent component to the relaxing
mechanisms ofNO in smooth muscle. These findings are in line with various others
reporting NO-mediated sGC-independent effects in smooth muscle (Bellamy et al.,
2002; Bradley et al., 1998; Miller et al., 2004). Direct modulation of Ca2+ -
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dependent K+ channels by NO has been shown to produce relaxation in smooth
muscle highlighting a possible route by which NO can exert vasorelaxation in the
absence of sGC (Bolotina et al., 1994). Better understanding of how NO exerts
these sGC-independent effects could provide new pathways for pharmacological
manipulation that have the potential to mimic the effects of NO in the body in the
absence of NO itself. To this end, the results demonstrated here warrant further
investigation.
The use of the NO scavenger haemoglobin had little impact on the effects observed,
particularly with the high composition zeolites, which release massive concentrations
of NO. This could suggest that NO was not the effector molecule and perhaps
another species was producing the effects, however it is more likely that these high
concentrations ofNO are saturating the reaction sites for NO on Hb. NO reacts with
Hb in a 4:1 ratio, thus the presence of 10p,M Hb would effectively scavenge up to
40qM NO. This concentration would be very quickly reached as shown by NO-
electrode experiments, more so by the 75% Zn zeolite that has a very rapid onset of
NO release (figure 3.1 A). As the platelet assay uses light transmission to measure
aggregation, the Hb content, which is strongly pigmented, could not be used at high
concentrations. However, a higher concentration of Hb was used in the myography
experiments (40uM), which still was not sufficient to completely reverse relaxation
responses induced by NO-loaded zeolite exposure. However, the marked reduction
in anti-platelet effects in the whole blood aggregation experiments, demonstrates a
physiological scavenging of NO by scavengers found in blood. Despite problems
with effective scavenging of NO, the use of NO-free counterpart zeolites provides
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the best indication of the involvement ofNO. These discs had no effect in either the
aggregation or the myography assays. Thus, it is fair to assume that NO is the major
effector molecule in the observed effects.
Although the NO-release profiles of zeolites appear exhausted by approximately 1 h,
the anti-thrombotic effects last over 2 h. This prolongation of effects is not evident
in the smooth muscle relaxant properties of zeolites, indicating that there may be a
platelet/plasma specific component to this effect. Previous work has implicated low
molecular weight thiol plasma constituents in the prolongation of anti-platelet effects
ofNO-donors (Crane et al., 2002). Low molecular weight thiols were shown to be
important for the transfer of NO from protein S-nitrosothiol reservoirs that can
subsequently inhibit platelet aggregation for prolonged periods of time, exceeding
the observed biological half-life ofNO-donors (Crane et al., 2005). Washed platelet
experiments were used to examine the role of plasma-borne S-nitrosothiol reservoirs
in our experiment. It was shown that 50% Zn2+ NO-loaded zeolites were able to
inhibit aggregation of washed platelets for over 90mins, still beyond the apparent
NO-release time of the disc. Further time-points were not studied due to the short
functional life of platelets ex vivo. It is important to note that the NO-release
concentration in the aggregation assay may be double that seen in the electrode
experiment due to differences in experimental volume. Also, the NO-electrode was
at minimal sensitivity due to the high concentrations released throughout the
experiments to ensure the full NO release remained on scale. It is likely that
increasing the sensitivity would have produced an NO signal after 60 min in the
range known to inhibit platelet aggregation. The zeolite discs were pre-incubated in
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either PPP or Tyrode's solution prior to transfer to PRP or WP at the appropriate
time-point. This hypothesis is further supported when considering the pre-incubation
technique used (figure 3.8), which meant that the zeolites were only in contact with
the platelet sample for 1 min prior to collagen stimulation following varying
incubation times in the platelet free sample. This further down-plays the
involvement of plasma-borne NO reservoirs in the anti-platelet effects ofNO-loaded
zeolites and indicates that NO released at those specific time-points was adequate to
inhibit aggregation. Furthermore, the pre-incubation of ODQ in PRP had no effect
on the inhibition of aggregation, suggesting the effect is sGC-independent and
therefore possibly associated with high concentrations of NO in the extracellular
environment. The relative lack of sGC-independent effects reported in the presence
of OONO" or S-nitrosothiols (nitrosonium; Sogo el al., 2000) further supports the
claim that extracellular NO radical from zeolite stores are producing these effects.
The short duration of effects seen in smooth muscle is probably due to lower NO
concentrations in this assay as the zeolite discs were placed in a 6ml volume. Future
studies should simultaneously produce NO electrode measurements along with
aggregation and myography experiments to examine the actual concentrations
present producing the observed effects.
3.4.3 Toxicity ofNO-loaded zeolites to human platelets.
Cytotoxicity of NO is an area with much contention within the literature. The
involvement of other NO-related species, such as peroxynitrite (ONOO") has been
suggested to be the major cause of death in a number of cell types (Flalliwell et al.,
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1999; Pacher et al., 2007; Sies & de Groot, 1992; Virag et al., 2003). ONOO" is
formed through the interaction of NO with O2" and is a potent oxidant, resulting in
lipid peroxidation, DNA fragmentation and protein nitration and oxidation (Taylor et
al., 2004; Virag et al., 2003). LDH-release from platelets following treatment with
NO-loaded zeolites for 2h was found to be comparable to control, suggesting no
adverse effects of these high concentrations of NO on platelet death (figure 3.9).
Platelet function was difficult to assess at later time-points due to the potent and
lasting anti-platelet effects of the zeolites and the short functional life of platelets ex
vivo. Smooth muscle contraction and relaxation responses were unaffected
following zeolite treatments although the concentration of NO in this assay is lower
than that used for aggregation. These results show promise in the future
development of NO-loaded zeolites for in vivo practices, although further
characterisation of NO cytotoxicity to other relevant cell types is required,
particularly endothelial cell lines which would come into close proximity with many
potential medical device surfaces such as stents and vascular grafts.
3.4.4 Summary and conclusions
In summary, NO-loaded zeolites provide promising tools to deliver NO locally at
physiologically relevant concentrations and are potential candidates for development
of anti-thrombotic coatings on medical devices. At present, the NO-release profiles
are not optimal for most medical device applications, which would require longer
durations of NO release to provide adequate anti-thrombotic protection throughout
the working life of the device and avoid the use of prophylactic, systemic anti¬
thrombotic therapies. Of particular interest are the anti-thrombotic, anti-proliferative
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and anti-inflammatory effects of NO in relation to vascular stent devices. These
devices are currently associated with high levels of restenosis due to the remodelling
of the vessel wall caused by proliferating smooth mucscle cells. Stent-based NO
delivery could provide the answer to many of the burdens associated with stent
failure, including platelet and inflammatory cell adhesion and aggregation, and limit
these effects to a localised area, providing a clear advantage to potentially
detrimental polypharmacy approaches. Indeed, NO-releasing stents have already
produced promising results in various animal models (Buergler et al., 2000; Do et al.,
2004; Kaposzta et al., 2002; Vermeersch et al., 2001; Yoon et al., 2002).
Temporal limitations in current NO-release characteristics of cation-exchanged
zeolites have the potential to be overcome with further optimisation of zeolite design
and through increased consideration of the biological surroundings. Despite these
drawbacks, zeolite materials have been shown to be high capacity storage and release
materials of biologically active concentrations of NO, which may be more suited to
alternative clinical applications rather than long-term anti-thrombotic therapies.
There are likely short-term procedures that could benefit significantly from NO
release, especially when considering the potential advantage of NO-induced vessel
dilatation and reduction in vasospasm in cannulation procedures (Clatterbuck et al.,
2005; Keefer, 2003). With this in mind, the optimal NO-releasing zeolite so far was
2"bconsidered to be the 50% Zn exchanged zeolite which had a steadier, more
prolonged release of NO compared to other types of zeolite. Cytotoxicity of this
zeolite in platelets was investigated through measurement of LDH. It was shown
that, despite high concentrations of NO being released into the platelet sample, no
increase in LDH release was observed suggesting that these zeolites do not induce
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cell necrosis. This zeolite was chosen for further testing in more diverse biological
settings.
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CHAPTER FOUR
The Effect of Zn2+-Exchanged Zeolites on
Human Neutrophil Function.
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Chapter 4. The Effect of Zn2+-Exchanged
Zeolites on Human Neutrophil Function.
4.1 Introduction
The inflammatory response is a fundamental process for host defence against
infection and for mediating tissue repair. The inflammatory reaction involves the
recruitment of inflammatory cells to the site of injury or infection in response to
noxious chemical stimuli or microbial toxins (Driscoll et al., 1997). The
identification of foreign substances in the body is essential for the rapid and
successful clearance of infection, however, when the formidable array of
inflammatory effector molecules is targeted inappropriately, such as in chronic
inflammatory diseases and medical device placement, the resulting damage to host
tissue is harmful and potentially fatal. Biomaterial-elicited inflammatory reactions
can also interfere with the functioning of medical devices as a result of increased
adhesion of inflammatory cells and platelets to the surface of the device (Shin &
Schoenfisch, 2006) and the associated rise in radical species, that can increase errors
in measurements from biosensing equipment (Patel et al., 2007). The development
of more biocompatible coatings on medical devices that actively inhibit the
inflammatory response by presenting anti-inflammatory agents is one method of
overcoming these issues (Chitkara et al., 2006; Luscher et al., 2007). Alternatively,
coatings that can mimic host tissue, so as to avoid the identification of the device as
foreign are also eagerly investigated. The seeding of host endothelial cells around
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vascular stents have produced promising results in this field, highlighting a potential
long-term solution to the inflammatory, restenotic and thrombogenic responses
associated with stent failure (Consigny, 2000; Ratcliffe, 2000; Rogers et al., 1996).
The vascular endothelium produces numerous factors important for the maintenance
of haemostasis, and NO is recognised as one factor central to the anti-thrombogenic
and anti-inflammatory properties of the endothelium. Moreover, the diverse actions
of NO in the body extend to inhibition of smooth muscle proliferation and anti¬
microbial properties, making NO a prime candidate for the development of
biomaterials with superior biocompatibility. NO-releasing polymers have shown
promise in reducing platelet activation and adhesion, making them potential
candidates for blood contacting medical devices (Frost et al., 2005). Furthermore,
NO-releasing polymers that reduce bacterial adhesion have also made some headway
in the development of anti-infective coatings for medical devices (Nablo et al.,
2005).
The use ofNO as an anti-inflammatory agent is controversial due to the paradoxical
effects of NO in immunomodulation. NO is involved in many stages of the
inflammatory response (Guzik et al., 2003). For example, constitutively active
eNOS produces low concentrations ofNO released from the vascular endothelium to
inhibit platelet and inflammatory cell adhesion to its surface (Granger & Kubes,
1994; Kubes et al., 1993). In contrast, high concentrations of NO are released by
inflammatory cells, via activation of iNOS in response to various inflammatory
mediators and bacterial products such as LPS (Moncada & Palmer, 1991). Here, NO
is important for the clearance of infecting pathogens (Bogdan, 1997) and for
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promoting tissue repair (Stallmeyer el al., 1999). NO also has a paradoxical role in
the regulation of inflammatory cell apoptosis (Albina & Reichner, 1998; Brune et al.,
1998b; Mannick et al., 1997; Nicotera et al., 1995). The induction and inhibition of
apoptosis of inflammatory cells by NO donors have been reported in the literature
(Taylor et al., 2003; Ward et al., 2000) This contradiction in the effects ofNO is one
that is mirrored in many areas of NO biology, particularly with respect to
cytotoxicity (Wink et al., 1995; Wink et al., 1998a; Wink et al., 1998b). In most
cases, the explanation for the difference lies in the species and concentration ofNO
present (Brune et al., 1998a; Dusting et al., 1998; Sandau el al., 1999). For example,
the concentration ofNO can vary considerably according to the distance of the target
to the site of NO production. Moreover, a variety of effects associated with NO are
produced by NO-related species, resulting from the reaction ofNO with constituents
of the biological milieu via redox or additive chemistry. Thus, the make-up of the
biological milieu can govern the reaction pathway down which NO will proceed,
thereby altering the biological effects produced. For instance, the increased
production of superoxide (O2") during an inflammatory response leads to increased
production of the potent oxidant, peroxynitrite (ONOO") following the reaction of
NO with O2" (Beckman & Koppenol, 1996; Koppenol et al., 1992). In many
situations, the increased presence of ONOO" correlates with increased cytotoxicty
(Beckman & Koppenol, 1996; Nakazawa et al., 2000; Szabo, 2003; Wink et al.,
2001). On the contrary, NO can also protect cells from injury (Sandau et at, 1997;
Wink et al., 1993). The supplementation ofNO has been shown to reduce death of
cardiomyocytes following ischeamia reperfusion injury (Iwase et al., 2007; Sandau
et al., 1997; Wink et al., 1993) and at low concentrations NO has been shown to
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delay apoptosis of inflammatory cells such as neutrophils (Taylor et al., 2003). This,
"double-edged sword" effect ofNO in the body holds many barriers to the successful
use ofNO as a therapeutic. Careful consideration of the concentration ofNO and the
surrounding biological milieu is required to design NO therapeutics that can avoid
adverse side effects.
During the inflammatory response, neutrophils are the most abundant type of
immune cell present at sites of infection. They circulate in the blood stream from
where they are recruited to sites of injury or infection in response to various
inflammatory mediators and cytokines (Gompertz & Stockley, 2000). They migrate
into the tissue through adhesive interactions with the vascular endothelium where
they kill and clear pathogens and cell debris via phagocytosis (Quie, 1980).
Neutrophils have numerous granules within the cytoplasm that contain a toxic soup
of proteases and cationic peptides that kill and digest phagocytosed pathogens
(Faurschou & Borregaard, 2003). Granule contents and O2" are also released into the
local environment to aid in killing surrounding pathogens, however, the non-specific
effects of these toxic agents can contribute to host tissue damage and the
pathogenesis of several diseases (Kitsis & Weissmann, 1991; Wong & Lord, 2004).
Consequently, the fine control of the inflammatory response is important in reducing
the indiscriminate attack on host tissues whilst retaining the anti-pathogenic effects
of neutrophil attack. Apoptosis, or programmed cell death, of neutrophils is a
process that is crucial for the resolution of the inflammatory response (Haslett, 1999;
Savill, 1997; Savill & Haslett, 1995). Neutrophil apoptosis involves a characteristic
stream of events that allow for the clearance of these cells and their histotoxic
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contents by phagocytes in an anti-inflammatory fashion. In the absence of apoptotic
clearance, necrotic cell death occurs which is a pro-inflammatory process, causing
exacerbation of inflammation due the rupture of neutrophils and the release of their
histotoxic contents. Thus, the lifecycle of the neutrophil and the factors regulating
apoptosis are interesting targets for the production of novel anti-inflammatory drugs
(Rossi et al., 2006; Ward el al., 1999). The role of NO as an inducer of apoptosis
has been explored, although the involvement of NO per se in these effects is
controversial (Shaw et al., 2005).
In this chapter, the effects of a novel NO-releasing zeolite on the activation status
and death of human neutrophils in vitro was investigated with the view to their use as
biocompatible coatings for medical devices. NO-releasing zeolites are high capacity
storage and release materials ofNO that have previously been shown to be powerful
inhibitors of platelet activation (Wheatley et al., 2006). The infiltration of
neutrophils to the site of device placement is a common feature associated with
medical device usage and so the application of NO-loaded zeolite materials in vivo
requires the characterisation of the effects ofNO on inflammatory cell function. The
involvement ofNO in the inhibition of inflammatory cell adhesion suggests a benefit
of releasing NO from the surface of such devices. However the multifaceted
relationship of NO with pro and anti-inflammatory processes can mean detrimental
effects may prevail. NO-releasing zeolites have been shown in previous chapters to
release high concentrations ofNO over a short period of time, mirroring the profile
of NO released by iNOS rather than the anti-inflammatory, low concentrations
released by eNOS. This chapter investigates the potential of these materials to
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promote or prevent neutrophil activation in vitro with respect to changes in
neutrophil activation and cell death markers. Correlation of these effects with the
concentration of NO exposed is also investigated in an attempt to address the
associated paradox of the pro and anti-inflammatory effects ofNO.
• • 2IThis chapter investigates the effect of a 50% Zn -exchanged zeolite: PTFE material
(NO-loaded and NO-free) on human neutrophil activation and viability in the
absence and presence of the neutrophil activator fMLP (formylated-Met- Leu- Phe),
a synthetic formylated peptide which mimics the bacterially derived peptides with
formylated N-terminal methionine groups. These studies will form part of the
primary characterisation of these novel materials as biocompatible materials for
medical device coatings.
Experiments described in this chapter were designed to test the hypothesis that NO-
loaded zeolites have pro or anti-inflammatory effects in human neutrophils that are
dependent upon the concentration ofNO exposed in the assay.
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4.2 Materials and Methods
4.2.1. Isolation and purification of human neutrophils from whole
blood.
Neutrophils were purified and suspended in PBS (with Ca2+ and Mg2+) as described
in section 2.5.1. Briefly, whole blood was collected and centrifuged to separate the
erythrocyte/leukocyte rich layer from the platelet rich plasma. Erythrocytes were
then separated from the leukocyte cell population by Dextran sedimentation. The
leukocytes were isolated into purified monocyte and neutrophil populations by
centrifugation of the leukocyte cell layer through discontinuous, layered Percoll
gradients at 81%, 70% and 55%. Monocytes were harvested from the 55/70%
interface and neutrophils were harvested from the 70/81% interface. Figure 4.1
shows representative flow profiles and microscopic pictures of the different cell
populations found throughout the purification process.
4.2.2. Cytocentrifuge Preparations
Cytospins of cell populations (figure 4.1) isolated from whole blood were prepared
using 100pi of the cell suspension + 10% autologous serum. The suspension was
centrifuged (300rpm; 3min) through filters onto glass slides. The cells on the slide
were allowed to dry at room temp and then stained in methanol (1 min), Quik-Diff
Red® (1 min) and Quik Diff-Blue® (1 min) and then washed in H2O. Cells were
analysed for cell purity using light microscopy through an oil immersion lens (X250
magnification).
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N-neutrophil, M-monocyte, E-erythrocyte, L-lymphocyte
Figure 4.1 Purification of human neutrophils from whole blood.
Flow dot plots showing different gated cell populations indicated by forward scatter (FS; x-
axis) and side scatter (SS; y-axis) parameters and microscopic pictures (x250 magnification)
from cytocentrifuge preparations of cells at different stages of the cell purification process
(following dextran sedimentation and centrifiigation through Percoll gradients). The larger
mononuclear cell population fall at higher forward scatter levels, whereas the highly granular
neutrophils are found at high side scatter levels, allowing the gating of separate populations.
126
Chapter 4 - The effect ofZn2 -exchanged zeolites on human neutrophilfunction
2~i~4.2.3. Neutrophil treatment with 50% Zn -exchanged zeolites.
50% Zn2+-exchanged zeolites in a PTFE polymer binder were synthesised as
described in section 2.8.1. Discs were approximately 3mm diameter xlmm height.
NO-loaded discs were stored in sealed Schlenk tubes containing Argon at room
temperature until ready for use. Throughout these experiments zeolite treatments
will be expressed in units/ml, where 1 unit = 1 zeolite disc and 0.5 units/ml is either
Vz zeolite disc or 1 disc in 2ml as indicated.
Isolated neutrophils (5x106 cells/ml; PBS plus Ca2+ and Mg2+) were incubated with
zeolites (NO-loaded or NO-free) for 60min in various volumes (l-8ml; 0.125-
• • 7
1unit/ml) in the presence or absence of the neutrophil activator, fMLP (10" M).
fMLP or vehicle (PBS) was administered at 30min of the 60min incubation period.
Control samples were run in parallel to zeolite treatments both in the absence or
presence of fMLP.
4.2.4 Flow cytometric analysis of neutrophil shape change and
expression ofactivation markers, CD62L and CDllb.
Following treatments, samples were cooled on ice for lOmin and 200pl aliquots from
each treatment were then labelled (6pg/ml) with fluorescently labelled conjugates of
antibodies against CD62L, CDllb or isotype controls (IgG-PE, IgG-FITC; or IgG-
APC). The antibodies were incubated (4°C) for 30 min with gentle shaking, prior to
analysis by flow cytometry. Flow cytometric analysis was performed using a
Coulter FACSCalibur flow cytometer (Beckman Coulter, California, USA) and data
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were captured using EXPO™ 32 v 2.1 analysis software (Beckman Coulter,
California, USA). Fluorescence of the PE-conjugate ofCD62L was measured via the
FL-2 channel. Fluorescence of FITC and APC conjugates of CD1 lb were measured
through FL-1 and FL-4 channels respectively. Shape-change was measured in
parallel as changes in forward scatter (FS) profiles.
4.2.5. Flow cytometric analysis ofneutrophil viability in vitro; Annexin
V/Propidium Iodide (PI) staining.
Following zeolite treatments, cells were cooled for lOmin on ice and then a 20pl
sample of the neutrophil suspension (5million cells/ml in PBS with Ca2+ and Mg2+)
was incubated (4°C; lOmin) in 180pl of FITC-conjugated Annexin-V in Annexin V-
binding buffer (PBS solution containing 5mM CaCfi). Following the 10 min
incubation, the Annexin-V labelled cells were stained with PI (2pg/ml final
concentration) 1 min prior to analysis by flow cytometry. Flow cytometric analysis
was performed using a Coulter FACSCalibur flow cytometer (Beckman Coulter,
California, USA) and data were captured using EXPO™ 32 v 2.1 analysis software
(Beckman Coulter, California, USA). Apoptosis and necrosis was measured as
Annexin-V positive (FL-1) and Annexin-V/PI positive (FL-1 and 2) as a percentage
of total gated cells. Cells negative for both markers were considered healthy.
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4.2.6 NO electrode study.
Experiments were carried out using a 2 mm isolated NO electrode (ISO-NOP, World
Precision Instruments, Stevenage, U.K) and data captured using an analogue-digital
converter (Maclab 4e, AD Instruments, Sussex, U.K). The electrode was calibrated
as described in section 2.3.1 prior to use each day.
The electrode was placed in a cuvette containing 1ml of pre-warmed (37°C)
neutrophil suspension (5x106 cells; PBS) and allowed to reach a steady baseline. The
NO-loaded zeolite discs were suspended in the solution using a stainless steel wire
holding device and the electrode was left to record for 60 min post-suspension of the
zeolite disc. Time-points were chosen for the calculation of NO concentration
released from the zeolite disc using linear regression analysis obtained from the
electrode calibration.
4.2.7Statistics.
Statistical analyses were performed using one-way or two-way analysis of variance
with either Dunnet's or Bonferroni's post hoc test and confirmed using non-
parametric Kruskel-Wallis with Dunn's post hoc, where appropriate. Statistical
significance was assumed when p < 0.05 at the 95% confidence interval.
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4.3 Results
n
4.3.1 Activation of isolated human neutrophils byfMLP (Iff M).
Figure 4.2 shows the characteristic changes in neutrophil shape following activation
with fMLP (10"7M). Shape-change is measured by flow cytometry as a shift in
forward scatter (FS). This is demonstrated by the shift in the cell population shown
in the dot plot and the histogram. Approximately 60% of the neutrophils undergo
shape change upon stimulation with fMLP (figure 4.2). The shedding of CD62L
upon neutrophil activation is indicated by the leftward-shift in peak fluorescence of
the PE conjugated antibody, measured through the FL-2 channel (figure 4.3). Up-
regulation of the neutrophil adhesion marker CDllb following stimulation with
fMLP is shown by the increase in fluorescence measured through channels FL-1 and
FL-4, which correspond to the binding of fluorescent conjugated antibodies CD1 lb-
FITC and CDllb-APC respectively (figure 4.4). The fluorescence profiles of the
isotype-fluorescent antibodies (ISO-FITC, ISO-APC and ISO-PE) show there is no
overlap with the surface marker antibodies, thereby demonstrating that the antibody
isotype is not binding in a non-specific manner and that the increase in fluorescence
observed is associated with antigen specific binding.
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Figure 4.2. Activation of isolated human neutrophils by fMLP (10~7M); neutrophil
shape change.
Flow dot plots and histograms show the rightward shift in forward scatter (FS; x-axis)
following stimulation of neutrophils with fMLP (10"7M) indicating an increase in size of the
fMLP-stimulted neutrophils. The marker Ml, shows the percentage of the total neutrophil
count for each treatment that falls in the marked region (purple-unstimulated; green-
stimulated).
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Figure 4.3. Activation of isolated human neutrophils by fMLP (10"7M); shedding of
CD62L.
The expression ofCD62L in human neutrophil populations through measurement of
fluorescent conjugates of anti-human CD62L-PE via the FL-2 channel. The levels of
fluorescence (FL-2) ofneutrophils labelled with isotype fluorescent conjugates (red), and
fluorescent conjugates of anti-human CD62L in unstimulated (purple) and fMLP-stimulated
neutrophils (green) are indicated by flow dot plots and histogram.
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Figure 4.4. Activation of isolated human neutrophils by fMLP (10"7M); up-regulation of
CDllb.
The expression of CDllb in human neutrophil populations through the measurement of
fluorescent conjugates of anti-human CDllb- FITC and anti-human CDllb- APC via FL-1
and FL-4 channels respectively. The levels of fluorescence (FL-1 and FL-4) of neutrophils
labelled with isotype fluorescent conjugates (red), and fluorescent conjugates of anti-human
CDllb in unstimulated (purple) and fMLP-stimulated neutrophils (green) are indicated by
flow dot plots and histograms.
133
Chapter 4 - The effect ofZn -exchanged zeolites on human neutrophilfunction
4.3.2. The effect of 50% Zn2+-exchanged zeolites on neutrophil shape
change.
Neutrophil stimulation with fMLP results in shape-change as indicated by the shift in
forward scatter profiles of control fMLP stimulated neutrophils compared to
unstimulated cells (figure 4.2 and 4.4-5). Treatment with 0.5unit/ml Zn2+-zeolites
(NO-free and NO-loaded) produced no apparent change in the forward scatter
profiles of unstimulated and fMLP-stimulated neutrophils compared to control
(figure 4.5). At 1 unit/ml zeolite treatments, NO-free zeolite treatments produced
comparable profiles to control in both unstimulated and fMLP-stimulated
neutrophils. The NO-loaded zeolite treatment produced a shift in the forward-scatter
profiles of unstimulated neutrophils, with approximately 40% more cells undergoing
shape change compared to control. This augmentation of forward scatter profiles
was not mirrored in fMLP-stimulated neutrophils following NO-loaded zeolite
treatment, which remained similar to control (figure 4.6).
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Figure 4.5. The effect of 50% Zn2+-exchanged zeolites on neutrophil shape change;
0.5unit/ml zeolite treatment.
Forward-scatter (FSC; x-axis) profiles of unstimulated (purple) and fMLP-stimulated (10"
7M) neutrophils following control (top), NO-free (middle) and NO-loaded zeolite treatments
(0.5unit/ml; 60 min). Percent of unstimulated and fMLP-treated neutrophils falling within
marker range, Ml have been included for comparison between treatments.
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Figure 4.6. The effect of 50% Zn2+-exchanged zeolites on neutrophil shape change;
lunit/ml zeolite treatment.
Forward-scatter (FSC; x-axis) profiles of unstimulated (purple) and fMLP-stimulated (10"
7M) neutrophils following control (top), NO-free (middle) and NO-loaded zeolite treatments
(lunit/ml; 60 min). The percentage of unstimulated and fMLP-stimulated neutrophils falling
within marker range, Ml have been included for comparison between treatments.
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23~ •
4.3.3. The effect of 50% Zn -exchanged zeolites on neutrophil
activation marker CD62L.
The shedding of CD62L following stimulation of isolated neutrophils with 10"7M
fMLP is demonstrated by the reduction in peak fluorescence measured through the
FL-2 channel shown in the representative flow histograms. Neutrophils treated with
0.5unit/ml of the NO-free or NO-loaded zeolite discs demonstrated no significant
shedding of CD62L compared to control in unstimulated or fMLP-stimulated
conditions (Figure 4.7). The incubation of 1unit/ml of the NO-free zeolite disc had
no significant effects whereas the NO-loaded zeolite (1unit/ml) produced significant
CD62L shedding in unstimulated neutrophils (figure 4.8). The histogram shows a
clear leftward shift in fluorescence (FL-1) in unstimulated (purple) neutrophils
following NO-loaded zeolite treatment and lower mean fluorescence values
compared to control and NO-free zeolite treatments.
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Figure 4.7. The effect of 50% Zn2+-exchanged zeolites on CD62L shedding in isolated
human neutrophils; 0.5unit/ml zeolite treatment.
Representative flow histograms showing fluorescence profiles and mean fluorescence values
of PE-conjugated anti-human CD62L (log FL-2; x-axis) from control and zeolite (NO-ffee
and NO-loaded; 0.5unit/ml) treated neutrophils in unstimulated (purple) and fMLP-
stimulated (10"7M; green) conditions. The bar graph represents the cumulative data of
CD62L expression of neutrophils(5 x 106cells; 1ml; PBS) incubated (60 min; 37°C) with
0.5unit/ml NO-loaded zeolite disc (grey bar), 0.5unit/ml NO-ffee zeolite disc (white bar) or
control (black) in the absence and presence of the neutrophil activator fMLP (10"7M; 30
min). Data is expressed as % of control (unstimulated) values and represent the mean +/-
SEM of n=5 independent experiments. Mean fluorescence (FL-2) of control (unstim)
treatments was 554.0 +/- 68.9.
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Figure 4.8. The effect of 50% Zn2+-exchanged zeolites on CD62L shedding in isolated
human neutrophils; 1 unit/ml zeolite treatment.
Representative flow histograms showing fluorescence profiles and mean fluorescence values
of PE-conjugated anti-human CD62L (log FL-2; x-axis) from control and zeolite (NO-free
and NO-loaded; lunit/ml) treated neutrophils in unstimulated (purple) and fMLP-stimulated
(10"7M; green) conditions. The bar graph represents the cumulative data of CD62L
expression of neutrophils (5 x 106cells; lml; PBS) incubated (60 min; 37°C) with lunit/ml
NO-loaded zeolite disc (grey bar), lunit/ml NO-free zeolite disc (white bar) or control
(black) in the absence and presence of the neutrophil activator fMLP (10"7M; 30 min). Data
is expressed as % of control (unstimulated) values and represent the mean +/- SEM of n=6
independent experiments. Mean fluorescence (FL-2) of control (unstim) treatments was
531.6 +/- 70.8. Asterisk denotes statistical significance compared to NO-free zeolite
treatment.
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4.3.4. The effect of 50% Zn - exchanged zeolites on neutrophil
activation marker CDlib.
Figure 4.9 and 4.10 show the effect of incubation (60 min; 37°C) of 0.5unit/ml and
lunit/ml of zeolite (50% Zn2+ NO-loaded and NO-free) in 1ml neutrophil
(5xl06cells) suspension respectively. Representative histograms show a rightward
shift in fluorescence of fMLP-treated (10"7M) neutrophils that is more pronounced
following NO-loaded zeolite treatment and is confirmed by higher mean
fluorescence values.
NO-free zeolite treatments produced similar levels of CD1 lb expression to control at
both zeolite concentrations in both unstimulated and fMLP-stimulated conditions.
NO-loaded zeolites had no significant effect on CDllb expression in unstimulated
neutrophils but significantly enhanced expression in fMLP-stimulated neutrophils at
both 0.5unit/ml and lunit/ml zeolite treatment (figure 4.9- 4.10).
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Figure 4.9. The effect of 50% Zn2+-exchanged zeolites on CDllb up-regulation in
isolated human neutrophils; 0.5unit/ml zeolite treatment.
Representative flow histograms showing fluorescence profiles and mean fluorescence values
of FITC-conjugated anti-human CDllb (log FL-1; x-axis) from control and zeolite (NO-
free and NO-loaded; 1unit/ml) treated neutrophils in unstimulated (purple) and fMLP-
stimulated (10"7M; green) conditions. The bar graph represents the cumulative data of
CDllb expression of neutrophils (5 x 106cells; 1ml; PBS) incubated (60 min; 37°C) with
lunit/ml NO-loaded zeolite disc (grey bar), lunit/ml NO-lfee zeolite disc (white bar) or
control (black) in the absence and presence of the neutrophil activator fMLP (10"7M; 30
min). Data are expressed as % of control (unstimulated) values and represent the mean +/-
SEM of n=4 independent experiments. Mean fluorescence (FL-1) of control (unstim)
treatments was 294.2 +/- 55.9.
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Figure 4.10. The effect of 50% Zn2+-exchanged zeolites on CDllb up-regulation in
isolated human neutrophils; lunit/ml zeolite treatment.
Representative flow histograms showing fluorescence profiles and mean fluorescence values
of FITC-conjugated anti-human CDllb (log FL-2; x-axis) from control and zeolite (NO-
free and NO-loaded; lunit/ml) treated neutrophils in unstimulated (purple) and fMLP-
stimulated (10"7M; green) conditions. The bar graph represents the cumulative data of
CDllb expression of neutrophils (5 x 106cells; lml; PBS) incubated (60 min; 37°C) with
lunit/ml NO-loaded zeolite disc (grey bar), lunit/ml NO-free zeolite disc (white bar) or
control (black) in the absence and presence of the neutrophil activator fMLP (10~7M; 30
min). Data are expressed as % of control (unstimulated) values and represent the mean +/-
SEM of n=4 independent experiments. Mean fluorescence (FL-1) of control (unstim)
treatments was 295.0 +/- 65.5. Asterisks denote significance compared to NO-free zeolite
treated neutrophils (*** p <0.001).
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4.3.5. The concentration-dependent effect ofNO-releasing zeolites on
neutrophil activation markers CD62L and CDllb.
To assess the effect of lower concentrations of NO on neutrophil activation, NO-
loaded zeolites discs were suspended in varying volumes (l-8ml) of the neutrophil
suspension in order to dilute the concentration ofNO released from the zeolite disc.
Increasing the NO-loaded zeolite exposure to the neutrophil suspension (5x106
cells/ml) from 0.125unit/ml to 1unit/ml produced a decreasing trend of CD62L
expression in both unstimulated and fMLP-stimulated neutrophils (figure 4.11).
CDllb expression in unstimulated neutrophils was not significantly different from
control at all concentrations of NO-loaded zeolite. CDllb expression in fMLP-
stimulated neutrophils was markedly enhanced from control at the highest NO-
loaded zeolite concentration only (lunit/ml; figure 4.12).
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Figure 4.12. The effect of NO-loaded zeolite disc dilutions on the expression of CDllb
in isolated human neutrophils.
The mean expression of CDllb-APC fluorescence measured via the FL-4 channel of
neutrophils treated with increasing concentrations (0.125-lunit/ml) of NO-loaded zeolite
(60min; 37°C) achieved through zeolite disc dilution in increasing volumes (l-8ml) of the
neutrophil suspension (5xl06 cells/ml; PBS) in untimulated (purple) and fMLP-stimulated
(10 7M; 30min; green) conditions. Bars represent the mean +/- SEM of n=3 independent
experiments. Asterisks denote significant difference between unstimulated and fMLP
stimulated neutrophils at the appropriate concentration.
4.3.6. NO-release from 50% Zn2+-exchanged zeolites in isolated
neutrophil suspensions.
NO-release from 50% Zn2T-exchanged zeolites (NO-loaded) in a suspension (1ml) of
isolated human neutrophils (5xl06cells; PBS; 37°C) shows a rapid release of high
concentrations (peak ~ 30pM) ofNO. Peak release ofNO is reached within the first
10 min and rapidly deteriorates to near baseline by 40 min (figure 4.13).
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Figure 4.12. The effect of NO-loaded zeolite disc dilutions on the expression of CDllb
in isolated human neutrophils.
The mean expression of CDllb-APC fluorescence measured via the FL-4 channel of
neutrophils treated with increasing concentrations (0.125-lunit/ml) of NO-loaded zeolite
(60min; 37°C) achieved through zeolite disc dilution in increasing volumes (l-8ml) of the
neutrophil suspension (5xl06 cells/ml; PBS) in untimulated (purple) and fMLP-stimulated
(10"7M; 30min; green) conditions. Bars represent the mean +/- SEM of n=3 independent
experiments. Asterisks denote significant difference between unstimulated and fMLP
stimulated neutrophils at the appropriate concentration.
4.3.6. NO-release from 50% Zn2+-exchanged zeolites in isolated
neutrophil suspensions.
NO-release from 50% Zn2^-exchanged zeolites (NO-loaded) in a suspension (1ml) of
isolated human neutrophils (5xl06cells; PBS; 37°C) shows a rapid release of high
concentrations (peak ~ 30pM) ofNO. Peak release ofNO is reached within the first
10 min and rapidly deteriorates to near baseline by 40 min (figure 4.13).
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Time (min)
Figure 4.13. NO generation from 50% Zn2+-exchanged NO-ioaded zeolites in
suspension with human isolated neutrophils.
NO-release profile following suspension of 50% Zn2+-exchanged zeolite (NO-loaded;
1 unit/ml) in isolated human neutrophils (PBS; lml; 37°C) for 60 min. The arrow indicates
the addition of fMLP (10"7M) at 30min.
2~h •
4.3.7. The effect of 50% Zn -exchanged zeolites on neutrophil
viability.
The incubation (60min; 37°C) of NO-free and NO-loaded zeolite disc (0.5unit/ml) in
the neutrophil suspension (5xl06cells; lml;PBS) had no significant effect on the
levels of apoptosis or necrosis compared to control in unstimulated (figure 4.14) or
fMLP-stimulated (figure 4.15) conditions. At lunit/ml NO-free zeolites also had no
significant effects on neutrophil apoptosis or necrosis compared to control in both
unstimulated (figure 4.16) or fMLP-stimulated (figure 4.17) neutrophils. The NO-
loaded disc at lunit/ml produced a significant increase in the levels of cell necrosis
compared to control in unstimulated neutrophils (figure 4.16) that was further
increased in fMLP-stimulated neutrophils (figure 4.17). The increase in necrosis
146
Chapter 4 - The effect ofZn2 -exchanged zeolites on human neutrophilfunction
following NO-loaded zeolite treatments correlated with a significant decrease in the
healthy cell populations compared to control. Representative flow dot-plots
demonstrate an increase in the % of cells positive for Annexin-V (FL-1) and PI (FL-
2) in the upper right quadrant following NO-loaded zeolite treatment at 1 unit/ml,
which is indicative of necrosis. Apoptotic cell responses (Annexin V positive; lower
right quadrant) were unaffected at this time-point for all treatments.
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Neutrophil Treatment (5x106cells;1ml)
Figure 4.14. The effect of Zn2+-exchanged zeolites on neutrophil viability - 0.5 unit/ml
zeolite incubation.
Representative dot plots and cumulative data expression of neutrophil viability in gated
populations of isolated cells using flow cytometric analysis of fluorescent cell markers. The
percentage of cells considered apoptotic (green; lower right quadrant) were cells positive for
the fluorescent apoptotic marker Annexin-V (FL-1; x-axis), necrotic populations (red; top
quadrants) were the positive for the necrotic cell marker PI (FL-2; y-axis). Healthy cell
populations (blue; bottom left quadrant) were cells that stained negative for both cell stains.
Neutrophil suspensions (5xl06cells; 1ml; PBS) were incubated (60 min; 37°C) with 0.5
unit/ml 50% Zn2+-exchanged zeolites (NO-free and NO-loaded) in the absence of neutrophil
activator, fMLP. Bars represent the mean +/- SEM for n=3 independent experiments.
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Neutrophil Treatment + fMLP (10 *7M;5x106cells;1ml)
Figure 4.15. The effect of Zn2+-exchanged zeolites on fMLP stimulated (10"7M)
neutrophil viability - 0.5 unit/ml zeolite incubation.
Representative dot plots and cumulative data expression of neutrophil viability in gated
populations of isolated cells using flow cytometric analysis of fluorescent cell markers. The
percentage of cells considered apoptotic (green; lower right quadrant) were cells positive for
the fluorescent apoptotic marker Annexin V (FL-1; x-axis), necrotic populations (red; top
quadrants) were positive for the nuclear stain PI (FL-2; y-axis). Healthy cell populations
(blue; bottom left quadrant) were cells that stained negative for both cell stains. Neutrophil
suspensions (5xl06cells; 1ml; PBS) were incubated (60 min; 37°C) with 0.5 unit/ml 50%
Zn2+-exchanged zeolites (NO-free and NO-loaded) in the presence of neutrophil activator,
fMLP (10"7M). Bars represent the mean +/- SEM for n=3 independent experiments.
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Neutrophil Treatment (5x10 cells;1ml)
Figure 4.16. The effect of Zn2+-exchanged zeolites on neutrophil viability - 1 unit/ml
zeolite incubation.
The representative dot plots and cumulative data expression of neutrophil viability in gated
populations of isolated cells using flow cytometric analysis of fluorescent cell markers. The
percentage of cells considered apoptotic (green; lower right quadrant) were cells positive for
the fluorescent apoptotic marker Annexin V (FL-1; x-axis), necrotic populations (red; upper
quadrants) were the positive for the nuclear stain, PI (FL-2; y-axis). Healthy cell populations
(blue; lower left quandrant) were cells that stained negative for both cell stains. Neutrophil
suspensions (5xl06cells; 1ml; PBS) were incubated (60 min; 37°C) with lunit/ml 50% Zn2+-
exchanged zeolite (NO-free and NO-loaded) in the absence of the neutrophil activator fMLP.
Bars represent the mean +/- SEM for n=4 independent experiments. * p < 0.05 vs control
healthy; § p < 0.05 vs control necrotic.
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Neutrophil Treatment + fMLP (1CT7M;5x10^cells;1ml)
Figure 4.17. The effect of Zn -exchanged zeolites on fMLP stimulated (10" M)
neutrophil viability - 1 unit/ml zeolite incubation.
The representative dot plots and cumulative data expression of neutrophil viability in gated
populations of isolated cells using flow cytometric analysis of fluorescent cell markers. The
percentage of cells considered apoptotic (green; lower right quadrant) were cells positive for
the fluorescent apoptotic marker Annexin V (FL-1; x-axis), necrotic populations (red; upper
quadrants) were the positive for the nuclear stain, PI (FL-2; y-axis). Healthy cell populations
(blue; lower left quandrant) were cells that stained negative for both cell stains. Neutrophil
suspensions (5xl06cells; 1ml; PBS) were incubated (60 min; 37°C) with lunit/ml 50% Zn2+-
exchanged zeolite (NO-free and NO-loaded) in the absence of the neutrophil activator fMLP.
Bars represent the mean +/- SEM for n=4 independent experiments. * p < 0.05 vs control
healthy; § p < 0.05; §§ p < 0.01 vs control necrotic.
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4.4 Discussion
The involvement of NO in neutrophil activation status is an area with much
contention within the literature. The inhibition and activation of neutrophil
responses has been demonstrated in numerous studies utilising effects of both
endogenous and exogenous NO production. For example, exogenous application of
NO donors has been shown to inhibit (Kosonen et al., 1999) and increase (Okayama
et al., 1999) neutrophil adhesion to endothelial cells in vitro. Differences in the
species and concentration of NO donor used in these experiments may account for
the discrepancy in the effects ofNO. Interestingly, the study by Kosonen et al, used
the closely related sydnonomine and mesoionic oxatriazole species which are
generally regarded as ONOO" generators due to the simultaneous generation of NO
and O2" (Feelisch & Kelm, 1991; Hogg et al., 1992; Taylor et al., 2004). The
inhibition of neutrophil adherence was linked to increases in cGMP, whereas the
increase in neutrophil adherence by ImM concentrations of the diazeniumdiolate
compound (SPER/NO) was linked to a PKG-dependent mechanism. The
inconsistencies encountered within the literature in many areas of NO biology
underlies the complex interactions of NO which are dependent upon the
concentration of NO and chemical species encountered by different cell types. The
paradoxical effects of NO on neutrophil adherence discussed above prompted the
present study into the effect of NO-releasing zeolites on neutrophil activation. The
biocompatibility of materials with respect to the inflammatory response is
fundamental in the successful development of such medical device coatings due to
the non-specific effects of the elicited immune response on host tissues which could
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result in host tissue damage as well as localised pain and swelling. To this end, we
have shown that NO-releasing zeolites have the potential to significantly induce the
shedding of CD62L (L-selectin) in isolated human neutrophils. This shedding was
associated with high concentrations of NO released in a small volume of the
neutrophil suspension and was reversed to control levels upon dilution of the zeolite
in greater volumes of the neutrophil suspension, thereby indicating a concentration
dependent effect of NO on L-selectin shedding. Interestingly, the shedding of L-
selectin occurred in the absence of the neutrophil activator, fMLP, and was linked
with concomitant changes in neutrophil shape change. This suggests that high
concentrations of NO are stimulating the neutrophil inflammatory response and are
consequently pro-inflammatory. In the absence of fMLP, CD1 lb expression was not
significantly up-regulated following zeolite treatments although there does appear to
be a slight enhancement, particularly at the 1unit/ml concentration. The induction of
neutrophil shape change and L-selectin shedding under the same experimental
conditions would suggest that this up-regulation is real and would be reflected
statistically following further investigation. The expression of CDllb upon
stimulation of the neutrophils with fMLP was markedly and significantly enhanced
compared to the NO-free zeolite control. This effect was maintained at the lower
NO concentration (0.5unit/ml) but was less marked. The enhancement of CDllb
expression was reversed to control levels upon further dilution of the zeolite disc
(<0.5unit/ml), suggesting this effect is dependent upon the presence of high
concentrations ofNO.
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Neutrophil priming is achieved through treatment with priming agents, such as GM-
CSF, TNF-a, PAF and IL-8 and is characterised by the enhancement of neutrophil
immune responses on subsequent exposure of the primed neutrophils to an activating
stimuli (Condliffe et al., 1998; Kitchen et al., 1996; Leino et al., 1993; Partrick et al.,
1997). Priming is considered to be one of the regulatory mechanisms implicated in
the control of neutrophil responses, allowing for an appropriate attack response
related to the severity of the stimulus. The enhancement of the neutrophil respiratory
burst is the most well described response of primed neutrophils (Bass et al., 1988;
Bauldry et al., 1991; Condliffe et al., 1996; Leino et al., 1993), although the
modulation of neutrophil cell-surface adhesion molecules, CD62L and CD lib has
also been reported in priming events (Condliffe et al., 1996; Partrick et al., 1997) .
The shedding of L-selectin and up-regulation of CD1 lb following NO-loaded zeolite
exposure in this study suggests that these neutrophils were primed. The significant
enhancement of CDllb following fMLP simulation further supports this hypothesis
and is characteristic of other priming agents. NO per se has not been previously
recognised as a priming agent, but the NO-related species, ONOO", has been shown
to demonstrate priming activity, similar to that observed in this study (Rohn et al.,
1999). The nitration of neutrophil surface proteins is suggested to produce the
majority of the priming responses observed by ONOO" (Swain et al., 2002), thereby
promoting degranulation and the modulation of surface adhesion markers.
Neutrophil concomitantly produce NO and Oi when activated, thus providing the
right conditions for ONOO" production. The priming effects of ONOO" add an extra
dimension to the immunomodulatory effects of this molecule, beyond that of its
potent oxidant and microbicidal properties. It is not clear from our experiments if
154
Chapter 4 - The effect ofZn -exchanged zeolites on human neutrophilfunction
NO or ONOO" are the likely candidates of our observed effects. The expected
production of the respiratory burst, and subsequent O2" generation following fMLP
stimulation could provide the appropriate conditions for sufficient ONOO" formation
and thus, could account for the marked enhancement of CDllb up-regulation
following NO-loaded zeolite exposure. The shedding of CD62L occurs in the
absence of fMLP stimulation and thus, in the absence of the respiratory burst,
thereby down playing the role of ONOO" in favour for NO in this effect. Moreover,
the concentration of ONOO" known to produce a priming effect is extremely high, at
150-300pM (Rohn et al., 1999). This suggests that the rate of O2" generation in our
assay would have to be equimolar with NO at this concentration range for ONOO" to
produce the apparent priming response observed. Future investigation using a
scavenger of O2", such as superoxide dismutase (SOD) or ONOO" scavenger,
methionine could help elucidate the effector molecule in these studies. This priming
hypothesis would benefit from further characterisation through the investigation of
other priming responses such as enhancement of the respiratory burst and
degranulation to more fully understand this interesting finding.
NO-releasing zeolites significantly increased levels of neutrophil necrosis following
1unit/ml NO-loaded zeolite. No significant increase in neutrophil apoptosis was
observed, although the 1-hour time-point used in this assay is very early to observe
any modulation of normal apoptotic responses in isolated neutrophils. However,
preliminary results following a 20 h zeolite incubation (data not shown) indicated
that NO-treatment produced low levels of apoptosis compared to control, in favour
of an enhancement of necrosis. The percentage of healthy cells remained
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comparable to control. It is possible that the necrotic response at this stage is
secondary necrosis following an earlier apoptotic event and further investigation
using appropriate time-points could determine this. Evidence for the pro¬
inflammatory effects of NO in this study are 3-fold; there was increased production
of necrotic cell death in neutrophils following only 1 h of NO-loaded zeolite
treatment, this effect was not apparent at the 0.5unit/ml zeolite treatment suggesting
a concentration dependent effect ofNO on neutrophil necrosis, and finally and most
importantly, the NO-free zeolite controls had no effect on neutrophil viability,
further highlighting the role ofNO in producing these effects.
The mechanism of NO -induced modulation of CD62L and CDllb and increase in
necrosis is unknown but is likely unrelated to up-regulation of cGMP which is
generally regarded as the mechanism involved with NO-mediated cell protection and
inhibition of activation (Kosonen et al., 1999; Wanikiat el al., 1997). Previous
studies describing NO-related neutrophil activation, implicate signalling pathways
involving PKG, protein nitration, phosphorylation and (Okayama et al., 1999, 1998)
activation of nuclear transcription factor kB (NF-kB; Swain et al., 2002).
Measurement of nitrotyrosine residues together with inhibitors of cell signalling
pathways may help to determine the mechanism involved in these effects.
Confirmation of cGMP levels and inhibition of sGC should also be done to ensure
these effects are mediated solely via an sGC-independent ONOO" dependent process
(Brune et al., 1995) although there still exists a role for high concentrations ofNO in
cell pathology. The inhibition of mitochondrial respiratory enzymes is one such
target that has been implicated in cytotoxicity of both ONOO" and NO (Brown, 1999;
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Brown et al., 1998). Low concentration (nanomolar) NO inhibits the cytochrome
oxidase enzyme in competition with oxygen and higher concentrations ofNO inhibit
a wider range of mitochondrial respiratory enzymes through thiol nitrosylation.
ONOO" irreversibly inhibits numerous mitochondrial respiratory enzymes as well as
causing mitochondrial damage through membrane and DNA nitration (Brown,
1999). Again, confirmation of the presence of ONOO" through co-incubation of O2"
scavengers or ONOO" scavengers to attempt to reverse NO-loaded zeolite necrotic
responses may provide insight into the significance of particular species in this
effect.
The activation of neutrophils in vivo, occurs in response to a variety of inflammatory
mediators including LPS, IL-8 and TNF-a. The bacterial peptide fMLP was one of
the first chemoattractants identified as a potent activator of neutrophils (Selvatici et
al., 2006). This formylated tripeptide has been synthetically produced and is
commonly used in the experimental investigation of neutrophil activation (Carrigan
et al., 2007; Saito et al., 2001; Wittmann et al., 2004). There are two known
receptors for fMLP, called formyl peptide receptor (FPR) and FPR-like 1 (FPRL1)
which are located on the neutrophil membrane and are members of the G-protein
coupled receptor family (Selvatici et al., 2006). The interaction of fMLP with its
receptor triggers many second messenger systems involving GTP-binding protein,
phospholipases, protein kinases, polyphosphoinisotide metabolism and phosphatases
(Selvatici et al., 2006). The non-specific triggering of many second messenger
systems means that many aspects of neutrophil activation are involved in the
response to fMLP. These include cytoskeletal rearrangement, degranulaton and
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production of the oxidative burst which are important for the phagocytic clearance of
infecting pathogens, thus making fMLP a good choice as an all-round neutrophil
activator (Jesaitis & Allen, 1988). The concentration of fMLP used in our
experiment is within the optimal range for neutrophil activation, however the
modulation of neutrophil activation markers by fMLP at this concentration may
mask any potential inhibitory effects of NO. Future work should titrate the
concentration of fMLP to better investigate any inhibition of neutrophil activation.
Neutrophils are activated by a number of inflammatory mediators present during
different sorts of inflammatory insults. The use of other neutophil activators, such as
C5a and IL-1, should be investigated to gain a better understanding of the effect of
NO-releasing zeolites in different inflammatory environments.
The development of NO-loaded zeolites for medical device coatings requires
consideration of the physiological conditions under which they are likely to be
employed. The presence of blood derived NO-scavengers and flow conditions would
reduce the bioavailabilty of NO for its targets and would therefore suggest that the
high NO concentrations reached in our assay would be improbable in vivo.
Flowever, NO is a truly local mediator and thus, the vicinity of the targets to the site
of production (ie the zeolite surface) would influence the effects produced.
Neutrophil infiltration to the site of device placement occurs rapidly and therefore
these cells could be subjected to the full brunt of NO release from these materials,
subsequently enhancing activation and adhesion. If this scenario was true, necrotic
death of neutrophils would also be enhanced at the site of device placement, possibly
further exacerbating the elicited inflammatory response (see figure 4.18). Of course,
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the fate of NO in the body is complex and the presence of many different factors
including thiols, GSH, albumin, ROS and many more are known to contribute to the
biological effects ofNO, good and bad (Wink et al., 1996a; Wink et al., 1996b). The
relative presence of these factors within the body are also subject to variation
depending on internal and external stimuli and thus, the only reliable way to confirm
the pro- or anti inflammatory effects of the NO-loaded 50% Zn2+-exchanged zeolite
is through the use of prototype zeolite-coated medical devices in animal models.
However, it is important to note that the 50% Zn2+-exchanged zeolite used in these
experiments does not produce the optimal NO release properties ideal for use in
medical devices, which would benefit from long duration, low NO concentration
release characteristics, more akin to the anti-inflammatory, cytoprotective
concentrations of NO described in the literature (Rauen et al., 2007; Wink et al.,
1995). Further optimisation of zeolite design should precede in vivo experimentation
in the search for biocompatible coatings that inhibit neutrophil adherence. Despite
the lack of beneficial effects of NO-loaded zeolites on neutrophil adhesion molecule
expression and viability in these experiments, high NO production via iNOS has
been shown to be anti-microbial and could provide an alternative route by which
current zeolite designs could increase biocompatibility ofmedical devices.
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Figure 4.18. Hypothetical model of neutrophil behaviour following NO-loaded zeolite
exposure; Low versus high NO concentration.
Low [NO] from zeolite dilution produced no effect on neutrophil activation in this study.
However, it is possible that further lowering the concentration could have inhibited
neutrophil activation and adhesion through inhibition of CD62L shedding and CDllb up-
regulation. High [NO] concentrations released from zeolites promoted CD62L shedding and
enhanced CD1 lb expression following fMLP-stimulation (1 0"7M), suggesting these cells are
primed and subsequently more likely to be adherent and pro-inflammatory. High [NO]
increased necrotic cell changes, indicating high concentrations ofNO are pro-inflammatory
in this assay, perhaps due to increased production of OONO" following reaction with 02~
produced by activated neutrophils.
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CHAPTER 5.
The Anti-Bacterial Properties of Zn2+-
Exchanged Zeolites.
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CHAPTER 5.
The Anti-Bacterial Properties of Zn2+-
Exchanged Zeolites.
5.1 Introduction
Catheter-associated urinary tract infections (CAUTIs) account for around 30-40% of
all nosocomial infections (Karchmer et al., 2000; Warren, 2001). The duration of
hospitalisation and catheterisation significantly increases the likelihood of patients
contracting a bacterial infection (Maki & Tambyah, 2001), resulting in more drug
therapy and lengthier hospital stays for patients. Not only is this a significant cause
of morbidity and mortality in patients, it is a greater financial burden on the
healthcare system due to increased drug and hospital care costs (Plumridge &
Golledge, 1996). The conventional treatment ofCAUTIs involves the administration
of antibiotics, which carry the inherent risk of the pathogen developing drug
resistance and reducing the long-term therapeutic value of these agents. The
increasing prevalence of multi-resistance bacterial strains, in particular the strain
methicillin-resistant Staphylococcus aureus (MRSA) is a cause for concern in
hospitals requiring the development of new, efficient anti-bacterial protocols.
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The prevention of the incidence of CAUTIs and nosocomial infections in general, is
challenging and novel therapeutics and preventative measures are required urgently.
The introduction of better sterile handling techniques for hospital staff and more
rigorous criteria for the application of urinary catheters has only impacted minimally
on this wide-scale problem (Goldmann, 1991). The infectious agents are more likely
to be already present within the patient's urinary tract. Therefore an anti-septic
strategy delivered directly to the site of potential colonisation could reduce infection
rates. The integration of non-antibiotic, bactericidal agents into the catheter structure
provides one promising strategy to reduce the incidence of CAUTIs. It has been
shown that the use of a silver-alloy/hydrogel incorporating catheter successfully
reduced infections by 27-73% in a range of studies (Karchmer et al., 2000; Liedberg
& Lundeberg, 1990; Lundeberg, 1986; Maki & Tambyah, 2001; Rupp et al., 2004).
However, these catheters are expensive and the economical impact of their
application is a major consideration. Nevertheless, despite their cost, it has been
shown that the prevention ofCAUTIs by silver alloy/hydrogel catheters is more cost-
effective than the treatment of the acquired infections (Seymour, 2006). The
production of cheaper and more effective bactericidal catheters could further
improve the troubling infection rate and impact more favourably on healthcare
budgets.
It has been demonstrated that nitric oxide (NO) has well characterised
immunomodulatory effects (Albina & Reichner, 1998; Brune et al., 1998;
MacMicking et al., 1997; Ward et al., 2000). The production of high concentrations
ofNO during the inflammatory response is mediated via iNOS, the inducible form of
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the NO synthase enzyme. iNOS is induced by various pro-inflammatory mediators,
such as TNF-a, IFN-y, IL-1 (3 and LPS, to produce micromolar concentrations ofNO
contributing to the pro-inflammatory response and microbial killing (Brandonisio et
al., 2001; Moncada & Palmer, 1991). The importance ofNO in combating bacterial
infection has been confirmed through the use of animal models, such as the murine
iNOS knock-out model. Studies have shown increased susceptibility of this mouse
to infection by bacterial products (MacMicking et al., 1995). The suppression or
dysfunction ofNO production by iNOS is also linked to a number of human disease
states where susceptibility to infection is common, such as cystic fibrosis (Kelley &
Drumm, 1998; Meng et al., 1998).
Research into the use of NO as an anti-microbial therapy has produced promising
results, with studies indicating that it is cytotoxic to a large number of species of
fungi, bacteria, viruses and parasites (Ascenzi et al., 2003; Coban et al., 2003;
Karupiah & Harris, 1995; Rementeria et al., 1995) . However, the multiple
physiological targets of NO and the potential cytotoxicity of high NO levels to host
tissue makes systemic delivery of NO using NO-donors potentially harmful and has
limited the translation of these agents into the clinic. The free radical property ofNO
requires it to be bound to molecular carriers to stabilize it until its release is required.
The diazeniumdiolate compounds are one such example of NO-donor, which
incorporate NONOate groups onto stable nucleophile adducts. The rate of
decomposition of NO from such species occurs spontaneously without the need for
biological cleavage. This property makes these donors predictable releasers of NO,
but the lack of tissue specificity upon systemic delivery means unwanted side effects,
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such as systemic hypotension can be a problem. However, the use of NO as a
specific anti-microbial agent has recently come closer to reality through the use of
NO donor-incorporating polymers that direct NO treatment to a localised area. NO-
releasing polymer materials are comprehensively researched for development of
coatings for medical devices to improve the biocompatibility. Here, the uses of NO
can range from inhibiting thrombus formation in blood-contacting devices (Fleser et
al., 2004; Mowery et al., 2000; Schoenfisch et al., 2000), prevention of smooth
muscle proliferation in stenting (Hou et al., 2005; Kaul et al., 2000), prevention of
vasospasm as well as the design of anti-infective surfaces for medical devices
(Hetrick & Schoenfisch, 2007). A range of studies by Nablo et al., demonstrate the
effectiveness of a NO-releasing sol-gel derived material for reducing bacterial
adhesion to the surface of sol gel/polymer based medical devices (Nablo et al., 2001;
Nablo et al., 2005a; Nablo et al., 2005b; Nablo & Schoenfisch, 2003, 2005, 2004).
The ability of these materials to inhibit adhesion of a range of bacterial strains ranged
from 30-95% (Nablo & Schoenfisch, 2003). The flux of NO from these materials
can be tailored by altering the composition of the NO-releasing sol gel with the
polymer matrix and by using NO-donor compounds with different rates of
decomposition. The NONOate compounds are most commonly researched in this
arena due to the existence ofmany types of compounds with different decomposition
rates, which are dependent upon the species of the nucleophile adduct (Smith et al.,
1996). Careful consideration of the species ofNO-donor is required to avoid adverse
effects of harmful by-products leaching from the surface of the material (Fitzhugh et
al., 2002; Nablo & Schoenfisch, 2005). Additionally, the flux of NO obtained from
the material has to be carefully engineered to ensure minimal cytotoxicity to
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surrounding host tissue (Nablo & Schoenfisch, 2005). At present, the anti-adhesive
properties of these materials to bacteria are impressive, however, no bactericidal
effect has been established with these materials. The inhibition of bacterial adhesion
is important in preventing bacterial colonisation, but due to the opportunistic nature
and rapidity of multiplication of bacteria, it remains possible that the successful
colonisation of just a few bacteria could lead to infection. The limited time of NO
release from these materials would also mean any viable bacteria surrounding could
colonise the surface when NO stores have been exhausted, reducing the therapeutic
value of these materials in long-term device placements, where infection rates are
most troublesome (Bissett, 2005; Huang et al., 2004). A direct bactericidal effect
together with the anti-adhesive properties of a NO-releasing material could serve to
eliminate medical device related infections completely by eradicating all infectious
agents from the surfaces surrounding the device.
In this chapter, the effectiveness of a novel, high capacity NO-storing and releasing
material at reducing bacterial growth in vitro was assessed with the view to their
potential use as anti-bacterial coatings for medical devices. As previously
mentioned, the composition of zeolite to the polymer matrix and the ion exchanged
within the zeolite structure can be altered to tailor the NO-release capacity of these
materials, making them an attractive candidate for a variety of biocompatible
medical device coatings. The release of short-lived, high concentrations of NO
associated with these materials draws similarities with the kinetics ofNO released by
the action of iNOS during the inflammatory responses in the body, suggesting a
benefit of these materials in localised clearance of infectious agents. Additionally,
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anti-microbial actions of high concentrations of NO released from these materials
could provide an anti-bacterial therapeutic that may avoid the development of
bacterial resistance.
Thus, we hypothesised that a NO-loaded 50% Zn2+-exchangd zeolite (PTFE), would
possess anti-bacterial properties against bacterial strains commonly found in
nosocomial device-related infections, and that the anti-bacterial properties would be
dependant upon high concentrations of NO released from zeolite stores, making
these materials candidates for further development as anti-infective coatings for
medical devices.
The Gram-negative, P.aeruginosa and Gram-positive bacteria, methicillin-sensitive
Staphylococcus aureus (MSSA) were used to assess anti-bacterial effects against
these two classes of bacteria, which are chiefly differentiated by the structure of the
bacterial membrane (see section 1.1.6.2.2). The use of a clinical specimen from a
lung infection of P.aeruginosa (J 1386) was investigated to ensure universal toxicity
of these materials to physiologically relevant, virulent strains of bacteria. Through
these experiments, aspects of the mechanism of the anti-bacterial effects of these
materials were also addressed.
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5.2 Methods
5.2.1 Materials
Zeolites were synthesised at St Andrews University (see section 2.8.1). Briefly,
Zn2+-ions were exchanged into zeolite configuration LTA. The resulting zeolite
powder was loaded with NO gas under 2 atmospheres pressure and pressed into 5mm
diameter discs composing 50 weight% zeolite and 50 weight%
polytetrafluoroethylene (PTFE). Unless otherwise stated, 50% Zn2+-exchanged
zeolites were used.
The bacterial strains used in the experiments (PA01 and MSSA) were established
strains used in the CIR/lung group lab. The clinical specimen, J1386, was kindly
donated by Dr John Govan.
LB (Luria Bertani) broth and LB agar were purchased from Sigma (Hertfordshire,
UK) was made up according to manufacturers instructions.
5.2.2 Bacterial Culture
Bacteria were cultured on a nutrient broth agar LB (Luria-Bertani) at room
temperature. Bacterial suspensions were prepared by inoculating 10ml of LB broth
with one colony of the relevant bacteria and incubating overnight at 37°C in an
orbital shaker. Bacteria were then sub-cultured with a 1/100 dilution of the original
bacterial suspension and incubated for 3 hours. The bacteria were harvested via
centrifugation (1500g; 15 min) and re-suspended in a 5%LB:PBS solution. This step
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was then repeated once more to ensure adequate washing of the cells. The
suspensions were standardised each day via dilution with 5% LB broth to an optical
density of 0.1 at 595nm using spectrophotometry (WPA UV 1101, Biotech
Photometer). A further 1 in 1000 dilution was performed for use in the assays.
The zeolite treatments were investigated in varying volumes (150-1200pl) of a 1/1
dilution of the bacterial suspension prepared above. Dilutions were prepared using
5% LB in PBS solution. The treatments were carried out at 37°C on a heated block
with shaking at 400rpm for varying times between 2-120 min.
The evaluation of bacterial growth following treatments was done using the colony
forming unit (cfu) assessment. A 100pi aliquot of 10~2, and 10"3 dilutions of the
original bacterial suspension were spread onto LB agar plates in triplicate. The
plates were left to incubate at 37°C overnight at 5% CO2 for approx 16 h and the
number of colonies formed were counted. The number of bacteria present in the
suspension following treatments was estimated, assuming that 1 colony arises from a
single bacterium and by multiplying by the dilution factors to obtain bacteria/ml.
Where appropriate, treatments were compared as a percentage of the number of
bacteria (cfus) at time zero (t=0).
5.2.3 NO Electrode
NO measurements were carried out using an isolated (2mm) NO electrode (ISO-
NOP; World Precision Instruments, Stevenage, UK), calibrated each day prior to use
with NaN02 (see chapter 2.3.1). Data were captured via an analogue-digital
converter (Maclab 4e, AD Instruments, Sussex, U.K).
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NO released from NO-loaded 50% Zn2+-exchanged zeolites was measured in 1ml of
5% LB:PBS solution. The electrode was suspended in the solution and allowed to
reach a baseline reading prior to zeolite suspension. NO measurements were
recorded for approx 60min following zeolite suspension. The zeolite disc was
suspended in the solution using a stainless steel holding device. Each sample was
incubated at 37°C and contained a magnetic stir bar, which stirred the solution at
1 OOOrpm for the duration of the experiment. Relevant time-points were selected for
analysis and traces ofNO release over time were plotted.
5.2.4 Statistics
Statistical analyses were performed using one-way or two-way analysis of variance
with either Dunnet's or Bonferroni's post hoc test and confirmed using non-
parametric Kruskel-Wallis with Dunn's post hoc, where appropriate. Statistical
significance was assumed when p < 0.05 at the 95% confidence interval.
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5.3 Results
5.3.1 The Effect of 50% Zn2+-Exchanged Zeolites on the Growth of
Gram-Negative Bacteria.
'j | #
NO-loaded Zn -exchanged zeolites at 50% composition of zeolite to PTFE binder
had a significant bactericidal effect when incubated in bacterial suspensions of a
laboratory (figure 5.1 A) and a clinical strain (figure 5.1 B) of Pseudomonas
aeruginosa (PA01 and J1386 respectively). This effect was seen after a 45 min
incubation of the zeolite disc in the bacterial suspension (5% LB:PBS; 150[fi; 37°C).
The NO-free zeolite discs had no significant effect on PA01 numbers but caused a
significant reduction of J1386 bacterial numbers. Bacterial growth of the J1386 strain
remained stagnant over the 45 min incubation period indicating the assay conditions
were not optimal for growth of this particular bacterial strain.
Figure 5.2 shows a representative photograph of PA01 colonies grown on LB agar
plates following treatments from which bacterial numbers were estimated. The lack
of colonies on the agar plate following NO-loaded treatment is visible, whereas the
control and NO-free zeolite treatments produced comparable numbers of colonies.
Bacterial killing was even more pronounced in the PA01 strain after 120 min zeolite
incubation (150p.l; 37°C), which produced zero colonies of PA01 following NO-
zeolite treatment (figure 5.3).
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PA01 Treatment (t=45 min)
t=0
Control
■■ + NO-loaded zeolite
I t+ NO-free zeolite
J1386 Treatment (t=45 min)
Figure 5.1- The effect of 50% Zn2+-exchanged zeolites on Gram-negative bacterial
growth; 45 min zeolite incubation.
Bacterial growth following NO-loaded zeolite (black bars) and NO-free zeolite (white bar)
treatment (45min; 37°C) in suspensions (5% LB broth:PBS; 150pi) of a laboratory strain (A;
PA01) and a clinical strain (B; J1386) of P.aeruginosa. Data are expressed as % of colony
forming units (cfus) at t=0 (broken line). Bars indicate the mean +/- the SEM of 3-6 plates
per treatment in n=6 (A) or n=4 (B) independent experiments. Asterisks denote significance
from control (t=45 min; striped bar) growth. (**p < 0.01).
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NO-free Zeolite NO-loaded Zeolite
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Figure 5.2 A photographic representation of PA01 colonies on LB agar plates following
50% Zn2+-exchanged zeolite treatment - 45 min.
A photograph showing typical LB agar plates from which PA01 colonies were counted to
estimate bacterial numbers present following the zeolite treatments (45 min). Samples from
lOOp.1 of a 10 2 dilution of the treated bacterial suspension were spread on LB agar plates and
incubated for 16 hours (37°C; 5% CO2) to allow colonies to form. The picture shows PA01
colonies following control (left), NO-free zeolite (middle) and NO-loaded zeolite (right)
treatments.
173
Chapter 5-The anti-bacterialproperties ofZn2 -exchanged zeolites
400
PA01 Treatment (t=120 min)
t=0
SSS3 Control
■■ + NO-loaded zeolite
nu + NO-free zeolite
Figure 5.3. The effect of 50% Zn2+-exchanged zeolites on PA01 growth - 120 min
zeolite incubation.
Bacterial growth following NO-loaded zeolite (black bars) and NO-free zeolite disc (white
bar) treatments (120 min; 37°C) in suspensions (5% LB broth:PBS; 150pl) of a laboratory
strain (PA01) of P.aeruginosa . Data are expressed as % of c.olony forming units (cfus) at
t=0. Bars indicate the mean +/- SEM of an average of 3-6 plates per treatment for n=3
independent experiments. Asterisks denote statistical significance from control (t=120 min;
striped bar) growth (*p < 0.05, n/s - not significant).
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5.3.2 The Effect of50% Zn2+-Exchanged Zeolites on the Growth ofa
Gram-positive Bacterial Strain, Methicillin-Sensitive
Staphylococcus Aureus (MSSA).
The incubation of NO-loaded and NO-free zeolites in bacterial suspensions of the
Gram-positive bacterial strain, MSSA, significantly reduced bacterial growth
compared to control samples incubated in the same conditions (Figure 5.4). The
reduction in bacterial growth by the NO-free zeolite does not appear to fall below
the number of bacteria at t=0, suggesting a bacteriostatic effect of the NO-free
zeolite disc. The reduction in bacterial numbers following NO-loaded zeolite
treatment is more significant and below the number of bacteria present at t=0,
suggesting a bactericidal effect ofNO.
Figure 5.5 shows a representative photograph of MSSA colonies on LB agar
following the zeolite treatments. The complete lack of colonies following NO-
loaded zeolite treatment is visible, as is the reduction of the number of colonies
present following NO-free zeolite treatments compared to control (t=45 min).
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H + NO-loaded zeolite
nn + NO-free zeolite
MSSA Treatment (t=45 min)
Figure 5.4 The effect of 50% Zn2+-exchanged zeolites on MSSA growth.
Bacterial growth following NO-loaded zeolite (black bar) and NO-free zeolite (white
bar) incubations (45 min; 37°C) in a MSSA suspension (5% LB broth:PBS; 150pl). Data
are expressed as a % of colony forming units (cfus) at t=0 (broken line). Bars represent
the mean +/- SEM of an average of 3-6 plates per treatment in n=6 independent
experiments. Asterisks denote statistical significance from control (t=45 min) growth. (*
p < 0.05, **/?<0.01).
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Figure 5.5. A photograph representation of MSSA colonies on LB agar plates following
50% Zn2+-exchanged zeolite treatment- 45 min.
The photograph of typical LB agar plates from which MSSA colonies were counted to
estimate bacterial numbers present following the zeolite treatments (45 min). Samples from
lOOpl of a 10~2 dilution of the treated bacterial suspension were spread on LB agar plates and
incubated for 16 hours (37°C; 5% C02) to allow colonies to grow. The picture shows MSSA
colonies following control (left), NO-free zeolite (middle) and NO-loaded zeolite (right)
treatments.
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5.3.3 The Effect ofP.Aeruginosa Suspension Volume on Bacterial
Killing by NO-loaded Zeolite Discs.
Zeolite discs were diluted in various volumes (150-1200^x1) of P. Aeruginosa
bacterial suspensions to assess the effect of volume, and subsequent dilution of NO
concentrations, on bacterial killing. The reduction in bacterial numbers by NO-
loaded zeolites was inversely related to the volume of the bacterial suspension in
both the laboratory (PA01; figure 5.6 A) and the clinical (J1386; figure 5.6 B) strains
of P.Aeruginosa. Bacterial killing by NO-loaded zeolites was significant in both
PA01 and J1386, at the lowest volumes (<;300|il) when NO concentrations are likely
to be highest.
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J1386 Treatment/Volume (t=45 min)
Figure 5.6 The concentration-dependent reduction of P.aeruginosa Growth by NO-
loaded 50% Zn2+-exchanged zeolites.
Bacterial growth following NO-loaded zeolite incubation (45 min;37°C) in increasing
volumes (150-1200pl) of J1386 (A) and PA01 (B), optical density equalised, bacterial
suspension (5% LB:PBS). Bars represent the mean +/- SEM of an average of 3-6 plates per
treatment in n=3 independent experiments. Data is expressed as % of colony forming units at
t=0 (dotted line). Asterisks denote statistical significance from control bacterial growth at
t=45 (* p <0.05, **/?<0.01).
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5.3.4 The Effect ofMSSA Bacterial Suspension Volume on Bacterial
Killing/Stasis by NO-loaded and NO-free Zeolite Discs.
The reduction of MSSA numbers by NO-loaded (figure 5.7A) and NO-free (figure
5.7B) zeolites is inhibited by increasing volumes (150-1200^1) of the MSSA
suspension (5% LB broth: PBS). Significant inhibition of MSSA growth was
achieved by NO-loaded discs suspended in volumes < 300pl (*p < 0.05; **p < 0.01
vs control). The NO-free disc produces a significant reduction in MSSA growth at
the lowest dilution only (150p,l; p < 0.01 v.s- control).
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MSSA Treatment/Volume (t=45 min)
Figure 5.7. The concentration-dependent reduction of MSSA growth by NO-loaded and
NO-free Zn2+-exchanged zeolites.
Bacterial growth following NO-loaded zeolite (A) and NO-free zeolite (B) incubation (45
min; 37°C) in increasing volumes (150-1200pl) of MSSA, optical density equalised,
bacterial suspension (5% LB:PBS). Bars represent the mean +/- SEM of an average of 3-6
plates per treatment in n=3 independent experiments. Data is expressed as % of colony
forming units at t=0. Asterisks denote statistical significance from control bacterial growth at
t=45 (*p <0.05, **p <0.01).
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5.3.5 The Effect of the Ion Exchanged in the Zeolite Structure on the
Inhibition ofMSSA Growth by NO-free Zeolites.
Figure 5.8 shows a photographic representation of MSSA growth on LB agar
plates following treatment with 50% Zn2+, Ca2+ and Co2+ -exchanged NO-free
zeolite discs (150pl; 37°C, 45 min). The reduction in colonies following Zn2+
2_|_ ,and Co -exchanged zeolite treatment is visible compared to control, however
the Ca2+-exchanged zeolite appears to enhance growth of MSSA bacteria
compared to control. The complete lack of colonies following the Co2+ zeolite
treatment suggests that this zeolite has more cytotoxic effects on MSSA bacteria
than the Zn2+ zeolite.
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Figure 5.8 A photograph representation ofMSSA colonies on LB agar plates following
NO-free (50% Zn2+, Ca2+ and Co2+-exchanged) zeolite treatment.
The photo shows representative MSSA colonies grown on LB agar following control (top),
50% NO- free Zn2+ (bottom right), Ca2+ (bottom middle) and Co2+-exchanged zeolite
treatments in 150ju.l MSSA suspension (5% LB:PBS; 37°C; 45 min). Colonies were grown
from lOOpl of a 10~2 dilution of the treated bacterial sample. The plates were incubated for
16 hours (37°C; 5% C02) to allow colonies to form.
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5.3.6 The Effect ofNitrite and Nitrate on bacterial growth ofMSSA.
Addition of NaNC>2 or NaNC>3 (ImM) to MSSA suspensions (150pl; 5% LB:PBS)
for 45 min (37°C) had no effect on MSSA growth and produced comparable















Fyocl + NaN02 (1mM)
[S3 + NaN03 (1mM)
MSSA Treatment (t=45 min)
Figure 5.9. The effect of nitrite and nitrate (ImM) on MSSA growth.
MSSA bacterial suspensions (150pi; 5% LB:PBS) were treated with NaN02 (ImM; red
striped bar), NaN03 (ImM; orange striped bar) or control (untreated; black striped bar) for
45 min (37°C). Data is expressed as the number of bacteria per ml, estimated using the
colony forming unit assay and are the mean of n=2 experiments.
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5.3.7 The Time-Dependent NO-release Reduction in PA01 Growth by
NO-loaded Zeolites.
The NO release profile as measured using a NO electrode, shows a large
concentration ofNO (peak approx 30p,M in 1ml 5% LB:PBS) released over a short
time period (figure 5.10, red line). The peak NO release occurs at approx 10 min
after disc suspension and the signal decomposes rapidly until NO reaches baseline by
approximately 40 min.
The inhibition of PA01 growth by NO-loaded zeolites suspended in 150pl of the
bacterial suspension (37°C; 5% LB:PBS) shows no significant reduction at disc
incubations < 30 min. No significant inhibition of bacterial growth is apparent at the
10 and 20 min time-point although the majority of the NO has been released by this
time. Significant reduction of PA01 growth by NO-loaded zeolites was only evident
following zeolite exposure >30 min (figure 5.10 B;*p < 0.05; **p < 0.01).
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Figure 5.10. The time-dependent NO-release and reduction ofP.aeruginosa growth by
NO-loaded 50% Zn2+-exchanged zeolites.
The NO release profile ofNO-loaded zeolites (50% Zn2; red line) measured in 5% LB:PBS
media (lml;37°C; 50 min). The [NO] was calculated at selected time-points and is the mean
+/- SEM ofn=5 individual experiments.
The bottom line graph shows PA01 growth following various incubation times (2-45 min) of
control (black line) and NO-loaded zeolite (broken line) treated bacterial suspensions (150pl;
5% LB:PBS; 37°C). Data points represent the mean +/- SEM of an average of 3-6 plates per
treatment in n=5 independent experiments. Data is expressed as the number of bacteria
present per ml, estimated from the colony forming unit assay following control and zeolite
treatments at each time-point. Asterisks denote significance from PA01 control growth at
the appropriate time-point (*p < 0.05; ** p < 0.01).
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5.4 Discussion
The colony forming unit (cfu) assay used to estimate the anti-bacterial potential of
zeolite treatments is a standard technique employed in the literature to assess the
antimicrobial activity of a number of agents. The reduction in bacterial numbers
compared to control is a good indicator of the inhibition of bacterial growth
following zeolite treatment. The estimation of the number of bacteria present at t=0
also allows the determination of a bactericidal or bacteriostatic effect of the
treatments as well as the growth potential of the bacteria in experimental conditions.
If the numbers of bacteria following treatments is reduced to levels < t=0, it can be
considered that the bacteria are being killed, a bactericidal effect. Alternatively, a
bacteriostatic response is suggested when bacterial growth fails to reach levels of the
control suspensions incubated for the same time and numbers remain comparable to
those estimated at t=0. In our experiments, NO-loaded zeolite treatment produced a
bactericidal effect following zeolite incubation time > 45 min against all bacterial
strains investigated. This effect was significant in both Gram-negative (PA01 and
J1386; figure 5.1-5.3) and Gram-positive (MSSA; figure 5.4-5.5) bacterial strains.
These findings are in concordance with previous literature describing the bactericidal
effect of NO (Hetrick & Schoenfisch, 2007; Hoehn et al., 1998; McMullin et al.,
2005; Nablo & Schoenfisch, 2003). The potency of these zeolites on a wider range
of bacterial strains together with potential anti-fungal and anti-viral effects remains
to be investigated. However, the potency of the NO-releasing zeolites in the
bacterial strains detailed, together with the rapidity of their anti-bacterial actions
provides promising results for their future development.
187
Chapter 5-The anti-bacterialproperties ofZn21 -exchanged zeolites
The adhesion of bacterial cells to surfaces is central to the formation of biofilms,
which are notoriously difficult to clear and are linked with the production of anti¬
biotic resistance (O'Neill et al., 2007). It is therefore important to consider the
adhesive properties of materials being developed for medical grade purposes. The
polymer PTFE is commonly used in a number ofmedical devices due to its structural
integrity and its favourable biocompatibility compared to other materials. The
zeolite:PTFE material has previously been shown to inhibit platelet adhesion to its
surface (Wheatley et al., 2006) through the release of NO. Preliminary scanning
electron micrograph images of the surface of zeolite discs following bacterial
incubation indicate NO-loaded discs have similar anti-adhesive properties against
bacteria (data not shown). The anti-adhesive properties of NO-releasing materials
are well documented in the literature, however few of these materials have
demonstrated antiseptic properties against bacteria, arguably the most important
consideration in the design of anti-infective coatings. Furthermore, the resistance of
current polymer based medical device coatings to bacterial adhesion is already
impressive for most strains and therefore, further preventing adhesion may not
improve infection rates significantly (Nablo et al., 2005b). The anti-bacterial
properties of NO-loaded zeolites are both bactericidal and anti-adhesive, further
substantiating our proposal for the development of these materials for medical device
coatings.
Small volumes of bacterial suspensions were used to suspend the zeolite discs, which
subsequently concentrate the NO released from the zeolite disc. It was hypothesised
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that high concentrations of NO are required to produce bactericidal effects. This
hypothesis was confirmed when further dilution of the zeolite discs in increasing
volumes, reversed the reduction in bacterial numbers observed at low dilution
volumes (figure 5.6-7). These findings are in line with previous findings
demonstrating NO-mediated reduction in bacterial viability (Coban et al., 2003;
Hetrick & Schoenfisch, 2007).
Differences in growth rates of control bacterial suspensions varied considerably
between strains. This could be attributed to variations in metabolic activities and the
biological niches in which these bacteria normally thrive. The clinical strain, J1386,
is a mucoid strain isolated from the lungs of patients with cystic fibrosis, whereas the
PA01 strain is a commonly used, laboratory strain isolated from skin infections.
J1386 bacterial numbers remained comparable to those present at t=0 following the
45 min incubation, whereas PA01 growth almost doubled, highlighting the
differences in the culture requirements for growth between these two species of
P.aeruginosa. It is likely that J1386 requires a more nutrient-rich medium than the
5% LB medium used throughout the experiment. Interestingly, the NO-free zeolite
produced a significant reduction in bacterial numbers in this strain. The reason for
this reduction is unclear, but it is possibly due to leaching of Zn2+ from the zeolite
surface. It is possible, however, that adhesion of these bacteria to the zeolite/PTFE
surface could account for a reduction in bacterial numbers, as less bacteria would be
left in the suspension for plating out for cfu analysis. The other Gram-negative
strain, PA01 demonstrated no significant reduction of bacterial numbers following
NO-free zeolite incubation, even after 120 min. It is possible that J1386 is more
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prone to adherence. Further investigation using SEM to visualise the surface of the
NO-free zeolite materials following exposure to J1386 would answer this.
The Gram-positive bacteria, MSSA is a strain commonly found colonising skin and
nasal passages. As well as the bactericidal effect produced by the NO-loaded zeolite,
the NO-free zeolite control disc also attenuated MSSA growth in vitro. The effects
seen with the NO-free disc were bacteriostatic as the bacterial numbers present
following treatments were comparable to those estimated at t=0. This finding
suggests the bactericidal effect of these zeolites is due to release of NO. The
bacteriostatic effect observed in MSSA could be due to the leaching of Zn2+ into the
bacterial suspension. Attempts were made to chelate Zn2+ from the bacterial
suspension through co-incubation of EDTA, however detrimental effects of EDTA
on bacterial growth made interpretation of the implication of Zn2+ not possible.
Future experiments could confirm of this hypothesis could be achieved through
measurement of Zn2+ from solutions containing zeolite materials over several time-
points. This could be done using flame atomic absorption spectroscopy (FAAS) or
inductively coupled plasma mass spectroscopy (ICP-MS), which are techniques that
can detect trace elements in biological sample through characteristic absorption
wavelength or charge-mass ratio (Bolann et al., 2007; Sarmiento-Gonzalez el al.,
2005).
Gram-positive and Gram-negative bacteria differ primarily in their membrane
structure. Soderberg et al demonstrated a similar bacteriostatic effect in Gram-
positive bacteria following zinc oxide treatment than that observed in this study.
Interestingly, Gram-negative strains were generally unaffected by zinc oxide at
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concentrations up to 1024pM and thus, it was speculated that the bacteriostatic effect
was due to the specific binding of Zn2+ to components of the Gram-positive bacterial
membrane, which subsequently inhibits bacterial replication (Soderberg et al., 1990).
No bacteriostatic effects were observed following NO-free zeolite treatments in the
Gram-negative strain PA01, which supports this hypothesis and could highlight a
possible mechanism for the bacteriostatic effects of NO-free zeolites in MSSA. A
bactericidal effect rather than a bacteriostatic effect was observed following NO-free
zeolite treatments in J1386, which implicates a different mechanism in this effect
(possibly adherence) and further supports the Gram-positive bacterial susceptibility
to Zn2+ induced bacteriostasis.
The antimicrobial effect ofmetal ions is best described through the use of silver ions
(Ag+) in wound dressings (Babu et al., 2006; Bergin & Wraight, 2006; Dowsett,
2004) and antimicrobial device coatings (Bechert et al., 1999; Harrison et al., 2007;
Kumar & Munstedt, 2005). The mechanism of the antimicrobial action is not fully
understood but has been linked to a number of mechanisms including inhibition of
the respiratory chain and the leakage of H+ through Ag+-bound membrane proteins
resulting in a loss of the trans-membrane proton gradient crucial for bacterial
metabolism (Dibrov et al., 2002; Holt & Bard, 2005). At high concentrations, the
bactericidal effects of Ag+ is less specific, inhibiting a number of enzymatic
activities and reacting with electron donor groups (Holt & Bard, 2005; Slawson et
al., 1992; Wells et al., 1995). The mechanism of the antimicrobial action of other
metal ions, including Zn2+ has also been reported in the literature (Aghatabay et al.,
2007; Silver, 1996; Soderberg et al., 1990). The mechanism of their anti-bacterial
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action is less well understood but is likely to target similar metabolic enzymes. The
approximate composition of Zn2+ present within each zeolite disc is 20 umoles,
which would equate to a possible 0.13M of Zn2+ in the 150pl bacterial suspension in
this assay. This is the very upper limit of what potentially could leach from the disc
and, in practice, the concentration is likely to be much lower. However, if only
1/100 of the Zn2+ is displaced from the structure into the solution, the Zn2+
concentration would still be in the millimolar range at this dilution. Thus, it is very
2"b • •
plausible that Zn leaching from these zeolites could produce cytotoxic and
cytostatic responses. The effects of the NO-free disc were only apparent at the
lowest dilution with control growth being restored when the disc was incubated in a
• • • 2"b300pi volume, suggesting a concentration-dependent response of bacteria to Zn .
The confirmation of the extent of the leaching is important in determining the
potential of these materials for in vivo clinical use as toxicity to bacterial cells could
translate to toxicity in host cells. Despite this, bacterial killing by Zn2+ within NO-
loaded zeolites, could have excellent ex vivo prospects. For example, a simple ring
of NO-loaded Zn2+ zeolite at the outer ends of a urinary cannula could provide
protection from bacterial infections resulting from external sources, thereby
bypassing the possible in vivo cytotoxicity of these agents to host tissue.
Additionally, the use of powdered Zn2+ zeolites could be used as surface
disinfectants. In this arena, the preliminary burst ofNO could provide the powerful
disinfectant effects to kill off any contaminating microbes, and once the NO reserves
are exhausted, the Zn2+ could provide continued anti-microbial defence against
susceptible strains. This is particularly attractive when considering the problems
associated with the Gram-positive bacteria, MRSA. This strain is a significant cause
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of morbidity and mortality within hospital environments and is diffucult to treat due
to the development of antibiotic resistance in this strain (Jarvis et al., 2007; Lodise &
McKinnon, 2007). NO-releasing Zn2+ -exchanged zeolites could be a potential
solution to the management of these antibiotic resistant strains, in both patient-based
therapies and as novel disinfectants in hospital cleaning regimes.
2_j_ . ... ... . •
Although Zn leaching could provide additional anti-microbial protection against
some strains, toxicity to host tissue remains a concern. One potential answer to the
application of zeolites in vivo is the use of different ion exchanged zeolites. We used
a Co2+ and a Ca2+ exchanged NO-free zeolite in the MSSA assay to assess the impact
of the type of ion on MSSA growth. Results following incubation with the Co2+-
exchanged zeolite showed that it enhanced toxicity to MSSA bacteria compared to
that seen with Zn2+-exchanged zeolites. Preliminary experiments with the NO-free
Ca2+-exchanged zeolite suggested that this zeolite enhanced growth of MSSA
compared to control. The anti-bacterial effects of the NO-loaded version of the Ca2+-
exchanged zeolite are yet to be investigated but are predicted to produce similar
bactericidal effects to other NO-loaded zeolites as the capacity for NO storage is
likely to be similar to that of Zn2+. Clearly, optimisation of zeolite design is
necessary to produce ion-exchanged zeolites with minimal potential toxicity while
retaining the anti-microbial effects associated with the high concentrations ofNO.
As well as a concentration dependent effect of NO on bacterial growth, a temporal
association was also demonstrated in the inhibition of PA01 growth. Zeolite
incubation times varying from 2-45min demonstrated that inhibition of PA01 growth
193
Chapter 5-The anti-bacterialproperties ofZn -exchanged zeolites
occurred only following at least 30 min of zeolite exposure. This was surprising
because the NO release profile for these zeolites shows a rapid release of NO,
reaching peak concentrations at approx lOmin and returning to near baseline levels
by 50min. The free radical properties ofNO and related species has been suggested
to produce a direct oxidative or nitrative stressing effect on cells at these
concentrations. Thus, killing would be predicted to take maximal effect when peak
NO concentrations are being released at 10-20 min. However, PA01 exposed to
zeolite discs for these times showed absolutely no bacterial killing and bacterial
numbers were comparable to control. In fact, a slight enhancement of growth at
these time-points is suggestive but not significant. The direct correlation with NO
concentration and degree of killing demonstrated by earlier experiments (figure 6.6
B) suggest that this temporal effect is not solely a concentration-dependent response
as a similar correlation of bacterial killing should be apparent at earlier time-points
when the NO concentration would be lower. It is possible therefore that NO released
by zeolite discs is triggering a biological response within the PA01 bacteria, which
subsequently only results in a bactericidal effect following 30-45min of NO
exposure. Further investigation is required to determine if the temporal association
of the bactericidal effect of NO is evident in other bacterial strains although
preliminary results with MSSA suggest a similar response (data not shown). The
exhaustion of bacterial defences against NO may be one explanation for the delayed
killing response in PA01. Pyocyanin is a phenazine pigment produced by
Pseudomonas Aeruginosa bacteria which has been shown to decrease the activity of
NO in a number of tissues (Gryglewski et al., 1992; Hussain et al., 1997; Warren et
al., 1990). The mechanism of the inactivation ofNO is not fully understood, but is
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suggested to be due to the formation of nitrosylated pyocyanin species, which in turn
inhibit the biological actions of NO. Bacteria can employ a number of antioxidant-
like defences that vary according to the species of bacteria. Variations in the types of
antioxidant produced by different bacterial strains are thought to contribute to the
disparity in the susceptibility of bacteria to different species of reactive nitrogen
species reported in the literature (De Groote et al., 1995; Zaki et al., 2005; Zhu et al.,
1992) . It is likely that bacteria release a deluge of defences against oxidant species,
which could possibly be exhausted or overcome by the presence of high
concentrations of oxidant species. In this assay, the majority of the NO is released
within the first 20 minutes and if antioxidant defences were present until this stage,
the subsequent release of lower concentrations of NO following this time-point
would be expected to produce a less significant killing response than that observed.
Previous disc dilution experiments (figure 6.6 B) demonstrated that high
concentrations of NO are required to produce the level of killing in PA01 bacteria
produced in the temporal assay. So, this brings us to hypothesise the involvement of
a bacterial receptor interaction with NO or related species. In inflammatory cells,
NO is suggested to act via a death receptor pathway to either up-regulate or down-
regulate survival signals important for the prevention or initiation of programmed
cell death (apoptosis) (Brune et al., 1995; Brune et al., 1998; Ward et al., 2000). The
involvement of apoptotic like signals in prokaryotes is controversial, however similar
cell death phenotypes have been described in unicellular organisms including DNA
fragmentation, cytoplasmic blebbing and vacuolization (Rice & Bayles, 2003).
Additionally, these responses have been associated with exposure to oxidative stress
(Rice & Bayles, 2003). Quorum sensing is another bacterial phenomenon that
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involves the communication between bacterial cells to control virulence factors.
PA01 has been described to use quorum sensing to develop biofilms. Quorum
quenching involves the interference of the signalling mechanism produced from
production of quorum sensing molecules and can result in the limitation of bacterial
virulence. The interference of bacterial communication can also result in a mass
death response in these organisms (You et al., 2004) which may be a possible
explanation for the dramatic reduction of bacterial numbers at a critical time-point.
The interesting temporal relationship of NO and bacterial killing described in this
chapter is one that has not been shown previously and is one which warrants further
investigation.
The complex chemistry of NO requires one to be careful when determining the
effector species of cytotoxic effects. It is suggested that NO in its pure form is not
cytotoxic in a number of cell types, and that the formation of OONO" species
through the interaction of NO with O2" is the main culprit of the majority of the
cytotoxicity associated with NO (Pacher et al., 2007). The upregulation of O2"
production by immune cells during inflammatory responses together with the
upregulation of NO production through iNOS provides the right conditions for
significant peroxynitrite production in the inflammatory microenvironment
important for microbial killing and clearance of infection in vivo. OONO" is a
potent oxidant with multiple targets including lipid peroxidation and DNA
fragmentation, which have detrimental effects on bacterial viability. The
involvement of O2" production in our experiments is not clear and efforts to
scavenge both peroxynitrite species and O2" in our bacterial suspensions were
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fraught with difficulty due to the non-specific effects of these agents on control
bacterial growth. The presence of a Of generating system in this experiment is
unconfirmed, however, the absence of cell types known to generate O2" would
suggest that only background levels of O2" would be present, thus peroxynitrite
levels could be insignificant especially compared to the levels ofNO released. It
still remains possible that NO itself is the cytotoxic agent given that the
concentration in the bacterial suspensions is remarkably high and the non-specific
effects of high concentrations of this free-radical could have detrimental effects on
bacterial viability. Indeed, some strains do have greater sensitivity to the
bactericidal effects of NO than OONO" (Assreuy et al., 1994; Fernandes &
Assreuy, 1997). Better understanding of the redox potential of bacterial products
and LB broth is required to elucidate the relative presence of NO and related
species. The end product ofNO production, NO2" and NO3", was not the cytotoxic
species in our experiments. ImM concentrations of the sodium salts ofMV and
NO3" failed to produce any significant effects on bacterial growth in MSSA (data
not shown). Many other potential mechanisms of anti-bacterial effects ofNO and
related species exist including the modulation of critical bacterial proteins through
interactions with sulphydryl, haem, and amine groups and aromatic residues (Fang,
1997). The elucidation of the mechanism of the anti-bacterial actions of NO is a
complex procedure due to the influence of many different components on NO
biochemistry. Understanding how NO produces anti-microbial actions could help
harness this potential for future development of successful anti-microbials.
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In summary, we have shown that 50% Zn2+-exchanged zeolite:PTFE materials
have potent anti-bacterial properties in Gram-negative and Gram-positive bacteria.
The mechanism of the observed bactericidal effect was associated with high
concentrations of NO release for over 30 minutes. The potential leaching of Zn2+
from the zeolite structure may contribute to the observed bacteriostatic effect of
NO-free discs in Gram-positive MSSA bacteria. The potential development of
these materials as anti-microbial coatings for use in medical devices requires the
further characterisation of these agents in a more diverse range of bacterial and
fungal strains together with a fuller understanding of the mechanism of action and
cytotoxicity in vivo is required before these materials can be used in the clinic.
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Chapter 6 - General Discussion.
6.1 Introduction
Nitric oxide (NO), the toxic by-product of combustion engines, atmospheric
pollutant and widely revered biological elixir, is a major focus of scientific research
spanning many disciplines. We go to great lengths to remove NO from exhaust
fumes, and yet, this organic free radical has been found to be a key component in a
variety of physiological and pathophysiological processes. NO is now known to be
important for vascular haemostasis, due to its intimate involvement in vasodilation,
smooth muscle proliferation and the inhibition of platelet activation and adhesion
(Moncada et al., 1988; Palmer et al., 1987; Radomski et al., 1987a, b). NO also
plays an integral role in various aspects of immune function and regulation,
including inflammatory cell activation, adhesion, apoptosis and microbial killing
(Albina & Reichner, 1998; Bogdan, 1997; Kubes et al., 1991). The impressive array
of effects is further expanded by the capacity ofNO to act as both a neurotransmitter
and an adjuvant to wound healing (Sanders & Ward, 1992; Shabani et al., 1996).
The dysfunction of NO production and signalling is implicated in a wide range of
diseases, such as hypertension, hypercholesterolemia, diabetes and septic shock, yet
NO-based therapeutics remain under-represented in clinical treatment options (Kojda
& Harrison, 1999; Megson & Webb, 2002). The lack of target specificity and the
notoriously difficult challenge of stablising this labile molecule for localised drug
delivery, has produced significant barriers to the widespread use of NO as a
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therapeutic agent. However, localised NO delivery, achieved through the use ofNO-
donor polymer bound materials provide a promising solution to overcoming the
barriers in NO therapy, avoiding the detrimental effects of untargeted, systemic
release (Frost et al., 2005). The supplementation ofNO by liberation from polymers
offers the potential in producing biocompatible surfaces for a variety of medical
devices, particularly those used in interventional procedures, such as vascular grafts,
extracorporeal loops and stents (Annich et al., 2000; Bohl & West, 2000; Hou et al.,
2005; Kaul et al., 2000; Kennedy et al., 2003). The release ofNO from the surface
of vascular stents would not only inhibit thrombus formation at the surface, but could
also aid in the prevention of neointimal thickening; a major cause of restenosis of
vessels following stent placement (Hou et al., 2005). The multifaceted effects ofNO
released from polymer surfaces have also been shown to have effective anti¬
microbial properties, highlighting a possible role for these materials in control of
nosocomial infections contracted through medical device usage (Dobmeier &
Schoenfisch, 2004; Nablo et al., 2005; Nablo & Schoenfisch, 2003).
Cation-exchanged zeolites are microporous materials that are excellent high capacity
NO gas storage materials. The large surface area allows for up to lmillimole ofNO
to be stored per milligram of zeolite, which is liberated upon contact of the material
with aqueous media (Wheatley et al., 2006). These zeolite materials provide a novel
means by which to deliver NO locally, using pure NO gas as the primary source,
avoiding the need for biological cleavage or by-product formation often required
with other NO-donor drug bound polymers (Frost et al., 2005). Furthermore, zeolite
design is easily altered to produce materials with variable NO storage and release
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capacities. This can be achieved through the following: careful choice of zeolite
structure, of which there are hundreds of man-made and naturally occurring
structures, changing the cation exchanged into the structure, the composition of the
zeolite to a polymer binder and changing the polymer binder material. Thus, these
zeolites provide an alternative and novel way to store and deliver NO that has
dynamic properties, ideal for development ofNO-releasing coatings for a wide range
of biomedical applications.
6.2 Summary
Chapter 3 characterised the NO-release capacities of several zeolite "designs" of two
cation-exchanged zeolites (Zn2+ and Co2+) at various compositions of zeolite to
PTFE or PDMS polymer binder, in different biological solutions. The results
indicated that NO-release capacities and rate of release are impacted significantly by
changes in each of the above parameters. High composition (>50%) zeolites were
shown to be high capacity storage materials of NO, releasing high micromolar
concentrations over approximately 1 h. Lower composition Zn2+-exchanged zeolites
released very small concentrations ofNO that did not correlate with the reduction in
NO reservoirs through changes in composition. Low composition zeolites did not
display significant anti-platelet properties in collagen-induced aggregation whereas
high composition zeolites had powerful anti-platelet properties, which lasted for up
to 2 h and were found to be largely sGC-independent, as determined by the use of the
selective inhibitor of sGC, ODQ. The anti-platelet properties of NO-loaded zeolites
were indeed attributed to NO, as the NO-free counterpart zeolites did not inhibit
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collagen-induced aggregation and the NO scavenger, Hb was able to partially reverse
the effects seen with the 50% zeolite. The sGC-independent effects were not
elucidated in this study but, as discussed, were suggested to be likely due to platelet
protein modifications.
Despite several zeolite modifications, the NO-release duration of all the zeolites
studied did not exceed approximately lh although anti-platelet effects lasted for up to
2 h. This discrepancy was hypothesised to be due to the storage of NO in S-
nitrosoalbumin reservoirs, which has previously been implicated in the prolongation
of anti-platelet effects by short half-life NO-donor compounds (Crane et al., 2002).
This mechanism did not appear to contribute significantly to the anti-platelet effects
of a 50% Zn2+-exchanged zeolite as these zeolites retained their potent anti-platelet
effects in washed platelet samples. Furthermore, this assay used pre-incubation
techniques where transfer of the zeolite material occurred 1 min before collagen
stimulation, compared to the previous incubation of zeolite materials in the sample
for the full duration prior to collagen stimulation. This technique did not reduce the
anti-platelet actions of the zeolite in PRP further downplaying the involvement of S-
nitrosoalbumin stores in the prolongation of the anti-platelet effects of NO. It was
concluded that these zeolites produce adequate concentrations to inhibit aggregation
beyond the apparent NO-release duration measured by the NO-electrode and that the
lack of NO signal at these time points was due to limitations in the sensitivity of the
NO electrode.
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The incubation of zeolite discs in PRP and physiological salt solutions produced
varying NO release profiles, demonstrating how components of a given solution can
mask NO induced effects and alter the concentration ofNO reaching the target. This
is further highlighted in the whole blood aggregation experiments, which show
dramatically reduced anti-thrombotic potential compared to that observed in PRP.
NO-released from Co2+-exchanged zeolites demonstrated powerful smooth muscle
relaxing effects in myography experiments that were influenced by the choice of
polymer binding the zeolite. The PTFE polymer produced more favourable peak
relaxation responses than a composition matched PDMS polymer bound zeolite.
The experiments performed in the first chapter indicate that the 50% Zn2+-exchanged
zeolite in a PTFE binder has the most promising NO release characteristics with
which to continue the investigation of the effects of these materials in other
biological assays. However, further optimisation of zeolite design is required to
produce the elusive low concentration, long-duration NO release profile ideal for
development of anti-thrombotic coatings for blood-contacting medical devices.
Chapter 4 further characterises the 50% Zn2+-exchanged zeolite in relation to its
effects on function and viability of human neutrophils. It was shown that the NO-
loaded zeolites produced concentration-dependent pro-inflammatory responses in
isolated human neutrophil suspensions in the absence of the neutrophil activator
fMLP. Changes in neutrophil shape were observed, together with modulation of
surface adhesion molecule expression in the form of shedding of L-selectin and up-
regulation of CD1 lb following NO-loaded zeolite incubation for only lhour. When
the neutrophils were stimulated with fMLP at 30 min of the 60 min zeolite
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incubation, there was an enhancement of CD lib expression. These effects were
similar to the priming activation of neutrophils by various factors including
peroxynitrite (ONOO"). The involvement of ONOO" in these effects is unknown
although there remains a possibility that NO is involved due to the requirement for
extremely high levels of O2" to form adequate concentrations of ONOO" known to
produce the priming effect described in the literature (Rohn et al., 1999). Further to
this, the reduction in zeolite size and/or zeolite dilution in the neutrophil suspension
quickly reversed the apparent priming response indicating that very high
concentrations of NO were required, despite the likeliness that ONOO" production
would still be substantial at lower dilutions, given that NO concentrations would
likely still be far in excess of O2". Flowever, a role for ONOO" in these effects cannot
be ruled out, especially when considering the concentration-dependent increase in
neutrophil necrosis at the highest zeolite concentration. NO has a controversial role
in cytotoxicity, and many studies have reported a requirement for ONOO" or H2O2
over NO in producing these effects (Pacher et al., 2007). It cannot be discounted, in
these experiments, that high concentrations ofNO produced at a localised site could
have cytotoxic effects against neutrophils. The lack of apparent lack of zeolite
toxicity against platelets, demonstrated in the previous chapter, suggests that there
may be a cell or cell suspension dependent component to the cytotoxic effects ofNO.
The enhancement of ONOO" production by reaction of NO with O2" generated by
neutrophils could potentially cause increased oxidant stress in these cells.
Furthermore, lack of cytotoxicity in platelet experiments may be due to 'buffering'
ofNO by plasma constituents.
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Chapter 5 investigated the anti-bacterial properties of the 50% Zn2+-exchanged
zeolite against strains of bacteria commonly associated with nosocomial infections.
It was shown that these zeolites are potent anti-bacterial agents that are able to
significantly reduce the numbers of bacterial colony forming units after only 60 min
treatments. The NO-loaded zeolite displayed bacteriocidal effects in all strains
studied, as bacterial numbers were decreased to below levels estimated at the start of
the experiment (t=0). The bactericidal effect of NO-loaded zeolites to a strain of the
Gram-negative bacterium, Pseudomonas aeruginosa was enhanced upon longer
zeolite treatment, (120 min) and bacterial numbers were completely eradicated at this
time-point. Interestingly, a bacteriostatic effect of NO-free zeolites was indicated,
likely due to leaching of Zn2+ from the zeolite structure. The bactericidal and
bacteriostatic effects of the NO-loaded and NO-free zeolites were shown to be
concentration dependent as dilution of the zeolite disc restored bacterial numbers.
The concentration of NO required to produce bactericidal effects varied between
strains but was always associated with very high concentrations of NO, released by
the zeolite disc into small volumes of the bacterial suspension.
The bactericidal effect ofNO-loaded zeolites had an interesting temporal component.
It was shown that bacterial numbers were not reduced until after a 30 min zeolite
incubation, despite peak NO-release occurring within the first 10 min. In fact,
following 10 min incubation, bacterial numbers appeared slightly increased. This
observation was not statistically significant although it is surprising that bacterial
numbers were not reduced at this point as previous experiments showed that bacterial
killing ability correlated with the concentration of NO present in the bacterial
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suspension. It was suggested that perhaps NO is either temporarily scavenged by
bacterial products, such as pyocyanin or that NO is triggering an unknown biological
mechanism, which in turn takes 30 min to induce cytotoxic effects.
6.3 Physiological and pharmacological implications and
future directions.
Cation-exchanged zeolites are high capacity storage materials of NO. NO is
liberated on contact with an aqueous solution at biologically relevant amounts that
have been demonstrated to have potent anti-platelet, anti-bacterial and smooth
muscle relaxant properties. The effects generated are dependent upon the
concentration of NO delivered from the zeolite material and the ability of NO to
reach its biological target. This thesis has demonstrated how zeolite design, volume
and components of biological solutions can affect NO storage and release capacities
of these materials. The 50% Zn2+-exchanged zeolite had the best NO-release
characteristics for further investigation in this thesis, however much more zeolite
optimisation is required before these materials can be considered as anti-thrombotic
coatings for blood-contacting medical devices. The lack of impressive anti¬
thrombotic effects produced during whole blood aggregation experiments (figure
3.8) as well as the short period of NO release indicates further work is required in
this area. The Cu2+-exchanged zeolite or alternatively, a Cu2+ containing metal
organic framework (another microporous material) could provide the 'magic bullet'
in localised NO delivery. These materials could offer the catalytic conversion ofNO
from nitrite at the surface of the material upon reduction of the Cu2+ to Cu1+ (Oh &
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Meyerhoff, 2004, 2003) thereby producing a constant, unending source of NO.
Preliminary work is being done to this end, although leaching of toxic Cu2+ ions has
2_j_.
proved problematic. Leaching of Zn ions is suggested to have potentially produced
the bacteriostatic effects described in chapter 5. Side effects of Zn2+-leakage
therefore must be taken into account when considering the in vivo application of
zeolite materials although no apparent detrimental effects were seen following use of
NO-free zeolites in platelet aggregation, myography or neutrophil experiments. The
bacteriostatic effect of NO-free zeolites occurred in very small volumes (150pl;
figure 5.4), and was insignificant upon dilution of the disc, suggesting that Zn2+ had
to be at very high concentrations in the solution to produce any effects (figure 5.7B).
These small volumes are not physiological in practice for blood-contacting medical
devices, which would come into contact with large volumes of pulsatile flowing
fluids and therefore the physiological impact of cation leaching from zeolites could
be negligible or enhanced due to washout phenomena. The ex vivo application of
current zeolite designs are promising, especially in anti-microbial coatings for
urinary catheters, which are common risk factors associated with nosocomial
infections, often acquired due to poor handling techniques during insertion
(Goldmann, 1991). Here, a ring of NO-loaded zeolite material would help prevent
the migration of external microbial pathogens up into the urinary tract of immuno¬
compromised patients. Therefore, leaching of cations from zeolite structures can be
used to an advantage when engineering these materials for a number of applications.
It would be beneficial to investigate the efficacy of these zeolite materials in
dressings to promote wound healing and in clearing skin conditions such as acne,
which has a significant bacterial component (Coenye et al., 2007). Here, cations
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such as Ag2+ and Zn2+ have already been shown to have beneficial effects (Babu et
al., 2006; Bergin & Wraight, 2006; Dowsett, 2004), further supporting the
incorporation of the ion leaching zeolite designs for future investigation in these
specialised areas.
The mechanism by which NO-loaded and NO-free zeolites exert their anti-microbial
effects has yet to be confirmed. Anti-microbial properties of NO and NO-related
species have been described in the literature. Microbial killing of NO and NO-
related species have shown varying degrees of susceptibility, which are strain
specific (De Groote et al., 1995; Zaki et al., 2005; Zhu et al., 1992). Indeed, a
difference in susceptibility of the bacterial strains used in chapter 5 to NO-loaded
zeolite materials was evident. Harnessing any differences in susceptibility of
commensal and pathogenic strains of microbes could help better design zeolite NO-
release to produce strain-specific killing and avoid the detrimental effect of non-
discriminate killing. It would be important to confirm the possible development of
resistance to NO by bacterial strains, especially with an increase in the emergence of
antibiotic resistant strains in hospitals and the community (Lodise & McKinnon,
2007). These experiments would likely involve repeated, long duration exposure of
bacteria to NO-loaded zeolites to assess if bacteria subsequently developed the
ability to withstand acute and prolonged exposure to NO. Further characterisation of
the anti-microbial effects of NO to other pathogenic organisms, including fungi and
viruses would better support the use of these materials as anti-microbial agents.
The interesting temporal association of PA01 killing and exposure to NO-loaded
zeolites (figure 5.8) raised the possibility that NO is not directly inducing a lethal
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oxidant stress on these prokaryotic cells and that perhaps there is a more complex
biological mechanism triggered by NO or NO related species. Investigation into
bacterial cell morphology, especially membrane integrity and DNA fragmentation
may help to determine if these cells show signs of direct oxidative stress. If there
was an alternative pathway by which NO is exerting its anti-microbial effects, such
as activation or inhibition of protein kinases, immunofluoresence and Western
blotting techniques could help determine the effectors in this instance.
Although there are significant drawbacks to the use of these zeolites in medical
device coatings, these materials have proved to be a unique tool to investigate
various aspects of NO biology. The mechanism of action of NO-loaded zeolite
materials was shown to have a significant sGC-independent component in platelet
aggregation and myography experiments, determined through the selective inhibition
of sGC by ODQ. Similar sGC independent effects ofNO have been reported in the
literature, especially in regards to inhibition of platelet activation and smooth muscle
relaxation. These effects were associated with high concentrations ofNO released in
the extracellular environment (Crane et al., 2005; Miller el al., 2004; Sogo et al.,
2000). NO-loaded zeolite materials produced sGC-independent effects similar to
those observed with the NO-donor DEA/NO, which releases NO spontaneously in
the extracellular environment. These effects are in contrast to those observed with
the intracellular NO donor, SNP, which demonstrated no inhibition of platelet
aggregation in the presence of ODQ. The sGC-independent pathway stimulated by
NO has been suggested to be associated with membrane protein modifications,
particularly Ca2+ transporting proteins, possibly through nitration of amine residues
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such as tyrosine (Crane et al., 2005; Eiserich et al., 1998). Further investigation into
protein structure modifications through measurements of nitrosotyrosine residues by
liquid chromatography or Western blotting techniques may help determine a possible
mechanism for the observed effects in these experiments.
Neutrophil priming is a phenomenon associated with many inflammatory agents such
as GM-CSF, TNF-a, PAF and IL-8 and is characterised by the enhancement of
neutrophil immune responses on subsequent exposure of the primed neutrophils to an
activating stimuli (Condliffe et al., 1998; Kitchen et al., 1996; Leino et al., 1993;
Partrick et al., 1997). Neutrophils produced modulations in activation marker
expression following NO-loaded zeolite exposure that were similar to priming
responses shown with other well-known priming agents (Condliffe et al., 1996).
Nitric oxide per se has not been previously recognised as a priming agent, but the
NO-related species, OONO" has been shown to demonstrate priming activity similar
to that observed in this study (Rohn et al., 1999). The nitration of neutrophil surface
proteins has been suggested to produce the majority of the priming responses
observed by OONO" (Swain et al., 2002) thereby promoting degranulation and the
modulation of surface adhesion markers. Again, measurement of nitrated tyrosine
residues and the addition of SOD to eliminate O2" from experimental conditions
could assist in characterising these interesting observations.
In conclusion, zeolite materials have been shown to be high capacity storage
materials ofNO that release NO stores at biologically relevant concentrations, which
have powerful anti-platelet and anti-bacterial properties. Although the NO-loaded
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zeolite materials studied in this thesis require optimisation before more favourable
NO release durations are achieved for development as biocompatible coatings, the
experiments performed have highlighted a variety of issues which should be
investigated in more detail. Furthermore, these materials have provided a unique
tool with which to investigate various aspects ofNO biology. Indeed, this thesis has
uncovered some interesting findings regarding the involvement of NO in neutrophil
activation and bacterial killing, which have not been previously reported. Increasing
the understanding of the effects of NO, particularly with respect to mechanism of
action, could help better harness the therapeutic value ofNO donating materials and
drugs and finally overcome the barriers to the successful use of these agents in the
clinic.
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Figure 6.1. Summary diagram.
Zeolites are high capacity storage materials ofNO. NO-released has been shown to inhibit
platelet aggregation and adhesion (Wheatley et al., 2006), have pro-inflammatory effects in
human neutrophils possibly related to priming activation and have anti-bacterial properties
against both Gram-positive and Gram-negative bacteria that demonstrated a dependence on
both high concentrations and time ofNO exposure. Zn2+-exchanged zeolites may leach Zn2+
ions that could have cytostatic effects in Gram-positive bacteria (e.g MSSA) and may
contribute to the cytotoxic properties of the zeolite against Gram-negative bacterial strain,
J1386. Thus, these materials show promise in the development of anti-thrombotic and anti-
infective coatings for medical devices. However, further optimisation of zeolite design is
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NITRIC OXIDE-LOADED Co2+ AND Zn2+-EXCHANGED ZEOLITES HAVE
POWERFUL ANTI-AGGREGATORY PROPERTIES IN HUMAN PLATELETS
Sarah Fox*, Paul S. Wheatleyf, Russell E. Morris*, Anthony R. Butler*, Adriano G.
Rossi , (Ian L. Megson). Queen's Medical Research Institute, University of
Edinburgh, EH16 4TJ; School of Chemistry, University of St Andrews, KYI 6 9ST.
Endothelium derived nitric oxide (NO) is a potent inhibitor of platelet activation
(Radomski et al 1987). Polymers incorporating NO donating substances (e.g.
diazeniumdiolates) have shown potential as antithrombotic surface coatings (Frost et al
2005), but have limited NO capacities. Zeolites are nanoporous solids that might offer
an alternative to polymer-based antithrombotic coatings because they can act as high
capacity storage materials for gases, including NO. The chemical characteristics of
zeolites are easily manipulated by altering the specific cation, the porosity of the zeolite
and the binding material in which it is embedded. In this study, we investigated the NO
release properties of Zn2+ and Co2+ cation-exchanged zeolites in human plasma, and
determined the extent and duration of their antiplatelet activity.
NO-loaded Zn2+ and Co2+-exchanged zeolites of various compositions (10%-75%) in
polytetrafluoroethylene binder (PTFE; pressed into 3 mm dia. discs) were found to
generate substantial NO for ~60 min upon immersion in platelet-rich plasma (PRP; 1
ml, 37°C; n=6). The NO-release profile was dependent on both the exchanged cation
(Zn2+ or Co24) and the composition of zeolite:PTFE binder (see Fig. 1).
Time (min)
Fig. 1: NO generation from Zn2+ and Co2+-exchanged zeolites (50-75%: PTFE) in PRP.
Turbidometric platelet aggregometry was used to determine the ability of NO-loaded
zeolites to inhibit collagen induced platelet aggregation in PRP in vitro. Discs (3 mm
dia.) containing NO-loaded Zn2+ and Co2+ ion-exchanged zeolites (10-75% in PTFE
binder) were suspended in PRP (500 pi; 37°C; 1-80 min) before stimulation with
collagen (2.5pl.mr'). Zn2+ exchanged zeolite (>50%) and Co2+ exchanged zeolite (75%
only) significantly inhibited platelet aggregation throughout the incubation period (80
min; p<0.01; n=6-8); NO-free counterparts failed to alter platelet aggregation over the
same period, indicating the essential role ofNO in the effect.
Our results suggest that Co2+ and Zn2+-exchanged zeolites are high capacity storage
materials ofNO with powerful antiplatelet activity in vitro. The NO release profiles and
antiplatelet effects were dependent on the specific cation exchanged and on the relative
proportion of zeolite:PTFE binder. These zeolites will act as prototypes for the
development of zeolites with optimal NO release capacities lasting for considerably
longer durations.
Frost M.C. et al (2005) Biomaterials 26, 1685 -1693
Radomski et al (1987) The Lancet 330 (8567), 1057-1058
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Abstract: Transition metal-exchanged zeolite-A adsorbs and stores nitric oxide in relatively high capacity
(up to 1 mmol of NO/g of zeolite). The stored NO is released on contact with an aqueous environment
under biologically relevant conditions of temperature and pH. The release of the NO can be tuned by
altering the chemical composition of the zeolite, by controlling the amount of water contacting the zeolite,
and by blending the zeolite with different polymers. The high capacity of zeolite for NO makes it extremely
attractive for use in biological and medical applications, and our experiments indicate that the NO released
from Co-exchanged zeolite-A inhibits platelet aggregation and adhesion of human platelets in vitro.
Introduction
Nitric oxide (NO) is a crucial biological agent in the
cardiovascular, nervous, and immune systems.1 NO synthesized
by endothelial cells that line blood vessels mediates a number
of vital functions, including vasodilatation2,3 and inhibition of
platelet4 and inflammatory cell5,6 activation and adhesion. In
addition, NO is an important neurotransmitter and neuromodu¬
lator in the peripheral and central nervous systems,7 and its
synthesis in high concentrations contributes to the cytotoxic
effects of inflammatory cells on invading pathogens.8
The delivery of exogenous NO is an attractive therapy for a
number of ailments, but the range and diversity of its effects
make target specificity a major concern, which has held back
the development of some NO applications. To overcome this
problem requires the development of materials that can store
significant quantities ofNO and then deliver it to specific sites
in the body. There is currently particular interest in using NO
delivery materials to prevent life-threatening complications
associated with thrombosis formation at the surface of medical
devices such as stents and catheters.9
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A number ofmaterials have been proposed as delivery agents
for exogenous NO. Perhaps the chemically most advanced are
those based on polymers or silica functionalized with secondary
amines, which, on reaction with NO, form ionic diazenium
diolates that can be used to increase the thromboresistivity of
polymers.9,10,11 Two molecules of NO react with each amine
(giving rise to the trivial name NONOate) and are released on
contact with moisture at an appropriate pH. Other methods of
release have also been explored, including the light-activated
release of NO from metal-containing polymers.12
A specific potential use for NO-releasing materials in the
cardiovascular arena centers on the prevention of thrombosis
on artificial surfaces that come into contact with blood,
particularly in relation to procedures that require extracorporeal
circuits, like bypass and renal replacement therapy, catheter
implantations, or stents that are used in interventional cardiology
to improve the patency of partially blocked arteries.9 Current
best practice to prevent thrombosis in these situations involves
the administration ofheparin, other anticoagulants, or antiplatelet
agents to the patient, with the inherent risk of hemorrhagic13,14
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or paradoxical thrombotic15 complications. Stent coatings that
release antithrombotic,16 antiinflammatory,17 and antimitogenic18
agents to reduce in-stent thrombosis or restenosis have had some
success, but NO might be expected to have all of these effects
ifdelivered at the appropriate rate for a sufficient duration. Other
potential uses of these types of solids, as shown by a number
of different biological effects, include antibacterial coatings19
and wound-healing promotors.20
Zeolites have well-known applications in ion exchange, gas
adsorption, and catalysis (including DeNO,, the removal of
nitrogen oxides from exhaust gases21,22), and they are of
increasing interest as hosts for nanotechnology applications.23
New zeolites24 and new methods for zeolite preparation25,26
continue to attract attention as catalysts, but their use in medicine
is limited to nontoxic medical diagnosis tools and clotting
enhancers.23 Zeolites have also been studied as microporous
storage media for gases such as hydrogen.27
A great deal is known about the interaction of NO with
zeolites, particularly from catalytic and separation studies.
Pressure swing adsorption experiments indicate that there are
two types of adsorbed NO in zeolites, commonly called
reversibly and irreversibly adsorbed NO.28-30 As its name
suggests, reversibly adsorbed NO is a weakly held, predomi¬
nantly physisorbed species. In contrast, irreversibly adsorbed
NO is relatively strongly held and is not spontaneously released
from the zeolite even at very low pressures. Irreversible NO is
primarily chemisorbed, as has been shown by single-crystal
X-ray diffraction31 and IR spectroscopy32 and supported by
recent modeling experiments,33 where the NO interacts with the
extraframework cations in zeolites through the nitrogen atom
to form eithermononitrosyl or dinitrosyl complexes. Irreversible
adsorption of this kind is a good method of storing a gas in a
material as it is not lost too easily. However, suitable methods
of initiating delivery of the gas must be found before the
materials can be utilized in applications. Here we show how a
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Figure 1. Structure of the cobalt—NO complex in zeolite-A as revealed
by single-crystal X-ray diffraction (data taken from ref 31). The cobalt is
bound to three oxygen atoms of a six-ring unit in the zeolite framework
and bonds to the nitrogen of a bent mononitrosyl ligand. Oxygen atoms of
the zeolite framework are shown smaller than the NO oxygen for clarity.
suitable nucleophile (water) can be used to displace the
"irreversibly" adsorbed NO from ion-exchanged zeolite-A at
biologically relevant temperatures. The release of NO can be
customized by altering the chemical composition of the zeolite.
Experiments with human platelets confirm that NO released
from a zeolite is sufficient to abolish platelet activation and
adhesion in vitro, pointing to potential applications in coating
surgically implanted catheters that are ordinarily regarded to
be prothrombogenic. The tuneable nature of NO release from
cation-exchanged zeolites extends the potential applications to
tubing and instruments used in procedures such as bypass
surgery and renal replacement therapy.
Zeolite-A (given the three letter framework code LTA34) is
manufactured in > 1 M tonne amounts annually for use as a
detergent builder and water softener. Zeolite-A35,36 consists of
alternating Si04 and AIO4 tetrahedra that share corners to
produce the open framework depicted in Figure 1, with
exchangeable extraframework cations residing in the channels.
Zeolite-A is a poor DeNO.v catalyst but is used in a number of
adsorption applications. It is therefore an ideal choice of zeolite
for studies of NO storage. Also, it has a well-known affinity
for water, often being used by organic chemists to dry solvents.
Figure 2 shows the adsorption and desorption isotherms for
NO on Co-exchanged zeolite-A and illustrates the natural
affinity of the zeolite for NO, as even at low pressures the
majority of the gas remains bound inside the zeolite (i.e. is
irreversibly adsorbed). The hysteretic nature of the adsoption/
desorption isotherm means that the zeolite can be used to hold
NO at pressures below those needed to load NO onto the
material. This is ideal for the storage of significant amounts of
NO. Similar hysteretic adsorption has recently been seen for
hydrogen storage in other types of nanoporous material.37 The
maximum amount of NO adsorbed by cobalt-exchanged zeo¬
lite-A is approximately 1.7 rnmol/g ofzeolite, although reduction
of the NO pressure leads to loss of the reversibly adsorbed
(34) For more information on the nomenclature of zeolites, including details of
the framework topologies, visit the International Zeolite association website
www.iza-online.org.
(35) Pluth, J. J.; Smith, J. V. J. Am. Chem. Soc. 1980. 102, 4704.
(36) Cheetham, A. K.; Eddy, M. M.; Jefferson, D. A.; Thomas, J. M. Nature
1982, 299, 24.
(37) Zhao, X.; Xiao, B.; Fletcher, A. J.; Thomas, K. M.; Bradshaw, D.;
Rosseinsky, M. J. Science 2004, 306, 1012.
J. AM. CHEM. SOC. ■ VOL 128, NO. 2, 2006 503
ARTICLES Wheatley et al.
Pressure/ mmHg
Figure 2. Adsorption/desorption isotherm ofnitric oxide on Co-exchanged
zeolite-A The irreversible nature of the adsorption of the majority ofNO
on the zeolite is indicated by the hysteresis.
(weakly physisorbed NO) leading to a maximum storage
capacity of ~1.2—1.3 mmol/g. The only remaining problem is
then how to release (deliver) the NO from the zeolite when
required. Fortunately, zeolites also interact strongly with water,
and our hypothesis was that exposure to moisture would result
in replacement of the NO by water in the zeolite, leaving the
gaseous NO to diffuse out of the zeolite. Our aim in this study
was to synthesize metal-containing zeolites that store NO and
release it in biologically relevant amounts on contact with water.
We envisaged that the rate ofNO release could be modified by
altering the chemical composition of the material for a range
of different medical and biological applications in which
exogenous NO might be beneficial.
Results and Discussion
Samples of zeolite-A were synthesized according to the
procedure given in ref 38. The transition exposed to dry NO
and stored in sealed vials under argon at room temperature ready
for use.
Zeolites are well-known as extremely good drying agents and
interact strongly with water, and this has led to their use in
numerous applications, including as a method of rapidly
absorbing water from blood to aid in clotting after serious
wounding.39 It is not surprising then that the NO is released
very quickly when contacted by water in a physiological
solution. Unfortunately, it is difficult to quantify the release rate
of NO in this fashion accurately because the powder zeolite
tends not to disperse well in the liquid, with much remaining
floating on the surface. An alternative, and much more repeat-
able, method is to flow a wet gas (of controlled relative
humidity) through the sample at a steady rate and measure the
NO concentration of the gas using chemiluminescence measure¬
ments. The NO release profiles ofNO-loaded cobalt exchanged
zeolite-A expressed as a total concentration of NO in the gas
stream versus time (a) and a cumulative total amount of NO
(38) Robson, H.; Lillerud, K. P. Verified Syntheses of Zeolitic Materials, 2nd
revised ed.; International Zeolite Association: Amsterdam, Netherlands,
2001; www.iza-synthesis.org.
(39) Wright, F. L.; Hua, H. T.; Velhamos, G.; Thoman, D.; Demitriades, D.;
Rhee, P. M.J. Trauma Inj. Inf. Crit. Care 2004, 56, 205.
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Figure 3. Two NO-release profiles for NO-loaded Co-exchanged zeolite-
A: (a) NO concentration (ppm) in the gas stream passing through the
chemiluminescence detector versus time; (b) total mount of NO released
by the material with time (per g of zeolite). The conditions for this
experiment were 31 mg of zeolite and a flow rate of 200 mL/min of wet
argon at a relative humidity of 11%.
released/g of zeolite (b) are shown in Figure 3. In this case the
flow rate ofgas used was 200 mL/min and the relative humidity
of the gas was 11%. The total amount of NO released is
approximately 1 mmol ofNO/g of zeolite. The duration ofNO
release approaches 2500 s with a half-life (t\a, the time it takes
for half the NO to be released) of ~340 s. The total amount of
NO released is also very consistent between different samples
as long as care is taken to ensure that the chemical composition
of the zeolite and its dehydration properties are the same. The
average amount ofNO released from 130 separate measurements
on different samples was 1.02 mmol of NO/g with a standard
deviation of 0.05. Storage of the NO-loaded zeolites under a
dry atmosphere also has no effect on the total NO released by
the materials. Samples ofNO-loaded cobalt-exchanged zeolite-A
were stored under argon in sealed ampules for up to 16 weeks.
The quantification of the NO released by these samples is shown
in Figure 4, with each measurement repeated at least 16 times
on different samples. There is no drop off in total NO released
indicating that under dry conditions cobalt-exchanged zeolite-A
is a stable NO storage material with a gas storage capacity
similar to that of the best NO-storing polymers reported and
significantly higher than most.10'11
The amount of moisture present in the gas flow is also
important in controlling the release of the NO. Increasing the
relative humidity (while keeping the flow rate constant) to 22%
increases the rate ofNO release (t\n = 208 s), while an almost
dry gas (relative humidity 1.5%) increases the tm to more than
3000 s. It should be remembered though that there are two
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Figure 4. Storage stability experiments showing the total amount ofNO
released by a cobalt-exchanged zeolite-A after storage under dry conditions
for different amounts of time. The results are the average of at least 16
different measurements for each storage period, and the error bars indicate










Figure 5. NO-release profiles of NO-loaded metal-exchanged zeolite-A.
Top: Effect of metal ion on NO release. The control is a Co2+-exchanged
zeolite that has not been exposed to NO. The electrode response results
have been normalized to give the concentration of NO in solution/mg of
zeolite material. Bottom: Dependence of NO release on Co2+ exchange
level. Co—zeolite-A (Co—LTA(A)) contains 19.8 wt % cobalt, while Co—
zeolite-ZK4 (Co—LTA(ZK4)) contains 9.0 wt % cobalt. All zeolite samples
were from the same synthesis batch to minimize particle size differences
in the materials.
components to the storage ofNO and that any physisorbed NO
will be released even in completely dry conditions.
An alternative way to measure the release of NO from the
zeolites involves contacting the zeolite with a moist gas that is
subsequently bubbled through a liquid phase (phosphate buffered
saline, pH 7.4 at 25 °C). The amount of NO dissolved in the
solution is then measured electrochemically. This allows the
flow rate to be reduced down to 5 mL/min showing that even
in moisture-saturated argon the release of the NO now takes
place much more slowly and lasts up to 10 h (Figure 5). Again
this is consistent with the reduced flux ofwater on the sample
from the much reduced flow rate. Figure 5 also shows the NO
release profiles measured electrochemically for a number of
other transition metal-exchanged zeolite-A samples in contact
with an argon flow that has been saturated with water vapor.
The order of how much NO is released for each metal agrees
well with the NO adsorption properties of transition metal
zeolites in pressure swing adsorption studies.28-29 Co-exchanged
zeolites released the most NO while the original sodium form
of the zeolite released least NO. At first glance the Cu-
exchanged zeolite-A results seem anomalously low, especially
since Cu—zeolites are well-known deNOx catalysts and that Cu-
exchanged zeolites do adsorb significant quantities ofNO.28-29
This is because the zeolite is overexchanged, with more Cu2+
ions in the channels than is strictly necessary for charge balance
reasons. Many of the "extra" Cu2+ ions are probably present as
hydroxide species and so reduce the availability of the metal
ions for NO coordination.
The amount ofNO released by the zeolite depends not only
on which transition metal is present but also on how much of
the metal is there. Zeolite-ZK4 is a variant of zeolite-A that
has the same framework structure and so has the same
framework code (LTA). Flowever, there are fewer exchangeable
cations in zeolite-ZK4 as there is less aluminum in the
framework than in zeolite-A. This means that there are fewer
metal cation sites in the channels of the structure to bind NO.
It is clear from Figure 5b that Co-exchanged zeolite-A releases
more NO than Co-exchanged zeolite ZK4, consistent with the
reduced level of cobalt in the ZK4 structure. Interestingly, Co-
exchanged zeolite-A samples are self-indicating; when initially
dried they are a bright blue, and when loaded with NO they are
a gray/blue but change to pink as the NO is displaced by water.
These color changes emphasize the importance of the metal—
NO interactions in the storage of the gas and the replacement
of these by metal—water interactions on delivery of the NO.
Bioactivity. The need for improvements in the biocompat-
ibility ofmaterials is a very important target. This is particularly
true for blood-contacting solids that are used in vascular grafts
and in extracorporeal tubing used in coronary bypass surgery
and kidney dialysis. Life-threatening complications can occur
if thrombosis formation (platelet aggregation and adhesion
together with coagulation) is induced by artificial materials that
are in contact with blood. Thrombus formation in healthy
circulatory systems is inhibited in a number ofways, including
the production of small quantities (approximately 1 pmol min-1
mm-2; see ref 9) of NO by the endothelial cells that line the
blood vessels and also by platelets. A potentially important
strategy for reducing postoperative complications is to make
medical devices out of an NO-releasing material, thereby
mimicking the antithrombotic action of the endothelial cells.
To overcome the problem of the nondispersion of zeolite
powders in the liquid phase, samples of zeolite were prepared
as pressed disks with small amounts of polymers as binders.
The Co-exchanged zeolite samples, in 75:25 or 50:50 wt %
mixtures with powdered poly(tetrafluoroethylene) (PTFE) or
poly(dimethylsiloxane) (PDMS), were prepared as pressed disks
and subsequently dehydrated and loaded with NO in the same
way as the powdered samples. Pressed disks made from only
zeolites are slightly brittle; some material breaks off easily under
stirring, and so the polymer is there primarily to add mechanical
stability to the disks. Flowever, this process clearly affects the
NO release properties of the materials. Figure 6 shows that on
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Figure 6. Chemiluminescence response to NO (in ppb) from two disks of
cobalt-exchanged zeolite-A (8.5 mg) mixed with PTFE and PDMS (8.5
mg, respectively) immersed in water.
exposure to liquid water (25 °C) the release of NO is slowed
considerably as compared to the powdered zeolite, with 11/2 of
509 s for the PTFE disk and a ty2 of 3076 s for the PDMS
disk. In addition, the total amount ofNO released is very much
reduced compared to the free zeolite powders (1.4 x 10-5 and
2.4 x 10~5 mol of NO/g of zeolite for PTFE and PDMS,
respectively). This is not at all surprising given that the
preparation of the disk will affect the accessibility of the zeolite
to the NO considerably. However, given the small quantities
ofNO required for biological action this is not a major drawback
in terms of testing the materials for their antithrombotic
behavior. Clearly the nature ofpolymer used in any formulation
can have a significant affect on the rates of release and is another
method of tuning the release rate to match any potential
application. Figure 7c shows that the electrochemically measured
released profile of the Co—zeolite-A/PTFE disk is very similar
to that seen in plasma. The NO-loaded disks were stored under
an inert atmosphere in a manner similar to that described above
for the powdered zeolite samples. The disks were stored for up
to several weeks before being used in further experiments.
Zeolite/PTFE disks were suspended by a stainless steel wire
holder below the surface of platelet-rich plasma (PRP) in the
cuvette of a four-channel platelet aggregometer (Chronolog,
Labmedics, Stockport, U.K.) at 37 °C. After a short induction
period (1 min), platelet aggregation was initiated using the
thromboxane A2 analogue, U46619 (8 «M) and then measured
as a change in turbidity (light transmission) of PRP against a
platelet poor plasma (PPP) reference. The results (Figure 7)
show that a NO-loaded Co-exchanged zeolite-A/PTFE sample
completely inhibits platelet aggregation. Addition of the NO
scavenger, oxyhemoglobin (40 /tM), prevents the inhibitory
effect, confirming the central role for NO in the inhibitory
process and excluding the possibility that the effects of the NO—
zeolite were merely cytotoxic. Furthermore, a Co-exchanged
zeolite/PTFE sample that has not been loaded with NO failed
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Figure 7. Effect of NO-loaded Co—zeolite-A and the NO-free Co—zeolite A (both 75% in PTFE) on platelet aggregation in response to U46619 (8 /At):
(a) aggregation recordings from a single experiment in the presence and absence of the NO scavenger, oxyhemoglobin (Hb; 40 ,«M); (b) mean ± standard
error of the mean (SEM) data for aggregation under different conditions, expressed as % of platelet aggregation in the absence of zeolite \ **P < 0.01,
Dunn's multiple comparison test after nonparametric Kruskal Wallis comparison for samples with different variances; NS = not significant (n = 6)]; (c)
electrochemically detected NO generation profile from NO-loaded Co—zeolite (75% in PTFE) suspended in PRP (n = 5); (d) time—course of the inhibitory
effect ofNO-loaded Co—zeolite A and the NO-free counterpart (both 75% in PTFE) on agonist-induced platelet aggregation at timed intervals after immersion
of the zeolite in PRP (n = 6; P < 0.001, 2-factor ANOVA).
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Figure 8. Scanning electron micrographs of the surface of (a) untreated
Co—zeolite-A/PTFE disks (Z/PTFE) and of (b) NO-loaded Co—zeolite-A/
PTFE disks, (a) shows large platelet aggregants (PA) on the surface on the
surface of the untreated zeolite/PTFE disk, while (b) shows only a few,
isolated platelets (P) on the surface of the NO-treated zeolite—PTFE disk.
The scale bar is 10 [im.
were conducted to determine the concentration ofNO generated
by 75% NO-loaded zeolite disks in PTFE suspended in PRP
(Figure 7c). The profile of release is similar to that shown in
Figure 6, suggesting that plasma components have little impact
on the water-mediated release of NO from this compound. In
addition, a time—course study for the effect of equivalent disks
on platelet aggregation (Figure 7d) indicate a prolonged
inhibitory effect throughout the 2 h period of study, which is
not shared by the NO-free counterpart. However, it is worth
noting that an element of the persistent inhibition is likely to
be mediated via formation of a durable NO store in plasma40
rather than necessarily through the persistent delivery of NO
directly from the zeolite. Indeed, it is clear that the zeolite/
PTFE NO release profile is not ideal for maintaining a protracted
antithrombotic effect, as the NO release is exhausted after ~30
min (Figures 6 and 7c). The release profile for the zeolite/PDMS
disks (Figure 6) shows a considerably lower peak NO concen¬
tration and a considerable prolonged release profile. This
indicates that it may be possible to tune the release profile for
a protracted thrombotic effect.
Platelet aggregants (PA; Figure 8a) on the surface of the
zeolite/PTFE (Z/PTFE) were visualized using scanning electron
microscopy, which conclusively demonstrates the extent to
which platelet aggregation and adhesion is inhibited at the
(40) Crane, M. C; Olloson, R.; Moore, K.; Rossi, A. G.; Megson, I. L. J. Biol.
Chew. 2002, 277, 46858.
surface ofNO-treated zeolite/PTFE (NO—Z/PTFE; Figure 8b),
on which only a small number of isolated platelets (P) can be
seen.
The toxicology of zeolites has been extensively studied, and
the frameworks themselves are regarded as benign materials.
Zeolite-A, because of its wide range of uses in detergent
powders, has been particularly well studied in terms of its
potential toxicity. There are no reported adverse effects on the
body from zeolite frameworks, except possible pulmonary
problems caused by breathing small particles of zeolite dust.41
Unlike zeolites for detergent applications, the zeolites reported
in this paper contain transition metal ions, and the toxicity of
these ions must also be taken into account. While zeolites have
been proposed as materials for the inhibition of transitionmetal
ion permeation in the skin42 and to inhibit the toxicity of
gadolinium in orally ingested MRI contrast agents 43 long-term
contact with blood will undoubtedly lead to some leaching of
metal ions. As long as this leaching does not lead to excessive
increases in local concentrations above normal in vivo values,
then there will be no adverse effects, but this must be studied
in greater detail.
Concluding Remarks
Gas storage by porous materials is currently an important
topic but tends to concentrate on the storage of gases for energy
applications.44 We have demonstrated that zeolites have great
potential as NO storage and release materials for biological and
medical applications. Their preparation and loading with NO
is relatively facile, the release ofNO occurs by simple reaction
with water, and the amount of NO released can be tailored by
altering both the type and number of metal cations in the
structures. Taking into consideration the other advantages of
zeolites, such as their low cost and nontoxicity, these materials
clearly have great potential as NO storage materials. We have
also demonstrated that NO-releasing zeolites inhibit platelet
aggregation and adhesion in plasma, a potentially important
application of such solids in the prevention of thrombus
formation. This work overturns the conventional idea that
zeolites can be used only to destroy NO and adds a new delivery
system to the armament of researchers developing NO-based
therapies. The multiple roles for NO at different concentrations
means that the potential for NO-release materials extends far
beyond the confines of reduced thrombogenicity of prosthetic
grafts, catheters, and extracorporeal blood conduits; it could also
encompass other medical uses including antimicrobial adjuncts
to prevent infection, for example, in chronically implanted
catheters and in wound dressings for enhanced angiogenesis.
Experimental Section
Synthesis of Zeolites. Zeolites Linde type A and ZK-4 possessing
the LTA framework topology were synthesized as previously pub¬
lished.38
Linde Type A. Sodium hydroxide (2.892 g) was dissolved in distilled
water (320 mL) and divided equally into two nalgene bottles. To half
(41) Thomas, J. A.; Ballantyne, B. J. Am. Coll. Toxicol. 1992, 1, 1 259.
(42) Kassai, Z.; Bauerova, K.; Koprda, V.; Bujnova, A. Biologia 2000, 55, 55.
(43) Young, S. W.; Qing, F.; Rubin, D.; Balkus, K. J.; Engel, J. S.; Lang, J.;
Dow, W. C.; Mutch, J. D.; Miller, R. A. J. Magn. Resort. Imag. 1995, 5,
499.
(44) Eddaoudi, M.; Kim, J.; Rosi, N.; Vodak, D.; Wachter, J.; O'Keefe, M.;
Yaghi, O. M. Science 2002, 295, 469.
J. AM. CHEM. SOC. ■ VOL. 128, NO. 2, 2006 507
ARTICLES Wheatley et al.
Table 1. Elemental Analysis (%) of Metal-Exchanged Zeolites with
Metals Reported Relative to Al Content
metal sample a sample b







"This sample is ~100% overexchanged.
was added sodium aluminate (33.032 g), into the other halfwas added
sodium metasilicate (61.92 g), and both portions were stirred until
dissolved. Then the silicate solution was transferred quickly into the
aluminate solution and mixed until homogeneous. This was sealed in
a nalgene bottle (500 mL) and heated at 99 °C for 4 h. This was allowed
to cool to room temperature, filtered, washed with distilled water until
the filtrate is below pH 9, and dried at 100 °C overnight.
ZK-4. Sodium hydroxide solution (3 g, 50 wt %) and sodium
aluminate (10.75 g) were added to distilled water (145 mL) and stirred
until dissolved. Tetramethylammonium hydroxide solution (25 wt %,
146 g) and silica sol (38 g, AS-30) were stirred for approximately 30
min. Solutions were combined, mixed thoroughly, sealed in a nalgene
bottle, and incubated at 25 °C for 24 h. This was then heated at 100
°C for 30 h, cooled to room temperature, filtered, washed with distilled
water (1 L), and dried at 100 °C overnight. The zeolites were calcined
in flowing oxygen at 600 °C (maintained for 600 min) with a heating
rate of 10 °C min-1 to remove organic content.
Powder X-ray diffraction data were collected on a STOE STADIP
difffactometer operating on monochromated Cu Keg radiation. Powder
data were collected in Debyc—Scherrer geometry using 0.5 mm quartz
capillaries over a period of 12 h to determine purity of the synthesized
phases.
Ion Exchange of Zeolites. Metal ion-exchanged zeolites were
prepared as follows. Typically, the zeolite (5 g) was placed in a 0.05
M solution of the metal acetate (400 mL, distilled water) and stirred
for 24 h. The products were recovered by filtration, washed with
distilled water (400 mL), and dried at 100 °C overnight. Elemental
analysis was carried out to determine the amount of metal ions
exchanged by an Agilent 7500 Series ICP-MS spectrometer (Table 1).
NO Adsorption/Desorption Isotherms. The adsorption/desorption
of nitric oxide gas in microporous materials was measured using a
gravimetric adsoiption system. A CI instruments microbalance was
thermally stabilized to eliminate the effect from external environment.
The microbalance has a sensitivity of 0.1 fig and reproducibility of
0.01% of the load. The pressure of adsorption system was monitored
by two BOC Edwards Active gauges in the ranges of 1 x 10 8— 1 x
10~2 and 1 x 10-4—1 x 103 mbar, respectively. The sample (—130
mg) was initially outgassed at 573 K under 1 x 10-4 mbar, until no
further weight loss was observed. The sample temperature was then
decreased to 298 K and kept constant by a circulation water bath with
temperature accuracy ±0.02 K. The counterbalance temperature was
kept the same as that of the sample to minimize the influence of
temperature difference on weight readings, and the sample temperature
was monitored using a K type of thermocouple, located close to sample
bucket (<5 mm). The variation in sample temperature was minimal
(<0.1 K) throughout the experiment. NO gas was introduced into the
system until the desired pressure was achieved, and the mass uptake
of the sample was measured as a function of time until the adsorption
equilibrium was achieved. In this manner an adsorption isotherm was
collected by incrementally increasing the pressure and noting the mass
gain of tlie sample at equilibrium. Desorption of nitric oxide gas
adsorbed in the samples was performed by gradually decreasing the
system pressure to a desired value (until 2 x 10 2 mbar).
NO Loading and Release Experiments. The ion-exchanged zeolite
(~0.3 g) was dehydrated for 2 h at 300 °C in vacuo (0.5 mmHg). This
was cooled to room temperature and exposed to approximately 2 atm
of dry NO (99.5%, Air Liquid) for 30 min, evacuated, and exposed to
dry argon. Evacuation and exposure to argon occurred three times.
Quantification of NO Release by Chemiluminescence. NO
measurements were performed using a Sievers NOA 280i chemilumi¬
nescence NO analyzer. The instrument was calibrated by passing air
through a zero filter (Sievers, <1 ppb NO) and 89.48 ppm NO gas
(Air Products, balance nitrogen). The flow rate was set to 200 mL/min
with a cell pressure of 8.5 Torr and an oxygen pressure of 6.1 psig. To
measure NO release from zeolite powders, nitrogen gas of known
humidity was passed over the powders, the resultant gas was directed
into the analyzer, and the concentration of NO in ppm or ppb was
recorded.
To measure the release of NO from pressed disks, the samples were
sealed in a glass vial with a septum through which the gas was sampled.
Nitrogen was supplied to the vial at a rate to maintain atmospheric
pressure inside the vial. Distilled water (0.5 mL) was injected to initiate
NO release.
Quantification of NO Release Using Electrochemical Methods.
A flow of argon (saturated with water vapor, 5 mL min-1) was passed
over a known amount of the NO-loaded zeolite. The gas was then
bubbled through phosphate-buffered saline solution (pH 7.4, 10 mL)
in which a previously calibrated NO electrode (World Precision
Instruments, ISO-NO Mark II) was immersed. The concentration of
NO was measured over the course of several hours. All experiments
were repeated three times and gave reproducible results. A similar
technique was used for measurement of NO in PRP samples (1 mL),
except the cuvette was incubated in the platelet aggregometer (37 °C)
and was constantly stirred (100 tpm). These experiments were repeated
6 times, and results are illustrated as mean ± se of mean.
Storage Experiments. Vials ofNO-loaded Co—LTA were evacuated
immediately after loading with NO, and the atmosphere was replaced
by dry argon. The flasks were then stored for up to 16 weeks, and the
measurements of NO release were repeated at regular intervals.
Platelet Aggregation. The zeolite was ground with PTFE in the
desired ratio (75% zcolite/25% PTFE). The mixture was then pressed
into disks (5 mm diameter, ~20 mg) under 2 tons for 30 s. The disks
were then dehydrated and loaded with NO as described for the powder
samples.
Venous blood was drawn from the antecubital fossa of six healthy
volunteers (aged 20—40 years) into citrated tubes (0.38% final
concentration). Volunteers had not taken any medication known to affect
platelet aggregation within the last 10 days. Platelet-rich plasma (PRP)
was obtained from whole blood by centrifugation (350g; 20 min; room
temperature). Platelet-poor plasma (PPP) was obtained by further
centrifugation of PRP (1200g; 5 min; room temperature).
Zeolite/PTFE disks were suspended in stainless steel wire holders
below the surface of the PRP in the aggregometer cuvette, ensuring
that they did not interfere with the light beam or the mechanical stirring
(1000 lpm). After variation of incubation periods (1—120 min), platelet
aggregation was initiated by addition of U46619 (8 «M). Aggregation
was measured as a change in turbidity (light transmission) of PRP
against a PPP blank.
Electron Microscopy. Parallel aggregation experiments were con¬
ducted on separate samples prior to gentle washing of the zeolite/PTFE
disks in phosphate buffered saline, fixing in 3% glutaraldehyde and
osmium tetroxide, dehydration in graded acetone, and critical point
drying with carbon dioxide. The surface of the disks was examined
using a Phillips 505 scanning electron microscope following gold-
palladium alloy sputter coating (SC500 sputter coater, Emscope
Laboratories).
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Abstract: Gas adsorption experiments have been carried out on a copper benzene tricarboxylate metal-
organic framework material, HKUST-1. Hydrogen adsorption at 1 and 10 bar (both 77 K) gives an adsorption
capacity of 11.16 mmol H2 per g of HKUST-1 (22.7 mg g~\ 2.27 wt %) at 1 bar and 18 mmol per g (36.28
mg g 1, 3.6 wt %) at 10 bar. Adsorption of D2 at 1 bar (77 K) is between 1.09 (at 1 bar) and 1.20(at <100
mbar) times the H2 values depending on the pressure, agreeing with the theoretical expectations. Gravimetric
adsorption measurements of NO on HKUST-1 at 196 K (1 bar) gives a large adsorption capacity of ~9
mmol g~1, which is significantly greater than any other adsorption capacity reported on a porous solid. At
298 K the adsorption capacity at 1 bar is just over 3 mmol g~1. Infra red experiments show that the NO
binds to the empty copper metal sites in HKUST-1. Chemiluminescence and platelet aggregometry
experiments indicate that the amount of NO recovered on exposure of the resulting complex to water is
enough to be biologically active, completely inhibiting platelet aggregation in platelet rich plasma.
Introduction
Porous materials of many different kinds' continue to be at
the forefront of attempts to develop many emerging technolo¬
gies; in particular, gas adsorption properties ofporous materials
are currently receiving great interest in many areas of science.
Potential uses of these solids range from separations ofmixtures
to gas storage media for energy,2 environmental,3 and biological
applications.4 Metal—organic frameworks (MOFs), with their
extremely high surface areas and porosity and their varied
' University of St. Andrews.
I University of Newcastle upon Tyne.
S Free Radical Research Facility, UHI Millennium Institute.
II University of Edinburgh.
1 Univerista di Torino.
(1) (a) Davis, M. E. Nature 2002, 417, 813. (b) Cotma, A.; Diaz-Cabanas,
M.; Jorda, J. L.; Martinez, C.; Moliner, M. Nature 2006, 443, 842. (c)
Cooper, E. R.; Andrews, C. D.; Wheatley, P. S.; Webb, P. B.; Wonnald,
P.; Morris, R. E. Nature 2004, 430, 1012.
(2) (a) Eddaoudi, M.; Kim, J.; Rosi, N.; Vodak, D.; Wachter, J.; O'Keefe, M.;
Yaghi, O. M. Science 2002, 295, 469. (b) Rosi, N. L.; Eckert, J.; Eddaoudi,
M.; Vodak, D.; Kim, J.; O'Keefe, M.; Yaghi, O. M. Science 2003, 300,
1127. (c) Zhao, X.; Xiao, B.; Fletcher, A. J.; Thomas, K. M.; Bradshaw,
D.; Rosseinsky, M. J. Science 2004, 306, 1012. (d) Ferey, G.; Mellot-
Draznieks, C.; Serre, C.; Millange, F.; Dutour, J.; Surble, S.; Margiolaki,
I. Science 2005, 309, 2040.
(3) Millward, A. R.; Yaghi, O. M../. Am. Chem. Soc. 2005, 127, 17998.
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chemical compositions, arc good candidates for high adsorption
capacities of various gases. HKUST-1 is a copper benzene
tricarboxylate porous material first reported by Williams and
co-workers5 and subsequently studied by numerous research
groups. Perhaps the most interesting feature of this material is
the presence of a metal site in the walls of the material that,
after dehydration, is potentially available to act as a site where
coordination to a gas molecule can take place.
Hydrogen adsorption and storage is of great interest as a
method ofproviding the gas as a fuel for zero-emission energy
production. The approaches currently being adopted for the
design of hydrogen storage materials are based on many
different types of material, ranging from metal hydrides6 and
carbon nanotubes and nanohorns7 to gas clathrates,8 although
all have significant problems attached to them. Nanoporous
materials, with their inherently large internal pore volumes and
(6) (a) Schlapbach, L.; Zuttel, A.; Nature 2001, 414, 353. (b) Bogdanovic, B.;
Felderhoff, M.; Pommerin, A.; Schuth, T.; Spielkamp, N. Adv. Mater. 2006,
18, 1998.
(7) (a) Dillon, A. C.; Jones, K. M.; Bekkedahl, T. A.; Kiang, C. H.; Bethune,
D. S.; Heben, M. J. Nature 1997, 386, 377. (b) Zhou, Y.; Feng, K.; Sun,
Y.; Zhou, L. Chem. Phys. Lett. 2003, 380, 526. (c) Shiraishi, M.; Takenobu,
T.; Kataura, H.; Ata, M. Appl. Phys. 2004, A78, 947. (d) H. Kanoh, II.;
Yudasaka, M.; Iijiraa, S.; Kaneko, K. J. Am. Chem. Soc. 2005, 127, 7511.
(8) Lee, H.; Lee, J. W.; Kim, D. Y.; Park, J.; Seo, Y. T.; Zeng, H.;
Moudrakovski, I. L.; Ratcliffe, C. I.; Ripmeester, J. A. Nature 2005, 434,
743.
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surface areas are obvious candidates for high-capacity storage
materials. MOFs have great promise in this area, and HKUST-1
has been shown to be capable of adsorbing significant amounts
of hydrogen at 77 K. There are, however, significant questions
still to be answered. From the literature it is clear that, while
hydrogen adsorption capacity is still usually below the levels
required for commercial application, high-capacity materials are
being prepared. The relatively weak interaction between the
hydrogen molecule and the walls of porous solids means that
this adsorption is only significant at low temperatures, which
might further limit the possible applications.
High nitric oxide (NO) adsorption is of great interest for
environmental applications in gas separation and NO* traps for
lean bum engines. NO is also an extremely important molecule
in biology, and NO-storing solids have potential applications
as antithrombosis materials.9 NO is a crucial biological agent
in the cardiovascular, nervous, and immune systems.10 NO
synthesized by endothelial cells that line blood vessels mediates
a number of vital functions, including vasodilation"'12 and
inhibition of platelet13 and inflammatory cell14'15 activation and
adhesion. In addition, NO is an important neurotransmitter and
neuromodulator in the peripheral and central nervous systems,16
and its synthesis in high concentrations contributes to the
cytotoxic effects of inflammatory cells on invading pathogens.17
The delivery of exogenous NO is an attractive therapy for a
number of ailments, but the range and diversity of its effects
make target specificity a major concern, which has held back
the development of some NO applications. To overcome this
problem requires the development of materials that can store
significant quantities ofNO and then deliver it to specific sites
in the body. There is currently particular interest in using NO
delivery materials to prevent life-threatening complications
associated with thrombosis formation at the surface of medical
devices such as stents and catheters.9
A number ofmaterials have been proposed as delivery agents
for exogenous NO. Perhaps the chemically most advanced are
those based on polymers or silica functionalized with secondary
amines, which, on reaction with NO, form ionic diazeniumdi-
olates that can be used to increase the thromboresistivity of
polymers.9'18,19 Two molecules of NO react with each amine
(giving rise to the trivial name NONOate) and are released on
contact with moisture at an appropriate pH. Other methods of
release have also been explored, including the light-activated
(9) Keefer, L. K. Nat. Mater. 2003, 2, 357.
(10) Moncada, S.; Palmer, R. M. J.; Higgs, E. A. Pharmacol. Rev. 1991. 43,
109.
(11) Furchgott, R. F.; Zawadzki, J. V. Nature 1980, 288, 373.
(12) Palmer, R. M. J.; Ferrige, A. G.; Moncada, S. Nature 1987, 327, 524.
(13) Radomski, M. W.; Palmer, R. M. J.; Moncada, S. Lancet 1987, 2, 1057.
(14) Bath, P. M. W.; Hassall, D. G.; Gladwin, A. M.; Palmer, R. M. J.; Martin,
J. F. Arterioscler. Thromb. 1991, 11, 254.
(15) Kubes, P.; Suzuki, M.; Granger, D. N. Proc. Natl. Acad. Sci. U.S.A. 1991.
87, 5193.
(16) Garthwaite, J. Trends Neurosci. 1991, 14, 60.
(17) Nathan, C. F.; Hibbs, J. B. Curr. Opin. Immunol. 1991, 3, 65.
(18) (a) Parzuchowski, P. G.; Frost, M. C.; Meyerhoff, M. E. J. Am. Chem.
Soc. 2002, 124, 12182. (b) Lee, Y.; Oh, B. K.; Meyerhoff, M. E. Anal.
Chem. 2004, 76, 536. (c) Zhang, H. P.; Annich, G. M.; Miskulin, J.;
Stankiewicz, K.; Osterholzer, K.; Merz, S. I.; Bartlett, R. H.; Meyerhoff,
M. E../. Am. Chem. Soc. 2003, 125, 5015. (d) Frost, M. C; Rudich, S. M.;
Zhang, II. P.; Maraschio, M. A.; Meyerhoff, M. E. Anal. Chem. 2002, 74,
5942. (e) Zhang, H. P.; Aiinich, G. M.; Miskulin, J.; Osterholzer, K.; Merz,
S. I.; Bartlett, R. PL; Meyerhoff, M. E. Biomaterials 2002, 23, 1485.
(19) (a) Mowery, K. A.; Schoenfisch, M. H.; Saavedra, J. E.; Keefer, L. K.;
Meyerhoff, M. E. Biomaterials 2000, 21, 9. (b) Mowery, K. A.; Schoenfisch,
M. H.; Baliga, N.; Wahr, J. A.; Meyerhoff, M. E. Electroanalysis 1999,
11 681. (c) Espadas-Torre, C.; Oklejas, V.; Mowery, K.; Meyerhoff,
M. E. J. Am. Chem. Soc. 1997, 119, 2321.
release of nitric oxide from metal containing polymers.20 More
recently zeolites, nanoporous inorganic framework materials
normally associated with the destruction of NO in deNOx
catalysis, have also been shown to be high-storage capacity
materials forNO, with maximum adsorption capacities of around
1 mmol g~' at 298 K.4
A specific potential use for NO-releasing materials in the
cardiovascular arena centers on the prevention of thrombosis
on artificial surfaces that come into contact with blood,
particularly in relation to procedures that require extracorporeal
circuits, such as bypass and renal replacement therapy, catheter
implantations, or stents that are used in interventional cardiology
to improve the patency of partially blocked arteries.9 Current
best practice to prevent thrombosis in these situations involves
the administration ofheparin, other anticoagulants, or antiplatelet
agents to the patient, with the inherent risk ofhemeorrhagic21'22
or paradoxical thrombotic23 complications. Stent coatings that
release antithrombotic,2424 antiinflammatory,25 and antimitoge-
nic26 agents to reduce in-stent thrombosis or restenosis have
met with some success, but NO might be expected to have all
of these effects if delivered at the appropriate rate for a sufficient
duration. Other potential uses of these types of solid, as shown
by a number of different biological effects, include antibacterial
coatings27 and wound-healing promoters.28
Here we report the full characterization of the porous nature
of HKUST-1 using N2 and CO2 adsorption together with a
demonstration of high H2 and D2 adsorption. We also show that
HKUST-1 adsorbs significantly more NO than any other porous
solid yet reported and that it releases enough NO on contact
with a physiological solution (platelet-rich plasma) to fully
inhibit platelet aggregation.
Results and Discussion
Hydrogen Adsorption Studies. HKUST-1 was synthesized
according to the method reported by Williams and co-workers.5
The powder X-ray diffraction pattern indicated that there were
none of the impurities reported in the initial publications.
Nitrogen (77 K) and carbon dioxide (195 K) adsorption studies
were used to characterize the pore volume in the material, giving
values of 0.684 and 0.703 cm3 g_1, respectively. Pore volumes
of HKUST-1 obtained from N2 adsorption have been reported
as 0.33 cm3 g"1 by Chui et al.5 and 0.4 cm3 g_1 in Lee's paper;29
(20) (a) Mitchell-Koch, J. T.; Reed, T. M.; Borovik, A. S. Angew. Chem. 2004,
43, 2806. (b) Padden, K. M.; Krebs, J. F.; MacBeth, C. E.; Scarrow, R. C.;
Borovik, A. S ./. Am. Chem. Soc. 2001, 123, 1072.
(21) Sundlof, D. W.; Rerkpattaaapitat, P.; Wongpraparut, N.; Pathi, P.; Kotler,
M. N.; Jacobs, L. E.; Ledley, G. S.; Yazdanfar, S. Am. ./. Cardiol. 1999,
83, 1569.
(22) Bennett, C. L.; Connors, J. M.; Carwile, J. M.; Moake, J. L.; Bell, W. R.;
Tarantolo, S, R.; McCarthy, L. J.; Sarode, R.; Hatfield, A. J.; Feldman,
M. D.; Davidson, C. J.; Tsai, H. M. N. Engl. J. Med 2000, 342, 1773.
(23) Chong, B. H. J. Thromb. Haemostasis 2003, 1, 1471.
(24) Aggarwal, R. K.; Martin, W. A.; Azrin, M. A.; Ezekowitz, M. D.; de Bono,
D. P.; Gershlick, A. H. Circulation 1996, 94, 1510.
(25) Strecker, E. P.; Gabelmann, A.; Boos, I.; Lucas, C.; Xu, Z. Y.; Haberstroh,
J.; Freudenberg, N.; Strieker, H.; Langer, M.; Betz, E. Cardiovasc. Intervenl.
Radiol. 1998, 21, 487.
(26) Colombo, A.; Drzewiecki, J.; Banning, A.; Grube, E.; Hauptmann, K.;
Silber, S.; Dudek, D.; Fort, S.; Schiele, F.; Zmudka, K.; Guagliumi, G.;
Russell, M. E. Circulation 2003, 108, 788.
(27) Nablo, B. J., Chen, T.-Y.: Schoenfisch, M. H. J. Am. Chem. Soc. 2001.
123, 9712.
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Figure 1. Adsorption and desorption isotherms (77 K) for Hi on HKUST-1
to 1 bar (red triangles) and to 10 bar (black circles). The repeatability is
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Figure 2. Hi and Di adsorption desorption isotherms (77 K to 1 bar) on
HKUST-1. The Di/Hi ratio of adsorption at 800 mbar is 1.09.
Rowsell et al.3i reported a value of 0.75 cm3 g~'. The calculated
crystallographic pore volume obtained from PLATON is ~0.72
cm3 g~'.
Highly crystalline materials such as HKUST-1 should have
very repeatable pore structures and adsorption properties, but
reports of hydrogen adsorption properties of HKUST-1 vary
quite substantially. Lee et al.29 and Prestipino et al.30 both report
a H2 uptake of ~6 mmol g~' (~12.5 mg g~', ~1.25 wt %),
while Yaghi and co-workers report 12.4 mmol g~' (25 mg g-1,
2.5 wt %)31 in one paper and nearer 7.9 mmol g_l (16 mg g-1,
1.6 wt %)32 in another (all measurements 77 K and 1 bar. Note
that the result from ref 32 is based on interpolation of a high-
pressure isotherm). The issues with regard to repeatability of
nitrogen adsorption measurements for HKUST-1 may be
attributed to (1) sample purity and (2) sample activation. The
presence of amorphous or nonporous impurity phases must be
eliminated. Activation involves removal of any guest molecules
that are contained within the pores of the material, either through
thermal or chemical means (or through a combination of the
two). The stage where the template has been completely
removed by evacuation to give the porous structure has to be
established carefully. Good agreement between pore volumes
obtained from crystallographic studies and gas adsorption is
necessary to confirm the purity of the material. In the case of
H2 adsorption measurements, there are additional considerations
since the experimental system must be ultraclean and it is
necessary to purify even ultrahigh-purity hydrogen before the
measurements.
Several hydrogen adsorption experiments were repeated using
samples of HKUST-1 from different batches and different
adsorption instruments and to pressures of 1 and 10 bar (77
K). We have carefully characterized the buoyancy corrections
needed, and the repeatability of the results gives us great
confidence that the sample- and instrument-dependent factors
have been controlled (See Supporting Information).
(30) Prestipino, C.; Regli, L.; Vitillo, J. G.; Bonino, F.; Damin, A.; Lamberti,
C.; Zecchina, A.; Solari, P. L.; Kongshaug, K. O.; Bordiga, S. Chem. Mater.
2006, 18, 1337.
(31) Rowsell, J. L. C.; Yaghi, O. M. J. Am. Chem. Soc. 2006, 128, 1304.
(32) Wong-Foy, A. G.; Matzger, A. J.; Yaghi, O. M../. Am. Chem. Soc. 2006,
128, 3494.
Gravimetric measurements at 1 bar indicate an average H2
adsorption capacity of ~11.16 mmol g-' of HKUST-1 (22.7
mg g~', 2.27 wt %, Figure 1) comparable to the highest results
reported by Yaghi and co-workers.31 The isotherm is repeatable
to within 1.8% on different instruments and using different
samples ofHKUST-1. At higher pressure (10 bar) the adsorption
capacity increases up to approximately 18 mmol per g (36.28
mg g~', 3.6 wt % Figure 1). Yaghi and co-workers32 reported
the adsorption isotherms up to 80 bar as only 16.17 mmol g~l
(32.6 mg g~', 3.26 wt %). D2 adsorption on HKUST-1 at 77 K
up to I bar (Figure 2) shows a slight increase in adsorption
capacity (from 1.09 to 1.20 times the H2 values depending on
the pressure). This is consistent with adsorption studies on
porous carbons33 and zeolites34 and is due to quantum mechan¬
ical effects. The density of the adsorbed hydrogen calculated
from the maximum amount adsorbed determined using the
Langmuir equation and the N2 pore volume was ~0.057 g cm-3.
This value is similar to densities for porous carbons and lower
than 0.0708 g cm-3 for liquid H2 at 20.2 K.35
These results show that the maximum adsorption capacity
of HKUST-1 for hydrogen at 77 K was 11.16 rnmol g"1, or
approximately 2.27 wt % at 1 bar rising to approximately 18
mmol g_1 at 10 bar. None of the samples we measured showed
the lower adsorption capacities reported by Lee et al. and
Prestipino et al.
Nitric Oxide Adsorption Studies
Nitric oxide adsorption is important for a number of applica¬
tions, with particular potential for impact in the medical and
biological areas. Materials based on organic19 and metal-
containing polymers,21 and zeolites4 have all been proposed as
NO adsorbents. The adsorption capacity of these materials
ranges from quite low values in the /rmol NO per g range21 up
to approximately 1 to 1.5 mmol NO per g of material.4'19
Although adsorption capacity is not the only consideration in
(33) (a) Zhao, X. B.; Xiao, B.; Fletcher, A. J.; Thomas, K. M. J. Phys. Chem.
B 2005, 109, 8880. (b) Zhao, X. B.; Villar-Rodil, S.; Fletcher, A. J.; Thomas,
K. M. J. Phys. Chem. B 2006, 110, 9947.
(34) Stephanie-Victoire, F.; Goulay, A. M.; de Lara, E. C. Langmuir 1998, 14,
7255.
(35) CRC Handbook ofChemistry andPhysics, 74th ed.; CRC Press: BocaRatan,
Florida, 1993.
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Figure 3. Adsorption (filled symbols) and desorption (open symbols)
isotherms at 196 K (squares) and 298 K (circles) for nitric oxide on
HKUST-1.
determining the effectiveness of a material, it is advantageous
to maximize the adsorption capacity of a material to increase
the reservoir of stored gas. NO is physisorbed in the pores and
also coordinates with the metal sites present in HKUST-1.
Gravimetric adsorption measurements on HKUST-1 at 196 K
(1 bar) gives a large adsorption capacity of ~9 mmol g-1, which
is significantly greater than any other adsorption capacity
reported on a porous solid. At 298 K the adsorption capacity at
1 bar is just over 3 mmol g-1. These values are high, bearing
in mind that the NO critical temperature and pressure are 180.1
K and 64.83 bar. There is significant isotherm hysteresis at both
temperatures, indicative of the strong irreversible adsoiption of
some of the NO molecules on the open copper sites that line
the walls of the pores in dehydrated HKUST-1. At both
temperatures, there is about 2.21 mmol g-1 that is not desorbed
when the pressure of NO is reduced to almost zero. This
corresponds to ~1 NO per dicopper(II) tetracarboxylate building
block for HKUST-1. The results indicate that HKUST-1 is
potentially a very good storage material for NO, with a very
high capacity compared to those of zeolites and organic
polymers.
1R studies
The dehydrated form ofHKUST-1 has accessible copper sites
in the walls of the framework itself. Given the well-known
tendency ofNO to form metal coordination complexes, it seems
likely that the hysteresis seen in the adsorption—desorption
isotherms ofNO on HKUST-1 (Figure 3) is due to trapping of
the gas on the metal. Infrared spectroscopy is the technique of
choice for probing such bond formation in these solids.
Figure 4 reports the effect NO interaction at room temperature
on HKUST-1 monitored by IR spectroscopy. The IR spectrum
of a dehydrated HKUST-1 sample is reported in red. The two
sharp bands at 1912 and 1886 cm-1 are due to overtones and
combination modes of framework vibrations, while the 1750—
1200 cm-1 region is dominated by very intense bands due to
asymmetric and symmetric modes of carboxylate (Raman
doublet at 1550 and 1460 cm-1), bands due to benzene ring
stretching modes and C—H bending vibrations.36
(36) Prestipino, C.; Regli, L.; Vitillo, J. G.; Bonino, F.; Damin, A.; Lamberti,




Figure 4. Interaction with NO monitored by IR spectroscopy. Red curve:
HKUST-1 outagassed at 180 °C. Blue curve: effect of 30 Torr of NO.
Black curves: effect of increasing pumping, residual pressure 10-3 Torr.
(Inset) Background-subtracted spectra in the region ofNO stretching (same
color code). In the upper part of the inset (blue dashed curve) the spectrum
of NO adsorbed at room temperature on a Cu—ZSM-5 zeolite is reported
for comparison.
Upon contact with 30 Torr of NO, (blue curve) the growth
of a new component at 1887 cm-1 is clearly visible, testifying
to the formation of a Cu(II)~NO adduct. In the meantime some
further changes are observed in the framework modes of
HKUST-1, suggesting that the material responds to the NO
adsorption. In particular, we observe the erosion of a shoulder
at 1755 cm-1, the parallel growth of a component at 1735 cm-1
(isosbestic point at 1745 cm-1), and the intensity increase of
the bands at 1700 and at 1237 cm-1. The effect of progressive
outgassing is reported with black curves. The last spectrum is
obtained after outgassing for 15 min at room temperature in
dynamic vacuo with a residual partial pressure of 10-3 Torr.
The spectroscopic features ofNO adsorbed on Cu(II) species
are better illustrated in the inset of Figure 4 (same color code)
where difference spectra are reported. The Cu(II)-NO adduct
is characterized by a band at 1887 cm-1 that decreases in
intensity without substantial shifts. A Av(NO) = +11 cm-1 with
respect to vNO in the gas phase (v°n-o = 1876 cm-1) is close
to what has been obtained in case of Cu(II)~(NO) complex in
copper-exchanged zeolites and similar systems,37-39 where a
band in the range 1910—1880 cm-1 has been observed. For sake
of comparison the spectrum obtained at room temperature on a
Cu(ZSM-5) is reported as dashed blue curve in the inset of
Figure 4.38
Spectroscopic data on copper nitrosylic complexes have been
obtained by Zhou et al.40 They have studied the formation of
Cu(NO), [Cu(NO)]+, and [Cu(NO)]- in neon matrices ,40-4'
finding a strong similarity between the spectroscopic features
of [Cu(NO)]+ species (1907.8 cm-1) and that obtained in the
case of Cu(II)-exchanged zeolites. In particular, it has been
observed that the N—O stretching frequency reported for Cu-
(37) Bordiga, S.; Paze, C.; Berlier, G.; Scaraiio, D.; Spoto, G.; Zecchina, A.
Catal. Today 2001, 70, 91.
(38) Laraberti, C.; Bordiga, S.; Salvalaggio, M.; Spoto, G.; Zecchina, A.;
Geobaldo, F.; Vlaic, G.; Bellatreccia, M. J. Phys. Chem. B 1997, 101, 344.
(39) Llabres i Xamena, F. X.; Fisicaro, P.; Berlier, G.; Zecchina, A.; Turnes
Palomino, G.; Prestipino, C.; Bordiga, S.; Giamello, E.; Lamberti, C.
J. Phys. Chem. B 2003, 107, 7036.
(40) Zhou, M.; Andrews, L. J. Phys. Chem. A 2000, 104, 2618.
(41) Andrews, L.; Citra A. Chem. Rev. 2002, 102, 885.
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(II)—NO/zeolite is near 1900 cm"1, a value very close to that
observed for [Cu(NO)]+, which suggests a +1.0 net charge on
the Cu(NO) center for this formal Cu(II)—NO/zeolite species.
The Cu(NO)+ complex has been described in an ab initio study
by Thomas et al.42who calculated a binding energy of 91 kj/
mol.
A strong interaction energy and the fact that v(NO) in the
Cu(II)~NO adduct appears only slightly shifted from that of
the molecule in the gas phase can be explained by considering
that the observed frequency is the final result of competitive
effects: (i) the polarization effect and a donation that give an
upward shift and (ii) the n back-donation that gives the opposite
effect. The fact that the v(NO) in the Cu(II)~NO adduct formed
in HKUST-1 is at lower frequency than that observed in Cu—
ZSM-5 suggests that in this case the back-donation is more
effective. This fact is in agreement with the qualitative observa¬
tion that the stability of the Cu(II)~NO adducts formed in Cu—
ZSM-5 is lower (complete reversibility at room temperature)
than that found in HKUST-1. A dedicated study to obtain more
quantitative data about the stability of the complex Cu(II)~NO
formed in HKUST-1 is in progress.
Quantification of NO Release
Of course, to make use of a material as a gas storage medium
does not just entail being able to adsorb large quantities of the
gas but to be able to control the release of the gas at the time
and at the rate required for the particular application. The
optimum rate of release ofNO differs, depending on the exact
nature of the target application. For example, for antithrombotic
applications the rate of release of NO required should ap¬
proximate the rate released by the endothelial cells that line
the blood vessels in mammals. This rate is quite slow, relating
to around 1 pmol mkT1 mm-2.9 On the other hand it seems
that the antibacterial effects of NO require greater flux of the
gas. In our work on zeolites we have shown that exposure of
the NO-loaded material to a nucleophile such as water triggers
release of the NO. The standard method of measuring NO
release from a powdered solid is to expose the material to a
flow of wet gas at a controlled relative humidity and measure
the NO in the outlet stream using the intensity of chemilumi-
nescence on reaction of NO with ozone. Such experiments
carried out on NO-loaded HKUST-1 (Figure 5) indicate that
NO is released on contact with water vapor in a manner similar
to that seen previously for zeolites. However, the total amount
of NO released is 2 orders ofmagnitude less (2 /tmol NO per
g of HKUST-1) than the amount initially adsorbed. This is not
necessarily a detrimental property as biological applications can
require only a very low flux of NO, and we show below that
this release of NO is sufficient to completely inhibit platelet
aggregation in biological experiments. The total amount ofNO
released is also significantly less than that seen for zeolites or
NONOate polymers but is comparable to the amount of NO
released by metal-containing polymers.
Bioactivity of NO-Loaded HKUST-1
The need for improvements in the biocompatibility of
materials is a very important target. This is particularly true for
(42) Thomas, J. L. C.; Bauschlicher, C. W., Jr.; Hall, M. B. J. Phys. Chetn. A
1997, 101, 8530.
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Figure 5. NO release profile for NO-loaded HKUST-1 (top) and the
cumulative NO released per g of HKUST-1 (bottom).
blood-contacting solids that are used in vascular grafts and in
extracorporeal tubing used in coronary bypass surgery and
kidney dialysis. Life-threatening complications can occur if
thrombosis formation (platelet aggregation and adhesion) is
induced by artificial materials that are in contact with blood.
Thrombus formation in healthy circulatory systems is inhibited
in a number ofways, including the production of small quantities
(approximately 1 pmol min-1 mm""2; see reference 9) of NO
by the endothelial cells that line the blood vessels and also by
platelets. A potentially important strategy for reducing postop¬
erative complications is to make medical devices out of a NO-
releasing material, thereby mimicking the antithrombotic action
of the endothelial cells.
To overcome the problem of the nondispersion of powders
in the liquid-phase, samples of HKUST-1 were prepared as
pressed disks with small amounts of poly(tetrafluoroethylene)
(PTFE) polymer as a binder. The NO-loaded disks were stored
under an inert atmosphere for up to several weeks before being
used in further experiments.
The HKUST-1/PTFE disks were suspended by a stainless
steel wire holder below the surface ofplatelet-rich plasma (PRP)
in the cuvette of a four-channel platelet aggregometer (Chro-
nolog, Labmedics, Stockport, UK) at 37 °C. After a short
induction period (1 min), platelet aggregation was initiated using
the pro-aggregatory agent, collagen (2.5 fig mL"1), and then
measured as a change in turbidity (light transmission) of PRP
against a platelet-poor plasma (PPP) reference. Figure 6 shows
that a NO-loaded HKUST-1/PTFE sample completely inhibits
platelet aggregation. Addition of the NO-scavenger, oxyhemo¬
globin (40 fiM), prevents the inhibitory effect, confirming the
central role for NO in the inhibitory process and excluding the
possibility that the effects of the NO—HKUST-1 were merely
cytotoxic. Furthermore, a control consisting of only HKUST-1
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Figure 6. Platelet aggregation experiments show that this material inhibits
platelet aggregation completely. (Pink = NO-HKUST-1. Blue = control.)
On initiation of aggregation (by addition of collagen marked by the arrow)
the aggregometer response for the control (blue) indicates that the platelets
have aggregated and fallen out of suspension. However, there is no such
response for the NO-loaded HKUST-1 sample (pink). This indicates that
the amount of NO released by the HKUST-1 is sufficient to completely
inhibit platelet aggregation in this experiment.
without NO failed to inhibit aggregation, ruling out any effect
from the material itself. For short term applications NO-loaded
HKUST-1 seems very promising for antithrombotic applications
in that it releases NO at a suitable rate. Unfortunately, however,
its stability in biological solutions is limited. Even after a few
hours exposure to platelet-rich plasma, the solution itselfbegan
to go green, indicating dissolution of the copper from the
framework material. Clearly this is an issue as the toxicological
implications of excess coppers ions in, for example, human
blood may be enough to prevent application of such materials.
Further work in this area is ongoing.
Concluding Remarks
Metal—organic frameworks, such as HKUST-1, are clearly
of interest because of their very high adsorption capacities. The
hydrogen adsorption measurements are entirely consistent with
other gas adsorption measurements and the crystallographic
studies. The relatively weak interaction of hydrogen with the
walls of a porous solid means that adsorption is restricted to
low temperatures. In addition, other gases may well adsorb more
strongly than hydrogen, leading to problems unless the hydrogen
is ultrapure. This may be exacerbated in materials such as
HKUST-1 where there are open metal sites that will interact
strongly with other gases or water. However, for adsorption of
gases such as NO that do interact strongly with metals, this
may be an advantage. In biological applications, the relatively
poor stability of MOFs in physiological solutions, and their
rather unstudied toxicology, mean that their undoubted promise
needs further development before applications can be found.
Having said that, however, it is clear that HKUST-1 is a very
high-capacity adsorption material. Both hydrogen and nitric
oxide adsorb in high quantities on HKUST-1, confirming their
applicability as potential gas storage materials for energy,
environmental, and biological applications.
Experimental Section
Synthesis of HKUST-1. In a typical synthesis, 3.0 mmol of Cu-
(N03)2-3H20 (0.716 g) and 2.0 mmol of benzene 1,3,5-tricarboxylic
acid (0.421 g) were mixed with 12 mL of EtOH/H20 (50:50) solution
in a Teflon-lined autoclave. The mixture was stirred for 30 min at
ambient temperature prior to heating in an oven preheated at 383 K,
followed by heating at 383 K for 24 h. After crystallization the autoclave
was naturally cooled down to room temperature. The yield was
sonicated for 5—10 min in a solution of EtOH/H20 (50:50). Large,
turquoise-blue crystals were isolated by Biichner filtration and dried
in air for 1 day.
Gas Adsorption/Desorption Measurements. Gases. Ultrapure
hydrogen (H2 99.9999%, H20 < 500 ppb, N2 < 200 ppb, 02 < 100
ppb, CO + C02 < 50 ppb, total hydrocarbons <50 ppb) hydrogen
was supplied by Air Products Ltd. Deuterium (99.98% D2), nitrogen
(99.9995%), and carbon dioxide (99.999%) were supplied by BOC Ltd.
Hi/Di Purification. Hydrogen and deuterium were purified using a
two-stage process involving adsorption on a zeolite (calcium alumino
silicate (1/16 in. pellets)), at 298 K to remove any water vapor present,
and activated carbon (G212, particle size 6 x 12 mesh) at 195 K to
remove hydrocarbons and other gas impurities.33 The impurities were
adsorbed under these conditions, while little or no hydrogen or
deuterium was adsorbed at 195 K. Both adsorbents were degassed at
700 K prior to use.
Adsorption Studies for H2, D2, Nj, and C02. The adsorption/
desorption characteristics of H2, D2, N2, and C02 were studied using a
Hiden Isochema Gravimetric Analyzer, which is an ultraclean, ultrahigh-
vacuum system with a diaphragm and turbo pumping system. The
microbalance had a long-term stability of ±1 fig with a weighing
resolution of 0.2 fig. The sample was degassed at 453 K under ultrahigh
vacuum (10_I° bar) until no further weight loss occurred prior to H2
and D2 adsorption. The approach to equilibrium was measured in real
time using a computer algorithm. The pressure was monitored by three
pressure transducers with ranges 0—0.2, 0—10, and 0—100 kPa and
maintained at the set point by active computer control of inlet/outlet
valves throughout the duration of the adsorption kinetic experiments.
The accuracy of the set-point pressure regulation was ±0.02% of the
range used. Both the sample and counterweight sides of the balance
were cooled to 77 K for the H2 and D2 adsorption/desorption
experiments in order to minimize buoyancy corrections and thermal
transpiration effects. A detailed buoyancy correction was carried out
on the basis of experimental measurements of the system buoyancy
and the helium density of HKUST-1.
The major problem with studying H2 and D2 adsorption and
desorption is the adsorption of impurities from both the adsorptive gas
used and within the UHV system.33 The measurement protocols used
in this study were validated by the complete desorption of H2 with
little or no isotherm hysteresis. More detailed validation of the protocols
has bccii picscnicd picviously.33
NO Adsorption/Desorption Measurements. The adsorption/de¬
sorption of NO gas in HKUST-1 was measured using a gravimetric
adsorption system. A CI instruments microbalance was thermally
stabilized to eliminate the effect from external environment. The
microbalance has a sensitivity of 0.1 fig and reproducibility of 0.01%
of the load. The pressure of the adsorption system was monitored by
two BOC Edwards Active gauges in the ranges of 1 x 10~8— 1 x 10~2
and 1 x 10~4—1 x 103 mbar, respectively. The sample (~130 mg)
was initially outgassed at 573 K under 1 x 10 4 mbar, until no further
weight loss was observed. The sample temperature was then decreased
to 298 K and kept constant by a circulation water bath with temperature
accuracy ±0.02 K. The counterbalance temperature was kept the same
as that of the sample to minimize the influence of temperature difference
on weight readings, and the sample temperature was monitored using
a K type of thermocouple, located close to the sample bucket (<5 mm).
The variation in sample temperature was minimal (<0.1 K) throughout
the experiment. Nitric oxide gas was introduced into the adsorption
system until the desired pressure was achieved, and the mass uptake
of the sample was measured as a function of time until the adsorption
equilibrium was achieved. In this manner an adsorption isotherm was
collected by incrementally increasing the pressure and noting the mass
gain of the sample after equilibrium was reached. The desorption of
nitric oxide gas adsorbed in the samples was performed by gradually
decreasing the system pressure to a desired value (until 2 x 10~2 mbar).
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Saturated Vapor Pressures. Hydrogen, deuterium, and nitric oxide
were used above their critical temperatures. The saturated vapor
pressures for carbon dioxide and nitrogen were calculated using the
following equation44
g
logioP ~ A — T + c 0)
where p is the saturated vapor pressure (Torr), T is the temperature in
degrees Celsius and A, B, and C are constants defined by the
adsorbate: carbon dioxide (77-303 K): T = 7.810237,5 = 995.7048,
C = 293.4754; nitrogen (75-373 K): A = 6-49457, B = 255-68, C =
266-550.
IR Studies. IR spectra were collected, at 2 cm-' resolution, on a
Bruker IFS 66 FT1R instrument equipped with a cryogenic MCT
detector in transmission mode on a self-supported pellet. Suitable
measurements cells were used allowing in situ thermal treatments at
180 °C in high vacuo and NO dosage at room temperature.
Quanitifaction of NO Release by Cheiniluminesccnce. Nitric oxide
measurements were performed using a Sievers NOA 280i chemilumi-
nescence Nitric Oxide Analyzer. The instrument was calibrated by
passing air through a zero filter (Sievers, <1 ppb NO) and 89.48 ppm
NO gas (Air Products, balance nitrogen). The flow rate was set to 200
mL/min with a cell pressure of 8.5 Torr and an oxygen pressure of 6.1
psig. To measure NO release from HKUST powders, nitrogen gas of
known humidity was passed over the powders, the resultant gas was
directed into the analyzer, and the concentration ofNO in ppm or ppb
was recorded.
Platelet Aggregation. The sample of HKUST-1 was ground with
PTFE in the desired ratio (75% zeolite/25% PTFE). The mixture was
then pressed into disks (5 mm diameter, ~-20 mg) under 2 tons for 30
s. The disks were then dehydrated and loaded with nitric oxide as
described for the powder samples.
Venous blood was drawn from the antecubital fossa of a healthy
volunteer into citrated tubes (0.38% final concentration). The volunteer
had not taken any medication known to affect platelet aggregation
within the last 10 days. Platelet-rich plasma (PRP) was obtained from
whole blood by centrifugation (350g; 20 min; room temperature).
Platelet-poor plasma (PPP) was obtained by further centrifugation of
PRP (1200g; 5 min; room temperature).
The HKUST-1/PTFE disks were suspended in a stainless steel wire
holder below the surface of the PRP in the aggregometer cuvette,
ensuring that they did not interfere with the light beam or the mechanical
stirring (1000 rpm). After a short incubation period (1 min), platelet
aggregation was initiated by addition of agonist collagen (2.5 ,«g/mL).
Aggregation was measured as a change in turbidity (light transmission)
of PRP against a PPP blank.
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